<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis - Simonetti, RG - 2020 | Cochrane Library</title> <meta content="Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis - Simonetti, RG - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000553.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis - Simonetti, RG - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000553.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000553.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis" name="citation_title"/> <meta content="Rosa G Simonetti&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital" name="citation_author_institution"/> <meta content="Giovanni Perricone&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Azienda Socio-Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda" name="citation_author_institution"/> <meta content="Helen L Robbins&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Narendra R Battula" name="citation_author"/> <meta content="University of Florida" name="citation_author_institution"/> <meta content="Martin O Weickert" name="citation_author"/> <meta content="University Hospitals Coventry and Warwickshire NHS Trust" name="citation_author_institution"/> <meta content="Robert Sutton" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Saboor Khan" name="citation_author"/> <meta content="University Hosptial Coventry and Warwickshire" name="citation_author_institution"/> <meta content="saboor.711@gmail.com" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD000553.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/10/22" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000553.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000553.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000553.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Cause of Death; Endoscopy [*methods]; Esophageal and Gastric Varices [prevention &amp; control, *therapy]; Gastrointestinal Hemorrhage [epidemiology, prevention &amp; control, *therapy]; Hepatic Encephalopathy [epidemiology, etiology]; Intention to Treat Analysis; Liver Cirrhosis [*complications]; Portasystemic Shunt, Surgical [adverse effects, *methods]; Portasystemic Shunt, Transjugular Intrahepatic [adverse effects]; Randomized Controlled Trials as Topic; Secondary Prevention; Splenorenal Shunt, Surgical [adverse effects]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000553.pub3&amp;doi=10.1002/14651858.CD000553.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="wbKFI7vu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000553\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000553\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","hr","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000553.pub3",title:"Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis",firstPublishedDate:"Oct 22, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Hepato-Biliary Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000553.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000553.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000553.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000553.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000553.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000553.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000553.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000553.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000553.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000553.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1770 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000553.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-sec-0165"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-sec-0048"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-sec-0159"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/appendices#CD000553-sec-0170"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/supinfo/CD000553StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/supinfo/CD000553StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="Rosa Simonetti shares first authorship with Giovanni Perricone and Helen Robbins as all three have worked together on the review and contributed equally."><a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#CD000553-cr-0004">Rosa G Simonetti</a><sup>a</sup></li> <li class="author custom-tooltip" title="Giovanni Perricone shares first authorship with Helen Robbins and Rosa Simonetti as all three have worked together on the review and contributed equally."><a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#CD000553-cr-0005">Giovanni Perricone</a><sup>a</sup></li> <li class="author custom-tooltip" title="Helen Robbins shares first authorship with Rosa Simonetti and Giovanni Perricone as all three have worked together on the review and contributed equally."><a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#CD000553-cr-0006">Helen L Robbins</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#CD000553-cr-0007">Narendra R Battula</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#CD000553-cr-0008">Martin O Weickert</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#CD000553-cr-0009">Robert Sutton</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information#CD000553-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Saboor Khan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information/en#CD000553-sec-0175">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 22 October 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000553.pub3">https://doi.org/10.1002/14651858.CD000553.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000553-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000553-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000553-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000553-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000553-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000553-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000553-abs-0001" lang="en"> <section id="CD000553-sec-0001"> <h3 class="title" id="CD000553-sec-0001">Background</h3> <p>People with liver cirrhosis who have had one episode of variceal bleeding are at risk for repeated episodes of bleeding. Endoscopic intervention and portosystemic shunts are used to prevent further bleeding, but there is no consensus as to which approach is preferable. </p> </section> <section id="CD000553-sec-0002"> <h3 class="title" id="CD000553-sec-0002">Objectives</h3> <p>To compare the benefits and harms of shunts (surgical shunts (total shunt (TS), distal splenorenal shunt (DSRS), or transjugular intrahepatic portosystemic shunt (TIPS)) versus endoscopic intervention (endoscopic sclerotherapy or banding, or both) with or without medical treatment (non‐selective beta blockers or nitrates, or both) for prevention of variceal rebleeding in people with liver cirrhosis. </p> </section> <section id="CD000553-sec-0003"> <h3 class="title" id="CD000553-sec-0003">Search methods</h3> <p>We searched the CHBG Controlled Trials Register; CENTRAL, in the Cochrane Library; MEDLINE Ovid; Embase Ovid; LILACS (Bireme); Science Citation Index ‐ Expanded (Web of Science); and Conference Proceedings Citation Index ‐ Science (Web of Science); as well as conference proceedings and the references of trials identified until 22 June 2020. We contacted study investigators and industry researchers. </p> </section> <section id="CD000553-sec-0004"> <h3 class="title" id="CD000553-sec-0004">Selection criteria</h3> <p>Randomised clinical trials comparing shunts versus endoscopic interventions with or without medical treatment in people with cirrhosis who had recovered from a variceal haemorrhage. </p> </section> <section id="CD000553-sec-0005"> <h3 class="title" id="CD000553-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane. When possible, we collected data to allow intention‐to‐treat analysis. For each outcome, we estimated a meta‐analysed estimate of treatment effect across trials (risk ratio for binary outcomes). We used random‐effects model meta‐analysis as our main analysis and as a means of presenting results. We reported differences in means for continuous outcomes without a meta‐analytic estimate due to high variability in their assessment among all trials. We assessed the certainty of evidence using GRADE. </p> </section> <section id="CD000553-sec-0006"> <h3 class="title" id="CD000553-sec-0006">Main results</h3> <p>We identified 27 randomised trials with 1828 participants. Three trials assessed TSs, five assessed DSRSs, and 19 trials assessed TIPSs. The endoscopic intervention was sclerotherapy in 16 trials, band ligation in eight trials, and a combination of band ligation and either sclerotherapy or glue injection in three trials. In eight trials, endoscopy was combined with beta blockers (in one trial plus isosorbide mononitrate). We judged all trials to be at high risk of bias. We assessed the certainty of evidence for all the outcome review results as very low (i.e. the true effects of the results are likely to be substantially different from the results of estimated effects). The very low evidence grading is due to the overall high risk of bias for all trials, and to imprecision and publication bias for some outcomes. Therefore, we are very uncertain whether portosystemic shunts versus endoscopy interventions with or without medical treatment have effects on all‐cause mortality (RR 0.99, 95% CI 0.86 to 1.13; 1828 participants; 27 trials), on rebleeding (RR 0.40, 95% CI 0.33 to 0.50; 1769 participants; 26 trials), on mortality due to rebleeding (RR 0.51, 95% CI 0.34 to 0.76; 1779 participants; 26 trials), and on occurrence of hepatic encephalopathy, both acute (RR 1.60, 95% CI 1.33 to 1.92; 1649 participants; 24 trials) and chronic (RR 2.51, 95% CI 1.38 to 4.55; 956 participants; 13 trials). No data were available regarding health‐related quality of life. </p> <p>Analysing each modality of portosystemic shunts individually (i.e. TS, DSRS, and TIPS) versus endoscopic interventions with or without medical treatment, we are very uncertain if each type of shunt has effect on all‐cause mortality: TS, RR 0.46, 95% CI 0.19 to 1.13; 164 participants; 3 trials; DSRS, RR 0.93, 95% CI 0.65 to 1.33; 352 participants; 4 trials; and TIPS, RR 1.10, 95% CI 0.92 to 1.31; 1312 participants; 19 trial; on rebleeding: TS, RR 0.28, 95% CI 0.14 to 0.56; 127 participants; 2 trials; DSRS, RR 0.26, 95% CI 0.11 to 0.65; 330 participants; 5 trials; and TIPS, RR 0.44, 95% CI 0.36 to 0.55; 1312 participants; 19 trials; on mortality due to rebleeding: TS, RR 0.25, 95% CI 0.06 to 0.96; 164 participants; 3 trials; DSRS, RR 0.31, 95% CI 0.13 to 0.74; 352 participants; 5 trials; and TIPS, RR 0.65, 95% CI 0.40 to 1.04; 1263 participants; 18 trials; on acute hepatic encephalopathy: TS, RR 1.66, 95% CI 0.70 to 3.92; 115 participants; 2 trials; DSRS, RR 1.70, 95% CI 0.94 to 3.08; 287 participants; 4 trials, TIPS, RR 1.61, 95% CI 1.29 to 1.99; 1247 participants; 18 trials; and chronic hepatic encephalopathy: TS, Fisher's exact test P = 0.11; 69 participants; 1 trial; DSRS, RR 4.87, 95% CI 1.46 to 16.23; 170 participants; 2 trials; and TIPS, RR 1.88, 95% CI 0.93 to 3.80; 717 participants; 10 trials. </p> <p>The proportion of participants with shunt occlusion or dysfunction was overall 37% (95% CI 33% to 40%). It was 3% (95% CI 0.8% to 10%) following TS, 7% (95% CI 3% to 13%) following DSRS, and 47.1% (95% CI 43% to 51%) following TIPS. Shunt dysfunction in trials utilising polytetrafluoroethylene‐covered stents was 17% (95% CI 11% to 24%). </p> <p>Length of inpatient hospital stay and cost were not comparable across trials.</p> <p>Funding was unclear in 16 trials; 11 trials were funded by government, local hospitals, or universities. </p> </section> <section id="CD000553-sec-0007"> <h3 class="title" id="CD000553-sec-0007">Authors' conclusions</h3> <p>Evidence on whether portosystemic shunts versus endoscopy interventions with or without medical treatment in people with cirrhosis and previous hypertensive portal bleeding have little or no effect on all‐cause mortality is very uncertain. Evidence on whether portosystemic shunts may reduce bleeding and mortality due to bleeding while increasing hepatic encephalopathy is also very uncertain. We need properly conducted trials to assess effects of these interventions not only on assessed outcomes, but also on quality of life, costs, and length of hospital stay. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000553-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000553-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000553-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000553-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000553-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD000553-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD000553-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000553-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000553-abs-0002" lang="en"> <h3>Shunts compared with endoscopic intervention to prevent further episodes of variceal bleeding in people with liver cirrhosis </h3> <p><b>Background</b> </p> <p>People with scarring of the liver (cirrhosis) may develop high pressure in the portal vein (the vein that carries blood from the gut to the liver). This high pressure results in abnormally dilated veins (varices) in the gullet (oesophagus), in the stomach, or in the intestine, which may cause life‐threatening bleeding. People who have bled once are at high risk of bleeding in the future, so it is important to prevent further bleeding episodes in these people. Different treatment options are available to prevent further bleeding. One option is endoscopic treatment, which uses a flexible camera to examine the affected area and to seal varices with elastic bands, or to inject the varices with a substance to close the veins. A second option is 'shunting', which diverts blood flow away from the problematic vein, reducing pressure and thereby reducing the chance of bleeding. There are three main types of shunts: total shunt, distal splenorenal shunt, and transjugular intrahepatic portosystemic shunt. Total shunt and distal splenorenal shunt were more commonly used in the past and require invasive surgical procedures. TIPS are now much more commonly used, as they do not require invasive surgery. </p> <p><b>Review question</b> </p> <p>The aim of this Cochrane Review was to compare shunts versus endoscopic treatments with or without further medications in people with liver cirrhosis who had previously bled from varices, by collecting and analysing all relevant studies in this topic area and by reviewing the evidence. </p> <p><b>Study characteristics</b> </p> <p>In June 2020, we reviewed the evidence. We found 27 randomised clinical trials (trials where participants are allocated to groups at random) involving 1828 participants. Three trials investigated total shunt (164 participants); five trials investigated distal splenorenal shunt (352 participants); and 19 trials investigated transjugular intrahepatic portosystemic shunt (1312 participants). The source of funding was unclear in 16 trials. Eleven trials were funded by the government or received grants from local hospitals or universities. </p> <p><b>Results</b> </p> <p>Evidence suggesting whether shunt treatments compared with endoscopic treatments with or without further medications alter the overall risk of death from any cause (all‐cause mortality), reduce the risk of bleeding from varices, or reduce the risk of dying from bleeding varices (death due to variceal bleeding) was very uncertain. </p> <p>Evidence that people treated with shunts compared with endoscopic treatments with or without further medications are at increased risk of acute hepatic encephalopathy (brain dysfunction associated with liver disease) or chronic hepatic encephalopathy (brain dysfunction that occurs repeatedly or does not fully improve) was also very uncertain. </p> <p>We could not conclude with certainty whether people treated with shunt stayed in hospital longer than people treated with endoscopy with or without further medications, or which treatment was more expensive, as we were not confident that combining the results from different studies would produce a meaningful result. No trials reported on the impact of treatments on patient quality of life. </p> <p><b>Risk of bias</b> </p> <p>The results of our analyses must be interpreted with caution due to concerns about the quality of included trials. Weaknesses in the design of these studies could influence results, making them potentially misleading. </p> <p><b>Conclusions</b> </p> <p>We cannot say for sure that portosystemic shunts when compared with endoscopic treatment associated sometimes with medical treatment modify the risk of overall death (all‐cause mortality), reduce the risk of repeated episodes of bleeding, or increase the risk of developing hepatic encephalopathy. We need properly conducted trials assessing important outcomes for people with cirrhosis and health providers. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000553-sec-0165" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000553-sec-0165"></div> <h3 class="title" id="CD000553-sec-0166">Implications for practice</h3> <section id="CD000553-sec-0166"> <p>Overall, the very low certainty of evidence on the effects of shunts in comparison with endoscopic interventions with or without medical treatment prevents us from drawing definitive conclusions about the role of shunts in preventing rebleeding and mortality due to rebleeding. We are very uncertain whether shunts had an impact on mortality. Shunts are used at the cost of one having to undergo major surgery or a radiological interventional procedure (with its attendant risks) and the need for a specialised team, which could be different in different countries and between low‐ and high‐income countries. So, the decision on which treatment should be used to prevent further bleeding and the choice of the type of treatment to be used could be based on the physician's and the patient's values and preferences after they have understood the uncertainty on which these choices are based and the significant risks of publication bias behind these results. </p> </section> <h3 class="title" id="CD000553-sec-0167">Implications for research</h3> <section id="CD000553-sec-0167"> <p>We propose adequately powered, adequately conducted, properly reported multi‐centre randomised clinical trials in this area. These trials should stratify patients at high risk of rebleeding and should consider an 'early' shunt procedure (in the early stage of the bleeding). The trials should consider to investigate hepatic venous pressure gradient (HVPG) as a prognostic variable at entry. The trials need to strive for outcome assessors blinded to intervention group. The issues of effects of interventions on quality of life and costs and their impact on length of hospital stay should also be adequately addressed. As patient recruitment will continue to be an impediment, the only way around this is the pooling of resources across different centres with similar interests. Furthermore, trial reporting should be done in such a way that it facilitates future meta‐analyses. These recommendations are not specific to the comparisons addressed here, but they have implications for randomised clinical trials examining the management of portal hypertension in general. Future trials should be designed according to the SPIRIT recommendations (<a href="http://www.spirit-statement.org" target="_blank">www.spirit-statement.org</a>), and trial details should be reported in keeping with the CONSORT recommendations (<a href="http://www.consort-statement.org" target="_blank">www.consort-statement.org</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000553-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000553-sec-0008"></div> <div class="table" id="CD000553-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis and with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> hospital; tertiary referral centres<br/><b>Intervention:</b> shunt intervention (total shunt (TS), distal splenorenal shunt (DSRS), or transjugular intrahepatic portosystemic shunt (TIPS))<br/><b>Comparison:</b> endoscopic intervention with or without medical treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention with or without medical treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with shunts</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 32.9 months (range 11.7 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.99 (0.86 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1828</p> <p>(27 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>288 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>286 per 1000 (248 to 325)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 33.8 months (range 13.5 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.40 (0.33 to 0.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1769<br/>(26 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/>(143 to 216) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 33.5 months (range 11.7 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.51 (0.34 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1779</p> <p>(26 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>48 per 1000 (32 to 72)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 33.8 months (range 13.5 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60 (1.33 to 1.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1649<br/>(24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(246 to 355) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 28.5 months (range 13.5 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.51 (1.38 to 4.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>956<br/>(13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(37 to 123) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; OIS: optimal information size; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); publication bias (‐1 level).<br/><sup>b</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); publication bias (‐1 level).<br/><sup>c</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: optimal information size (OIS) as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>d</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>e</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000553-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis and with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> hospital tertiary care centres<br/><b>Intervention</b> : total shunt<br/><b>Comparison:</b> endoscopic intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention with or without medical treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with total shunt</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 32.4 months (range 11.7 to 65.1)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.46 (0.19 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>164<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>198 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>91 per 1000<br/>(38 to 224) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 42.8 months (range 20.4 to 65.1)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.28 (0.14 to 0.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/>(61 to 244) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 32.4 months (range 11.7 to 65.1)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.25 (0.06 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>164</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>136 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 per 1000 (8 to 131)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 42.8 months (range 20.4 to 65.1)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.66 (0.70 to 3.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>115<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000<br/>(86 to 482) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 20.4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a single trial with 3/34 events in total shunt group and 0/35 in endoscopy with or without drugs group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: optimal information size (OIS) as calculated by GRADE was not met (‐1 level).<br/><sup>b</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>c</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>d</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met; there were few events and the CI included appreciable benefit and harm (‐2 levels). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000553-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Distal splenorenal shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Distal splenorenal shunt (DSRS) compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis and with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> hospital tertiary care centres<br/><b>Intervention:</b> DSRS<br/><b>Comparison:</b> endoscopic intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with distal splenorenal shunt</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.93 (0.65 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>352<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>469 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>436 per 1000 (305 to 624)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26 (0.11 to 0.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000<br/>(50 to 298) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.31 (0.13 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>352</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>126 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000 (16 to 93)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70 (0.94 to 3.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>287<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000<br/>(131 to 428) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 62.5 months (range 27.1 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.51 (1.38 to 4.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>170<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(37 to 123) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: optimal information size (OIS) as calculated by GRADE was not met; (‐1 levels); heterogeneity (‐1 level).<br/><sup>b</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); heterogeneity (‐1 level).<br/><sup>c</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>d</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>e</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 levels). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD000553-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Transjugular intrahepatic portosystemic shunt compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Transjugular intrahepatic portosystemic shunt (TIPS) compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> tertiary care centres<br/><b>Intervention:</b> TIPS<br/><b>Comparison:</b> endoscopic intervention with or without medical treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention with or without medical treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with TIPS</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24.5 months (range 13.5 to 46.2)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.10 (0.92 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1312</p> <p>(19 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>252 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>277 per 1000</p> <p>(232 to 330)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 24.5 months (range 13.5 to 46.2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44 (0.36 to 0.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1312<br/>(19 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>425 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/>(153 to 234) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 24.9 months (range 13.5 to 46.2)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.65 (0.40 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1263</p> <p>(18 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>53 per 1000</p> <p>(33 to 85)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 24.5 months (range 13.5 to 46.2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.61 (1.29 to 1.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1247<br/>(18 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>324 per 1000<br/>(259 to 400) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 22.5 months (range 13.5 to 46.2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.88 (0.93 to 3.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>717<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(26 to 106) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: Confidence interval; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty :</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); optimal information size (OIS) as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>b</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); publication bias (‐1 level).<br/><sup>c</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>d</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>e</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000553-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000553-sec-0009"></div> <section id="CD000553-sec-0010"> <h3 class="title" id="CD000553-sec-0010">Description of the condition</h3> <p>Portal hypertension is a common complication of liver cirrhosis, usually defined as an increase in pressure within the portal venous system. Portal hypertension leads to development of portosystemic collateral vessels, and of these, gastro‐oesophageal varices are the most clinically relevant (<a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>; <a href="./references#CD000553-bbs2-0060" title="CordonJP , TorresCF , GarciaAB , RodriguezFG , Suarez de PargaJM . Endoscopic management of esophageal varices. World Journal of Gastrointestinal Endoscopy2012;4(7):312-22. [DOI: 10.4253/wjge.v4.i7.312] [MEDLINE: 22816012]">Cordon 2012</a>). At the time of diagnosis of cirrhosis, around 30% of people with cirrhosis have gastro‐oesophageal varices; 90% of people with cirrhosis will develop varices during their lifetime (<a href="./references#CD000553-bbs2-0062" title="D'AmicoG . Esophageal varices: from appearance to rupture; natural history and prognostic indicators. In: Groszmann RJ, Bosch J (Editors). Portal Hypertension in the 21st Century. King's College London, UK: Springer, Kluwer Academic Publishers, 2004.">D'Amico 2004</a>; <a href="./references#CD000553-bbs2-0060" title="CordonJP , TorresCF , GarciaAB , RodriguezFG , Suarez de PargaJM . Endoscopic management of esophageal varices. World Journal of Gastrointestinal Endoscopy2012;4(7):312-22. [DOI: 10.4253/wjge.v4.i7.312] [MEDLINE: 22816012]">Cordon 2012</a>). The presence and extent of varices are related to the severity of cirrhosis, and individuals with decompensated liver cirrhosis are at highest risk (<a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>). Varices are at high risk of rupture, often resulting in catastrophic haemorrhage ― a major cause of death in people with cirrhotic liver disease. Other causes of bleeding related to portal hypertension in cirrhosis are hypertensive gastropathy and, less frequently, duodenopathy or colopathy. Improved treatment protocols have improved survival; however, mortality rates remain at around 15% to 20% for a first bleed (<a href="./references#CD000553-bbs2-0056" title="CarbonellN , PauwelsA , SerfatyL , FourdanO , LevyVG , PouponR . Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology (Baltimore, Md.)2004;40(3):652-9. [DOI: 10.1002/hep.20339] [MEDLINE: 15349904]">Cabonell 2004</a>). Early and vigorous resuscitation and early endoscopy, preferably in specialist units, are essential for these individuals (<a href="./references#CD000553-bbs2-0071" title="GraceND . Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. American Journal of Gastroenterology1997;92(7):1081-91. [MEDLINE: 9219775]">Grace 1997</a>; <a href="./references#CD000553-bbs2-0074" title="HerreraJL . Management of acute variceal bleeding. Clinics in Liver Disease2014;18(2):347-57. [DOI: 10.1016/j.cld.2014.01.001] [MEDLINE: 24679499]">Herrera 2014</a>). However, people who survive their first variceal bleed are at high risk of further episodes of bleeding ('rebleeding'). The risk of variceal rebleeding is up to 60% within one year, with mortality around 33% (<a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>; <a href="./references#CD000553-bbs2-0049" title="BariK , Garcia-TsaoG . Treatment of portal hypertension. World Journal of Gastroenterology2012;18(11):1166-75.">Bari 2012</a>). Risk factors specifically for rebleeding have not been well defined, and factors linked to the risk of initial bleeding include the size of varices, the appearance of varices (i.e. red wale marks), and variceal pressure (<a href="./references#CD000553-bbs2-0108" title="ZhaoJR , WangGC , HuJH , ZhangCQ . Risk factors for early rebleeding and mortality in acute variceal hemorrhage. World Journal of Gastroenterology2014;20(47):17941-8. [DOI: 10.3748/wjg.v20.i47.17941] [MEDLINE: 25548492]">Zhao 2014</a>). </p> <p>Due to high risk of rebleeding, secondary prophylaxis is required for individuals with a history of variceal haemorrhage. </p> <p>Many tools have been used to reduce the risk of rebleeding, such as surgical shunts to reduce portal hypertension, endoscopic obliteration of varices, and drugs like beta blockers (<a href="./references#CD000553-bbs2-0066" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406-60. [DOI: 10.1016/j.jhep.2018.03.024] [MEDLINE: 29653741]">EASL 2018</a>). Published guidelines recommend non‐selective beta‐blockers (NSBBs) and endoscopic band ligation (EBL) as preferable first‐line treatment for secondary prevention of variceal haemorrhage for cirrhotic portal hypertension (<a href="./references#CD000553-bbs2-0065" title="deFranchisR , Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of Hepatology2015;63(3):743-52. [DOI: 10.1016/j.jhep.2015.05.022] [MEDLINE: 26047908]">de Franchis 2015</a>; <a href="./references#CD000553-bbs2-0069" title="Garcia-TsaoG , AbraldesJG , BerzigottiA , BoschJ . Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology (Baltimore, Md.)2017;65(1):310-35. [DOI: 10.1002/hep.28906] [MEDLINE: 27786365]">Garcia‐Tsao 2017</a>; <a href="./references#CD000553-bbs2-0066" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406-60. [DOI: 10.1016/j.jhep.2018.03.024] [MEDLINE: 29653741]">EASL 2018</a>) because combination treatment decreases the probability of rebleeding compared to monotherapy or either EBL or drug treatment. Recommendations are based on recent meta‐analyses showing that combining EBL with NSBBs reduces overall rebleeding, variceal rebleeding, and bleeding‐related mortality versus banding alone (<a href="./references#CD000553-bbs2-0095" title="ThieleM , KragA , RohdeU , GluudLL . Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Alimentary Pharmacology &amp; Therapeutics2012;35(10):1155–65. [DOI: 10.1111/j.1365-2036.2012.05074.x] [MEDLINE: 22449261]">Thiele 2012</a>), and that adding NSBBs to EBL improves survival, whereas adding EBL to NSBBs has no effect on mortality (<a href="./references#CD000553-bbs2-0084" title="PuenteA , Hernandez-GeaV , GrauperaI , RoqueM , ColomoA , PocaM , et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver International2014;34(6):823-33. [DOI: 10.1111/liv.12452] [MEDLINE: 24373180]">Puente 2014</a>). </p> </section> <section id="CD000553-sec-0011"> <h3 class="title" id="CD000553-sec-0011">Description of the intervention</h3> <p>Portosystemic shunts represent an alternative approach for reducing portal hypertension and thereby the risk of rupture of varices. The role of portosystemic shunts, above all TIPSs in the last two decades, is usually limited to rescue treatment for acute persistent bleeding or rebleeding despite conventional treatment (i.e. endoscopic intervention and/or medical‐vasoactive drugs) and is limited for secondary prevention of bleeding. Current international guidelines suggest TIPSs for prevention of rebleeding in patients intolerant to beta blockers, or with contraindications to their use and/or concomitant refractory ascites (<a href="./references#CD000553-bbs2-0065" title="deFranchisR , Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. Journal of Hepatology2015;63(3):743-52. [DOI: 10.1016/j.jhep.2015.05.022] [MEDLINE: 26047908]">de Franchis 2015</a>; <a href="./references#CD000553-bbs2-0066" title="European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology2018;69(2):406-60. [DOI: 10.1016/j.jhep.2018.03.024] [MEDLINE: 29653741]">EASL 2018</a>), or in selected individuals due to patient choice (<a href="./references#CD000553-bbs2-0099" title="TripathiD , StanleyAJ , HayesPC , PatchD , MillsonC , MehrzadH , et al. UK Guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut2015;64(11):1680-704. [DOI: 10.1136/gutjnl-2015-309262] [MEDLINE: 25887380]">Tripathi 2015</a>). However, shunting following the first episode of variceal bleeding could provide more effective treatment earlier in a person's disease pathway, potentially avoiding repeated admissions with variceal bleeding, and thereby possibly reducing mortality. In addition, portosystemic shunts confer the further advantage of being a 'once‐only treatment', potentially preventing repeated hospital visits. </p> <p>Therapeutic portosystemic shunts are artificial conduits connecting the portal and systemic circulation; they may be inserted surgically or via interventional radiology. Shunts may be classified according to their haemodynamic consequences: the total surgical shunt (TS) has no prograde hepatopetal flow through the portal vein and, therefore, all portal blood is diverted into the systemic circulation (<a href="./references#CD000553-bbs2-0059" title="CollinsJC , SarfehJ . Surgical management of portal hypertension. Western Journal of Medicine1995;162(6):527-35. [MEDLINE: 7618313]">Collins 1995</a>). In contrast, selective or partial shunts preserve pre‐existing hepatopetal portal vein flow (<a href="./references#CD000553-bbs2-0059" title="CollinsJC , SarfehJ . Surgical management of portal hypertension. Western Journal of Medicine1995;162(6):527-35. [MEDLINE: 7618313]">Collins 1995</a>). The distal splenorenal shunt (DSRS) is a surgically placed selective shunt that has been associated with improved preservation of liver function and hence lower morbidity as compared to TS, although lower mortality has not been conclusively demonstrated (<a href="./references#CD000553-bbs2-0061" title="D'AmicoG , PagliaroL , BoschJ . The treatment of portal hypertension: a meta-analytic review. Hepatology (Baltimore, Md.)1995;22(1):332-54. [DOI: 10.1002/hep.1840220145] [MEDLINE: 7601427]">D'Amico 1995</a>). The selectivity of DSRSs can be further improved if the venous collaterals between the splenic vein and the pancreas are disconnected ‐ an additional procedure that is particularly important for alcoholics (<a href="./references#CD000553-bbs2-0103" title="WarrenWD , Millikan WJ Jr, HendersonJM , Abu-ElmagdKM , GallowayJR , Shires GT 3rd, et al. Splenopancreatic disconnection. Improved selectivity of distal splenorenal shunt. Annals of Surgery1986;204(4):346-55. [DOI: 10.1097/00000658-198610000-00002] [MEDLINE: 3532968]">Warren 1986</a>). Since the early 1990s, the radiologically placed transjugular intrahepatic portosystemic shunt (TIPS) has grown in popularity (<a href="./references#CD000553-bbs2-0078" title="LaBergeJM , RingEJ , GordonRL , LakeJR , DohertyMM , SombergKA , et al. Creation of transjugular intrahepatic portosystemic shunts with the wall stent endoprosthesis: results in 100 patients. Radiology1993;187(2):413-20. [DOI: 10.1148/radiology.187.2.8475283] [MEDLINE: 8475283]">LaBerge 1993</a>). It is inserted radiologically by minimal access and can usually be placed more quickly than a surgical shunt (<a href="./references#CD000553-bbs2-0053" title="Brown RS Jr, LakeJR . Transjugular intrahepatic portosystemic shunt as a form of treatment for portal hypertension: indications and contraindications. Advances in Internal Medicine1997;42:485-504. [MEDLINE: 9048128]">Brown 1997</a>). In essence, it is a side‐to‐side portosystemic shunt. TIPSs can, however, lead to serious acute and chronic complications and small but significant mortality (<a href="./references#CD000553-bbs2-0057" title="CasadoM , BoschJ , Garcia-PaganJC , BruC , BanaresR , BandiJC , et al. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology1998;114(6):1296-303. [MEDLINE: 9609767] [10.1016/s0016-5085(98)70436-6]">Casado 1998</a>). Stenosis and occlusion rates have been reported to exceed 75% at two years in randomised trials using TIPSs (<a href="./references#CD000553-bbs2-0082" title="PapatheodoridisGV , GoulisJ , LeandroG , PatchD , BurroughsAK . Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology (Baltimore, Md.)1999;30(3):612-22. [DOI: 10.1002/hep.510300316] [MEDLINE: 10462365]">Papatheodoridis 1999</a>), although the use of polytetrafluoroethylene‐coated stents in modern practice greatly reduces rates of stent dysfunction (<a href="./references#CD000553-bbs2-0054" title=" Bureau C , PaganJC , LayrarguesGP , MetivierS , BellotP , PerreaultP , et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver International2007;27(6):742-7. [DOI: 10.1111/j.1478-3231.2007.01522.x] [MEDLINE: 17617116]">Bureau 2007</a>). </p> <p>Endoscopic treatments are well established, and various techniques may be practised. Among these interventions, sclerotherapy represents an approach by which varices are obliterated through injection of sclerosants (such as ethanolamine oleate, polidocanol, sodium morrhuate, or other agents) (<a href="./references#CD000553-bbs2-0060" title="CordonJP , TorresCF , GarciaAB , RodriguezFG , Suarez de PargaJM . Endoscopic management of esophageal varices. World Journal of Gastrointestinal Endoscopy2012;4(7):312-22. [DOI: 10.4253/wjge.v4.i7.312] [MEDLINE: 22816012]">Cordon 2012</a>). A further alternative is endoscopic glue injection, whereby tissue adhesives (n‐butyl‐2‐cyanoacrylate (Histoacryl) or isobutyl‐2‐cyanoacrylate (Bucrylate)) are injected into varices (<a href="./references#CD000553-bbs2-0060" title="CordonJP , TorresCF , GarciaAB , RodriguezFG , Suarez de PargaJM . Endoscopic management of esophageal varices. World Journal of Gastrointestinal Endoscopy2012;4(7):312-22. [DOI: 10.4253/wjge.v4.i7.312] [MEDLINE: 22816012]">Cordon 2012</a>) ‐ a technique that is of particular use in the management of gastric varices (<a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>). An alternative is variceal band ligation ('variceal banding'): varices are obliterated by application of elastic bands via endoscopy (<a href="./references#CD000553-bbs2-0060" title="CordonJP , TorresCF , GarciaAB , RodriguezFG , Suarez de PargaJM . Endoscopic management of esophageal varices. World Journal of Gastrointestinal Endoscopy2012;4(7):312-22. [DOI: 10.4253/wjge.v4.i7.312] [MEDLINE: 22816012]">Cordon 2012</a>; <a href="./references#CD000553-bbs2-0099" title="TripathiD , StanleyAJ , HayesPC , PatchD , MillsonC , MehrzadH , et al. UK Guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut2015;64(11):1680-704. [DOI: 10.1136/gutjnl-2015-309262] [MEDLINE: 25887380]">Tripathi 2015</a>). It is important to note that effective endoscopic intervention generally requires multiple treatments; typically, varices are banded with an interval of one to four weeks until eradication of varices has been achieved (<a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>; <a href="./references#CD000553-bbs2-0099" title="TripathiD , StanleyAJ , HayesPC , PatchD , MillsonC , MehrzadH , et al. UK Guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut2015;64(11):1680-704. [DOI: 10.1136/gutjnl-2015-309262] [MEDLINE: 25887380]">Tripathi 2015</a>). Endoscopic intervention does carry risk of complications, such as provocation of further bleeding episodes, oesophageal ulcers, or bacteraemia (<a href="./references#CD000553-bbs2-0094" title="TerblancheJ , BornmanPC , KahnD , JonkerMA , CampbellJA , WrightJ , et al. Failure of repeated injection sclerotherapy to improve long-term survival after oesophageal variceal bleeding. A five-year prospective controlled clinical trial. Lancet1983;2(8363):1328-32. [DOI: 10.1016/s0140-6736(83)91090-5] [MEDLINE: 6139669]">Terblanche 1983</a>; <a href="./references#CD000553-bbs2-0081" title="McIntyreN , BurroughsAK . Cirrhosis and portal hypertension. In: WeatherallDJ , LedinghamJGG , WarrellDA , editors(s). Oxford Textbook of Medicine. London, UK: Churchill Livingstone, 1996:2085-100.">McIntyre 1996</a>; <a href="./references#CD000553-bbs2-0060" title="CordonJP , TorresCF , GarciaAB , RodriguezFG , Suarez de PargaJM . Endoscopic management of esophageal varices. World Journal of Gastrointestinal Endoscopy2012;4(7):312-22. [DOI: 10.4253/wjge.v4.i7.312] [MEDLINE: 22816012]">Cordon 2012</a>). However, endoscopic techniques are well established, are usually well tolerated, and significantly reduce rates of rebleeding compared with controls (<a href="./references#CD000553-bbs2-0073" title="GrahamDY , SmithJL . The course of patients after variceal haemorrhage. Gastroenterology1981;80(4):800-9. [MEDLINE: 6970703]">Graham 1981</a>). Current consensus suggests that variceal banding is the endoscopic method of choice (<a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>; <a href="./references#CD000553-bbs2-0064" title="deFranchisR , Braveno V Faculty. Revising consensus in portal hypertension: report of the Baverno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Journal of Hepatology2010;53(4):762-8. [DOI: 10.1016/j.jhep.2010.06.004] [MEDLINE: 20638742]">de Franchis 2010</a>; <a href="./references#CD000553-bbs2-0099" title="TripathiD , StanleyAJ , HayesPC , PatchD , MillsonC , MehrzadH , et al. UK Guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut2015;64(11):1680-704. [DOI: 10.1136/gutjnl-2015-309262] [MEDLINE: 25887380]">Tripathi 2015</a>) because it is more effective and has lower complication rates than sclerotherapy (<a href="./references#CD000553-bbs2-0079" title="LaineL , CookD . Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Annals of Internal Medicine1995;123(4):280-7. [DOI: 10.7326/0003-4819-123-4-199508150-00007] [MEDLINE: 7611595]">Laine 1995</a>; <a href="./references#CD000553-bbs2-0063" title="DaiC , LiuWX , JiangM , SunMJ . Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. World Journal of Gastroenterology2015;21(8):2534-41. [DOI: 10.3748/wjg.v21.i8.2534] [MEDLINE: 25741164]">Dai 2015</a>). </p> <p>Endoscopic treatments serve to locally obliterate varices. By obliterating varices, variceal rupture and haemorrhage may be prevented. However, endoscopic treatment alone does not combat portal hypertension; therefore, it does not target the underlying pathophysiology of varices formation (<a href="./references#CD000553-bbs2-0102" title="VillanuevaC , BalanzoJ . Variceal bleeding: pharmacological treatment and prophylactic strategies. Drugs2008;68(16):2303-24. [DOI: 10.2165/0003495-200868160-00004] [MEDLINE: 18973395]">Villanueva 2008</a>). As a result, endoscopic treatment is generally combined with pharmacological treatment, typically long‐term treatment with non‐cardioselective beta blockers (NSBBs), such as propranolol (<a href="./references#CD000553-bbs2-0050" title="BernardB , LebrecD , MathurinP , OpolonP , PoynardT . Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Journal of Hepatology1997;26(2):312-24. [DOI: 10.1016/s0168-8278(97)80047-5] [MEDLINE: 9059952]">Bernard 1997</a>, <a href="./references#CD000553-bbs2-0099" title="TripathiD , StanleyAJ , HayesPC , PatchD , MillsonC , MehrzadH , et al. UK Guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut2015;64(11):1680-704. [DOI: 10.1136/gutjnl-2015-309262] [MEDLINE: 25887380]">Tripathi 2015</a>), with or without nitrates. Beta blockade acts to reduce portal pressure by decreasing cardiac output (blockade of beta1 receptors), promoting splanchnic vasoconstriction (blockade of beta2 receptors), and reducing blood flow through collateral vessels (<a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>; <a href="./references#CD000553-bbs2-0102" title="VillanuevaC , BalanzoJ . Variceal bleeding: pharmacological treatment and prophylactic strategies. Drugs2008;68(16):2303-24. [DOI: 10.2165/0003495-200868160-00004] [MEDLINE: 18973395]">Villanueva 2008</a>), hence reducing the risk of variceal bleeding. Combining pharmacological and endoscopic treatments has a synergistic effect by targeting both localised and decompressing varices (<a href="./references#CD000553-bbs2-0050" title="BernardB , LebrecD , MathurinP , OpolonP , PoynardT . Propranolol and sclerotherapy in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Journal of Hepatology1997;26(2):312-24. [DOI: 10.1016/s0168-8278(97)80047-5] [MEDLINE: 9059952]">Bernard 1997;</a><a href="./references#CD000553-bbs2-0102" title="VillanuevaC , BalanzoJ . Variceal bleeding: pharmacological treatment and prophylactic strategies. Drugs2008;68(16):2303-24. [DOI: 10.2165/0003495-200868160-00004] [MEDLINE: 18973395]">Villanueva 2008;</a><a href="./references#CD000553-bbs2-0099" title="TripathiD , StanleyAJ , HayesPC , PatchD , MillsonC , MehrzadH , et al. UK Guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut2015;64(11):1680-704. [DOI: 10.1136/gutjnl-2015-309262] [MEDLINE: 25887380]">Tripathi 2015</a>). </p> </section> <section id="CD000553-sec-0012"> <h3 class="title" id="CD000553-sec-0012">How the intervention might work</h3> <p>Portosystemic shunts directly target portal hypertension. Portosystemic shunts act to divert blood from the portal circulation to the systemic circulation, decompressing varices and hence preventing rebleeding. By diverting blood flow, portosystemic shunts might provide a more effective treatment option than endoscopy. </p> <p>Historically, surgical creation of a shunt (e.g. distal splenorenal shunt, portacaval shunt) was performed to control bleeding and prevent recurrent haemorrhage if other methods failed. However, placement of TIPSs has become the preferred intervention in this setting because covered stents have favourable long‐term patency and the risks and morbidity associated with major abdominal surgery are avoided. </p> </section> <section id="CD000553-sec-0013"> <h3 class="title" id="CD000553-sec-0013">Why it is important to do this review</h3> <p>This current review represents an update of a Cochrane Review first published in 2006 (<a href="./references#CD000553-bbs2-0112" title="KhanSA , Tudur SmithC , WilliamsonPR , SuttonR . Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD000553. [DOI: 10.1002/14651858.CD000553.pub2] [MEDLINE: 17054131]">Khan 2006</a>), based on a protocol originally published in 1997 (<a href="./references#CD000553-bbs2-0111" title="KhanSA , WilliamsonP , SuttonR , TudurC . Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database of Systematic Reviews1997, Issue 4. Art. No: CD000553. [DOI: 10.1002/14651858.CD000553]">Khan 1997</a>). </p> <p>As stated above, shunts provide a once‐only treatment modality for prevention of variceal rebleeding and could potentially be more effective than endoscopic treatment for preventing repeated episodes of variceal bleeding. However, portosystemic shunting does have potential drawbacks. Portosystemic shunting, particularly with surgical shunts, represents a more invasive option than endoscopic treatment. Also, by diverting blood flow away from the liver, portosystemic shunts carry increased risk of hepatic encephalopathy, and portosystemic shunts pose a risk for shunt failure or dysfunction (<a href="./references#CD000553-bbs2-0080" title="LucaA , D'AmicaG , La GallaR , MidiriM , MorabitoA , PagliaroL . TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology1999;212(2):411-21. [DOI: 10.1148/radiology.212.2.r99au46411] [MEDLINE: 10429698]">Luca 1999</a>; <a href="./references#CD000553-bbs2-0082" title="PapatheodoridisGV , GoulisJ , LeandroG , PatchD , BurroughsAK . Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology (Baltimore, Md.)1999;30(3):612-22. [DOI: 10.1002/hep.510300316] [MEDLINE: 10462365]">Papatheodoridis 1999;</a><a href="./references#CD000553-bbs2-0055" title="BurroughsAK , VangeliM . Transjugular Intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scandinavian Journal of Gastroenterology2002;37(3):249-52. [DOI: 10.1080/003655202317284138] [MEDLINE: 11916185]">Burroughs 2002</a>; <a href="./references#CD000553-bbs2-0068" title="Garcia-TsaoG , SanyalAJ , GraceND , CareyWD , The Practice Guidelines Committee of the American Association of the Study of Liver Diseases, The Practice Parameters Committee of the American College of Gastroenterology. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology (Baltimore, Md.)2007;46(3):922-38. [DOI: 10.1002/hep.21907] [MEDLINE: 17879356]">Garcia‐Tsao 2007</a>). Therefore, it is important to ask whether a case can be made for more widespread use of shunting, and also to assess the relative safety and risk of complications of portosystemic shunting compared with endoscopic treatment. </p> <p>In one meta‐analysis in <a href="./references#CD000553-bbs2-0093" title="SpinaGP , HendersonJM , RikkersLF , TeresJ , BurroughsAK , ConnHO , et al. Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. A meta-analysis of 4 randomized clinical trials. Journal of Hepatology1992;16(3):338-45. [DOI: 10.1016/s0168-8278(05)80666-x] [MEDLINE: 1487611]">Spina 1992a</a>, DSRSs significantly reduced the risk of rebleeding compared to endoscopic sclerotherapy without increasing the risk of chronic hepatic encephalopathy. However, DSRSs did not significantly affect overall death risk. In <a href="./references#CD000553-bbs2-0061" title="D'AmicoG , PagliaroL , BoschJ . The treatment of portal hypertension: a meta-analytic review. Hepatology (Baltimore, Md.)1995;22(1):332-54. [DOI: 10.1002/hep.1840220145] [MEDLINE: 7601427]">D'Amico 1995</a>, a comparison of TSs and DSRSs is reported without differences between the two treatments. Several published meta‐analyses have assessed TIPSs versus endoscopic intervention (<a href="./references#CD000553-bbs2-0080" title="LucaA , D'AmicaG , La GallaR , MidiriM , MorabitoA , PagliaroL . TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology1999;212(2):411-21. [DOI: 10.1148/radiology.212.2.r99au46411] [MEDLINE: 10429698]">Luca 1999</a>; <a href="./references#CD000553-bbs2-0082" title="PapatheodoridisGV , GoulisJ , LeandroG , PatchD , BurroughsAK . Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology (Baltimore, Md.)1999;30(3):612-22. [DOI: 10.1002/hep.510300316] [MEDLINE: 10462365]">Papatheodoridis 1999;</a><a href="./references#CD000553-bbs2-0055" title="BurroughsAK , VangeliM . Transjugular Intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scandinavian Journal of Gastroenterology2002;37(3):249-52. [DOI: 10.1080/003655202317284138] [MEDLINE: 11916185]">Burroughs 2002</a>; <a href="./references#CD000553-bbs2-0109" title="ZhengM , ChenY , BaiJ , ZengQ , YouJ , JinR , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy in the secondary prophylaxis of variceal rebleeding in cirrhotic patients: meta-analysis update. Journal of Clinical Gastroenterology2008;42(5):507-15. [DOI: 10.1097/MCG.0b013e31815576e6] [MEDLINE: 18344888]">Zheng 2008</a>), all showing no differences in mortality, reduction in rebleeding, and increased incidence of hepatic encephalopathy. More recently, a multiple‐treatments meta‐analysis compared TIPSs, endoscopic treatment modalities, pharmacotherapies, and combination treatments (<a href="./references#CD000553-bbs2-0091" title="ShiKQ , LiuWY , PanZZ , LinZF , ChenSL , ChenYP , et al. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. European Journal of Clinical Investigation2013;43(8):844-54. [DOI: 10.1111/eci.12115] [MEDLINE: 23725530]">Shi 2013</a>), showing that endoscopic band ligation combined with argon plasma coagulation resulted in the best profile of reduction in rebleeding rate and all‐cause mortality, and TIPSs had the greatest impact on reducing mortality rate due to rebleeding. Further, a 2019 meta‐analysis compared portosystemic shunts (including transjugular portosystemic shunt) to endoscopy, but in this review, authors also included trials utilising emergency shunts to treat active bleeding (<a href="./references#CD000553-bbs2-0110" title="ZhouGP , SunLY , WeiL , QuW , ZengZG , LiuY , et al. Comparision between portosystemic shunts and endoscopic therapy for prevention of variceal re-bleeding: a systematic review and meta-analysis. Chinese Medical Journal2019;132(9):1087-99. [DOI: 10.1097/CM9.0000000000000212] [MEDLINE: 30913064]">Zhou 2019</a>). </p> <p>In the current work, we examined portosystemic shunts in the elective setting for patients with previous episodes of variceal bleeding. To comprehensively address the question, we have conducted a systematic review to compare shunts (TSs, DSRSs, and TIPSs) versus endoscopic interventions (sclerotherapy or banding, or both) with or without medical treatment for long‐term prophylaxis of rebleeding. </p> <p>The current update, along with updated Cochrane standards, incorporates new trials (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>) and results of updated trials (<a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000553-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000553-sec-0014"></div> <p>To compare the benefits and harms of shunts (surgical shunts (total shunt (TSs), distal splenorenal shunt (DSRS), or transjugular intrahepatic portosystemic shunt (TIPS </p> <p>)) versus endoscopic interventions (endoscopic sclerotherapy or banding, or both) with or without medical treatement (non‐selective beta blockers or nitrates, or both) for prevention of variceal rebleeding in people with liver cirrhosis. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000553-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000553-sec-0015"></div> <section id="CD000553-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000553-sec-0017"> <h4 class="title">Types of studies</h4> <p>We endeavoured to identify all possible randomised clinical trials (published and unpublished) in which shunts were compared with endoscopic interventions with or without medical treatment. </p> </section> <section id="CD000553-sec-0018"> <h4 class="title">Types of participants</h4> <p>People known to have cirrhosis who had bled from oesophagogastric varices but had subsequently stabilised (before randomisation), either spontaneously or via non‐surgical approaches, including vasoactive drugs or balloon tamponade, or endoscopic measures, or a combination of any two or three together. </p> </section> <section id="CD000553-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Surgical shunts (total shunt (TS), distal splenorenal shunt (DSRS), or transjugular intrahepatic portosystemic shunt (TIPS)) versus endoscopic interventions (endoscopic sclerotherapy or banding, or both) with or without concomitant long‐term medical treatment (e.g. non‐selective beta‐blockers, nitrates, both). </p> </section> <section id="CD000553-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>All outcomes were evaluated at the maximum available follow‐up.</p> <section id="CD000553-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD000553-list-0001"> <li> <p>All‐cause mortality, defined as death due to any cause</p> </li> <li> <p>Rebleeding, defined as a clinically significant episode of bleeding (i.e. requiring transfusion) from oesophagogastric varices or portal hypertensive gastropathy. The diagnosis should ideally have been confirmed by endoscopic examination to distinguish variceal bleeding or bleeding from portal hypertensive gastropathy from other causes of non‐portal hypertensive gastrointestinal haemorrhage </p> </li> <li> <p>Health‐related quality of life, as measured by trial authors</p> </li> </ul> </p> </section> <section id="CD000553-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD000553-list-0002"> <li> <p>Mortality due to rebleeding, defined as death resulting from a further episode of bleeding from oesophagogastric varices or portal hypertensive gastropathy following the primary (index) bleeding </p> </li> <li> <p>Acute hepatic encephalopathy, defined by classical signs detected on physical examination, signs unequivocally described by participants' relatives, psychometric testing, or electroencephalogram (EEG) </p> </li> <li> <p>Chronic hepatic encephalopathy, defined by recurrent episodes of acute hepatic encephalopathy or inability of the individual to attain previous level of function because of post‐treatment hepatic encephalopathy </p> </li> <li> <p>Complications, defined by untoward events reported by trial authors (aside from hepatic encephalopathy, which is reported separately) </p> </li> <li> <p>Hospital stay, defined by total days spent in hospital when treatments are applied</p> </li> <li> <p>Cost analysis, defined by actual financial costs of treatment complications of cirrhotic portal hypertension or of complications during the follow‐up period </p> </li> </ul> </p> </section> </section> </section> <section id="CD000553-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000553-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Hepato‐Biliary Group Controlled Trials Register (maintained and searched internally by the CHBG Information Specialist via the Cochrane Register of Studies Web; 22 June 2020); the Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 2), in the Cochrane Library (searched 22 June 2020); MEDLINE Ovid (1946 to 22 June 2020); Embase Ovid (1974 to 22 June 2020); Latin American Caribbean Health Sciences Literature (LILACS; Bireme; 1982 to 22 June 2020), and Science Citation Index ‐ Expanded (Web of Science; 1900 to 22 June 2020), as well as the Conference Proceedings Citation Index ‐ Science (Web of Science; 1990 to 25 February 2020) (<a href="./references#CD000553-bbs2-0088" title="RoyleP , MilneR . Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care2003;19(4):591-603. [DOI: 10.1017/s0266462303000552] [MEDLINE: 15095765]">Royle 2003</a>). For the current update, we reviewed all records arising from Conference Proceedings Citation Index and LILACS, as these databases had not been included in the previous permutation of this review. CENTRAL, MEDLINE, Embase, and Science Citation Index ‐ Expanded had all been included in the previously published version of the review, and we reviewed all records from September 2006 (inclusive) onwards from these databases for the current update. We performed an all language search, evaluating only human studies. <a href="./appendices#CD000553-sec-0171">Appendix 1</a> presents the search strategies with time spans for the searches. </p> </section> <section id="CD000553-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We investigated the reference lists of identified trials for relevant trials. We searched conference proceedings/abstracts for European Association for the Study of the Liver (EASL), American Association for the Study of Liver Disease (AASLD), and British Society of Gastroenterology<i>.</i> When practicable, authors of studies identified to be pertinent were asked to review the list of identified trials and to add any unidentified trials. Manufacturers (TIPSs, pharmacological firms) were contacted. We also searched ClinicalTrials.gov to identify protocols and any ongoing trials. </p> </section> </section> <section id="CD000553-sec-0026"> <h3 class="title" id="CD000553-sec-0026">Data collection and analysis</h3> <section id="CD000553-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Searches for the original updated review were conducted by at least two review authors (SK and CTS for the 1st version; and RGS, GP, and HR for the update), who independently applied the inclusion criteria to all identified studies. At least two review authors independently extracted data from publications of interest, and for the update, data were extracted in greater detail and were rechecked by RGS, GP, and HR. We selected studies for inclusion no matter whether they reported on outcomes of interest to our review. Unpublished data were sought by writing to study authors (see notes under <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). Review authors collected data for intention‐to‐treat analysis. We resolved any discrepancies or differences among us by discussion. </p> </section> <section id="CD000553-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted data using standardised forms, which captured data related to participant characteristics. Three review authors (RGS, GP, and HR) independently extracted data. We resolved disagreements by discussion. Data extraction encompassed comparability between groups randomised to alternative treatments regarding baseline prognostic variables, including aetiology of cirrhosis; mean age; proportion of males/females; participants with Child‐Pugh stage A, B, or C (<a href="./references#CD000553-bbs2-0085" title="PughRN , Murray-LyonIM , DawsonJL , PietroniMC , WilliamsR . Transection of the oesophagus for bleeding oesophageal varices. British Journal of Surgery1973;60(8):646-9. [MEDLINE: 4541913] [10.1002/bjs.1800600817]">Pugh 1973</a>); completeness and length of follow‐up of treatment groups and reasons for withdrawals; presence of, absence of, or unknown for‐profit support; and trial design, exclusions, losses to follow‐up, and cross‐over of patients. Review authors also extracted data of particular interest for shunt intervention, including whether assessments had been made to assess the suitability of shunt intervention, and whether splenopancreatic disconnection was undertaken in people undergoing DSRS. We also extracted data related to the timing and method of assessing shunt patency. </p> <p>We collected data for all‐cause mortality, rebleeding, health‐related quality of life, death due to rebleeding, development of acute hepatic encephalopathy, development of chronic hepatic encephalopathy, complications, hospital stay, and financial cost. When a trial had more than two groups, we extracted data only from groups that corresponded to the treatments compared in this review. </p> <p>When possible, we measured outcomes as 'time‐to‐event'. To prevent loss of data, we assessed outcomes as dichotomous variables, using raw incidence over the entire follow‐up period reported by study authors (or the longest time point reported whenever multiple time points were reported). </p> <p>For the outcomes of health‐related quality of life, complications, in‐hospital stay, and cost, we extracted data directly 'as reported' by study authors. </p> </section> <section id="CD000553-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RS and GP) independently assessed the risk of bias of included studies. In light of changes to Cochrane methods, we updated the risk of bias assessment using an adapted Cochrane risk of bias tool (adapted from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> ‐ <a href="./references#CD000553-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>; <a href="./references#CD000553-bbs2-0076" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a> ‐ and the <a href="https://hbg.cochrane.org/" target="_blank">Cochrane Hepato-Biliary Group Module</a>). Due to changes to the Cochrane risk of bias tool since conduct of the previous review, we reassessed the risk of bias in previously included trials, with any discrepancy resolved by discussion between review authors. </p> <section id="CD000553-sec-0030"> <h5 class="title">Allocation sequence generation</h5> <p> <ul id="CD000553-list-0003"> <li> <p>Low risk of bias: sequence generation was achieved using computer random number generation or a random numbers table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent person not otherwise involved in the trial </p> </li> <li> <p>Unclear risk of bias: the method of sequence generation was not specified</p> </li> <li> <p>High risk of bias: the sequence generation method was not random</p> </li> </ul> </p> </section> <section id="CD000553-sec-0031"> <h5 class="title">Allocation concealment</h5> <p> <ul id="CD000553-list-0004"> <li> <p>Low risk of bias: participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit; or the allocation sequence was unknown to the investigators (e.g. the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes) </p> </li> <li> <p>Unclear risk of bias: the method used to conceal the allocation was not described, so that intervention allocations may have been foreseen in advance of, or during, enrolment </p> </li> <li> <p>High risk of bias: the allocation sequence was likely to be known to investigators who assigned participants </p> </li> </ul> </p> </section> <section id="CD000553-sec-0032"> <h5 class="title">Blinding of participants and treatment providers</h5> <p> <ul id="CD000553-list-0005"> <li> <p>Low risk of bias: any of the following ‐ no blinding or incomplete blinding, but review authors judge that the outcome is not influenced by lack of blinding; or blinding of participant and study personnel ensured, and it is unlikely that blinding could have been broken </p> </li> <li> <p>Unclear risk of bias: insufficient information to permit judgement of 'low risk' or 'high risk' </p> </li> <li> <p>High risk of bias: no blinding or incomplete blinding, and outcome likely to be influenced by lack of blinding; or, blinding of key study participants and personnel attempted, but likely that blinding could have been broken, and outcome is likely to be influenced by lack of blinding </p> </li> </ul> </p> </section> <section id="CD000553-sec-0033"> <h5 class="title">Blinding of outcome assessment</h5> <p> <ul id="CD000553-list-0006"> <li> <p>Low risk of bias: any of the following: blinding of participants and key study personnel ensured, and unlikely that blinding could have been broken; or rarely no blinding or incomplete blinding, but review authors judged that the outcome was not likely to be influenced by lack of blinding </p> </li> <li> <p>Unclear risk of bias: any of the following: insufficient information to permit judgement of 'low risk' or 'high risk'; or the trial did not address this outcome </p> </li> <li> <p>High risk of bias: any of the following: no blinding of outcome assessment, and outcome measurement likely to be influenced by lack of blinding; or blinding of outcome assessment, but likely that blinding could have been broken, and the outcome measurement was likely to be influenced by lack of blinding </p> </li> </ul> </p> </section> <section id="CD000553-sec-0034"> <h5 class="title">Incomplete outcome data</h5> <p> <ul id="CD000553-list-0007"> <li> <p>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. The study used sufficient methods, such as multiple imputation, to handle missing data </p> </li> <li> <p>Unclear risk of bias: information was insufficient to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results </p> </li> <li> <p>High risk of bias: results were likely to be biased due to missing data</p> </li> </ul> </p> </section> <section id="CD000553-sec-0035"> <h5 class="title">Selective reporting</h5> <p> <ul id="CD000553-list-0008"> <li> <p>Low risk of bias: if the original trial protocol was available, outcomes should be those called for in that protocol. If the trial protocol was obtained from a trial registry, outcomes sought should have been those enumerated in the original protocol. If no protocol was available, the trial should have reported the following outcomes: all‐cause mortality, rebleeding, mortality due to rebleeding, complications, acute hepatic encephalopathy, and chronic hepatic encephalopathy </p> </li> <li> <p>Unclear risk of bias: information insufficient to permit judgement of 'low risk' or 'high risk' </p> </li> <li> <p>High risk: not all of the study's pre‐specified primary outcomes have been reported; one or more primary outcomes are reported via measurements, analyses, or subsets that were not pre‐specified; one or more primary outcomes were not pre‐specified; one or more outcomes of interest are reported incompletely; study fails to include results for a key outcome that would be expected to have been reported for such a study </p> </li> </ul> </p> </section> <section id="CD000553-sec-0036"> <h5 class="title">Other bias</h5> <p> <ul id="CD000553-list-0009"> <li> <p>Low risk of bias: the trial appeared to be free of other factors that could put it at risk of bias </p> </li> <li> <p>Unclear risk of bias: the trial may or may not have been free of other factors that could put it at risk of bias </p> </li> <li> <p>High risk of bias: other factors in the trial could put it at risk of bias</p> </li> </ul> </p> </section> <section id="CD000553-sec-0037"> <h5 class="title">Overall risk of bias</h5> <p>We assessed the overall risk of bias in a trial as:</p> <p> <ul id="CD000553-list-0010"> <li> <p>low risk of bias: if all bias domains in a trial, as described in the above paragraphs, are judged at 'low risk of bias'; or </p> </li> <li> <p>high risk of bias: if one or more of the bias domains in a trial, as described in the above paragraphs, are judged at 'unclear risk of bias' or 'high risk of bias'. </p> </li> </ul> </p> </section> </section> <section id="CD000553-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>We assessed all outcomes through a combined analysis of all shunt types together ('shunt therapy pooled'; i.e. TS, DSRS, and TIPS combined) and repeated the analysis for each shunt type individually (TS, DSRS, TIPS). We calculated hazard ratios (HRs) for time‐to‐event outcomes and calculated risk ratios (RRs) for binary outcomes, and we planned to use mean differences (MDs) for continuous outcomes. For the outcomes all‐cause mortality, rebleeding, death due to rebleeding, development of acute hepatic encephalopathy, and development of chronic hepatic encephalopathy, when possible, we carried out analyses to allow reporting of time‐to‐event outcomes. Therefore, for each outcome in each comparison (shunts versus endoscopic intervention with or without medical treatment: TS versus endoscopic intervention with or without medical treatment; DSRS versus endoscopic intervention with or without medical treatment; TIPS versus endoscopic intervention with or without medical treatment), we planned to calculate a pooled estimate of treatment effect as an HR. If estimates of log HR and its variance were not quoted directly in trial reports, we used alternative aggregate data (e.g. log rank test P values) to estimate log(HR) and its variance utilising methods proposed by <a href="./references#CD000553-bbs2-0083" title="ParmarMKB , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34. [DOI: 10.1002/(sici)1097-0258(19981230)17:24&lt;2815::aid-sim110&gt;3.0.co;2-8] [MEDLINE: 9921604]">Parmar 1998</a> and <a href="./references#CD000553-bbs2-0107" title="WilliamsonPR , Tudur SmithC , HuttonJL , MarsonAG . Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine2002;21(22):3337-51. [DOI: 10.1002/sim.1303] [MEDLINE: 12407676]">Williamson 2002</a>, and summarised by <a href="./references#CD000553-bbs2-0098" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16] [MEDLINE: 17555582]">Tierney 2007</a>. When possible, we planned to calculate variance and observed‐expected (O‐E) rank from reported HRs and confidence intervals (CIs) (<a href="./references#CD000553-bbs2-0098" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16] [MEDLINE: 17555582]">Tierney 2007</a>, Section 3 to 6). However, in most cases, we planned to estimate log(HR) and its variance and O‐E using the quoted P value of the log‐rank test (<a href="./references#CD000553-bbs2-0101" title="TudurC , WilliamsonPR , KhanS , BestLY . The value of the aggregate data approach in meta-analysis with time-to-event outcomes. Journal of the Royal Statistical Society: Series A (Statistics in Society)2001;2(164):357-70. [DOI: 10.1111/1467-985X.00207]">Tudur 2001</a>, Section 2.3; <a href="./references#CD000553-bbs2-0098" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16] [MEDLINE: 17555582]">Tierney 2007</a>, Sections 7 to 9). If no P value was quoted for the log‐rank test, we planned to estimate log(HR) and its variance from Kaplan‐Meier survival curves (<a href="./references#CD000553-bbs2-0101" title="TudurC , WilliamsonPR , KhanS , BestLY . The value of the aggregate data approach in meta-analysis with time-to-event outcomes. Journal of the Royal Statistical Society: Series A (Statistics in Society)2001;2(164):357-70. [DOI: 10.1111/1467-985X.00207]">Tudur 2001</a>, Sections 2.4 and 2.5; <a href="./references#CD000553-bbs2-0098" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [DOI: 10.1186/1745-6215-8-16] [MEDLINE: 17555582]">Tierney 2007</a>, Section 10). Full details and discussion of the reliability of results are given in <a href="./references#CD000553-bbs2-0101" title="TudurC , WilliamsonPR , KhanS , BestLY . The value of the aggregate data approach in meta-analysis with time-to-event outcomes. Journal of the Royal Statistical Society: Series A (Statistics in Society)2001;2(164):357-70. [DOI: 10.1111/1467-985X.00207]">Tudur 2001</a>. </p> <p>We were not able to extract sufficient data to allow time‐to‐event analysis from all reports. Therefore, to prevent loss of data, we also reported the same outcomes (i.e. all‐cause mortality, rebleeding, death due to rebleeding, development of acute hepatic encephalopathy, and development of chronic hepatic encephalopathy) as dichotomous outcomes, using binary data to calculate the RR. We decided to report only the results of analysis of dichotomous data because they were available for all trials, and because we used dichotomous data to grade the evidence (see below) and to perform Trial Sequential Analysis, while avoiding redundant information. We planned to report results of time‐to‐event analysis if discrepancies with the main analysis were found. </p> <p>For high variability on continuous outcomes (inpatient stay and costs), we did not meta‐analyse the results and reported mean differences for each trial when available. </p> <p>To ensure consistency across studies identified in the initial review and in the current update, calculations from the initial review were reviewed and any discrepancies were resolved by discussion between review authors. </p> <p>For this update, we decided to report 'financial cost' and 'length of hospital stay' as the raw data published by trialists in light of considerable inter‐trial variability in the definitions and methods used; therefore, overall, it was judged that reported data were not comparable across all trials. </p> </section> <section id="CD000553-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>Participants as randomised to an intervention group of a clinical trial are the unit of analysis. In trials of two–parallel group design, we compared the experimental intervention group versus the control. In trials with a parallel group design with more than two intervention groups of interest to our review, we planned to compare separately each of the experimental groups with each half of the control group. </p> <p>To avoid repeated observations on trial participants, we used participant trial data at the longest follow‐up (<a href="https://archie.cochrane.org/sections/documents/view?version=z1907161401317599819876537034364&amp;format=REVMAN#REF-Higgins-2011" target="_blank">Higgins 2011</a>; <a href="./references#CD000553-bbs2-0076" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). </p> <p>We identified no cluster‐randomised trials.</p> </section> <section id="CD000553-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>Whenever possible, we performed all calculations according to intention‐to‐treat principles (i.e. with all randomised trial participants included in the analysis within the group into which they were randomised). In some trials, results were presented on a per‐protocol basis, or the given information was insufficient to assess whether data had truly been presented with use of the 'intention‐to‐treat' principle (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>). When this was the case, we contacted study authors to retrieve pertinent data. As further information was not given, we used all data that were available to us. </p> </section> <section id="CD000553-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by visual examination of forest plots and overlapping CIs, and through use of the I² statistic. The I² statistic was interpreted as follows: 0% to 40% heterogeneity may not be important; 30% to 60% moderate heterogeneity; 50% to 90% heterogeneity may be substantial; 75% to 100% heterogeneity may be considerable (<a href="./references#CD000553-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). </p> </section> <section id="CD000553-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>Whenever we had 10 or more trials, we drew funnel plots to assess reporting biases from individual trials by plotting the risk ratio (RR) on a logarithmic scale against its standard error (<a href="./references#CD000553-bbs2-0067" title="EggerM , SmithGD , PhillipsAN . Meta-analysis: principles and procedure. BMJ (Clinical Research Ed.)1997;315(7121):1533-7. [DOI: 10.1136/bmj.315.7121.1533] [MEDLINE: 9432252]">Egger 1997</a>; <a href="./references#CD000553-bbs2-0075" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>; <a href="./references#CD000553-bbs2-0076" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). We examined the degree of asymmetry of the funnel plot. </p> </section> <section id="CD000553-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analyses using the software package Review Manager 5.4 (<a href="./references#CD000553-bbs2-0086" title="Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. https://community.cochrane.org/help/tools-and-software/revman-5.">Review Manager 2014</a>). We used a random‐effects model meta‐analysis approach because we expected that the trials were heterogeneous. When data were available from only one trial, we used Fisher's exact test for dichotomous data (<a href="https://archie.cochrane.org/sections/documents/view?version=z1909181039044525739621446615184&amp;format=REVMAN#REF-Fisher-1992" target="_blank">Fisher 1992</a>). We planned to use Student's t‐test for continuous data such as 'health‐related quality of life' (<a href="https://archie.cochrane.org/sections/documents/view?version=z1909181039044525739621446615184&amp;format=REVMAN#REF-Student-1908" target="_blank">Student 1908</a>). </p> </section> <section id="CD000553-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed all analyses with all shunt types but also with individual shunt types: TS, DSRS, and TIPS. </p> <p>We planned subgroup analyses according to risk of bias, analysing separately randomised clinical trials at low risk of bias compared to trials at high risk of bias. We did this because trials at high risk of bias can overestimate the benefits and underestimate the harms. </p> <p>We also analysed trials with for‐profit funding; without for‐profit support; and with unknown for‐profit support to evaluate whether for‐profit funding is associated with greater intervention benefit. </p> <p>No other subgroup analyses were planned a priori, and none were undertaken due to the small sample size in each group. </p> <p>Robustness of conclusions was assessed using sensitivity analyses (see below). When there was substantial heterogeneity, we considered and discussed the appropriateness of performing the meta‐analysis. We did not perform a meta‐analysis if viewed as inappropriate. We explored reasons for possible heterogeneity, while examining characteristics of trials. </p> </section> <section id="CD000553-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We employed sensitivity analyses within each type of portosystemic shunt to test the robustness of our results. </p> <p> <ul id="CD000553-list-0011"> <li> <p>Excluding trials examining participants with previous bleeding from gastric varices, as they were likely more difficult to treat with endoscopy. </p> </li> <li> <p>Including only trials specifying use of polytetrafluorethylene (PTFE)‐covered TIPSs, as this could reduce the risk of occlusion of the stent. </p> </li> <li> <p>Including only trials in which the PTFE‐covered TIPSs were not used, or in which the type of TIPS was not specified. </p> </li> <li> <p>Including only trials combining endoscopic interventions with medical therapies, as these medical interventions could influence the effects of endoscopy. </p> </li> <li> <p>Excluding trials combining endoscopic interventions with medical therapies to see if there are differences in the intervention effects. </p> </li> <li> <p>Including only trials using endoscopic banding exclusively (i.e. excluding those using glue injection, sclerotherapy, or combination treatments) as use of the mentioned example interventions could modify effects of endoscopic intervention. </p> </li> </ul> </p> <p>As further sensitivity analyses, we compared evaluation of imprecision with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible RRR and multiplicity correction, and according to our Trial Sequential Analysis (described below), with a similar choice of a plausible RRR and multiplicity correction, in addition to considering the choice of a meta‐analytic model and diversity (<a href="./references#CD000553-bbs2-0077" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [MEDLINE: 25416419]">Jakobsen 2014</a>; <a href="./references#CD000553-bbs2-0058" title="CastelliniG , BruschettiniM , GianolaS , GluudC , MojaL . Assessing imprecision in Cochrane systematic reviews: a comparison of GRADE and Trial Sequential Analysis. Systematic Reviews2018;7(1):110. [MEDLINE: 30055658] [10.1186/s13643-018-0770-1]">Castellini 2018</a>; <a href="./references#CD000553-bbs2-0070" title="GartlehnerG , Nussbaumer-StreitB , WagnerG , PatelS , Swinson-EvansT , DobrescuA , et al. Increased risks for random errors are common in outcomes graded as high certainty of evidence. Journal of Clinical Epidemiology2019;106:50-9. [DOI: 10.1016/j.jclinepi.2018.10.009] [MEDLINE: 30342970]">Gartlehner 2019</a>). </p> <section id="CD000553-sec-0046"> <h5 class="title">Trial Sequential Analysis</h5> <p>Trial Sequential Analysis considers the choice of statistical model (fixed‐effect or random‐effects meta‐analysis) and diversity (<a href="./references#CD000553-bbs2-0097" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed June 2019).">Thorlund 2011</a>; <a href="./references#CD000553-bbs2-0100" title="TSA - Trial Sequential Analysis. Version 0.9.5.10 Beta. Copenhagen: Copenhagen Trial Unit, 2011. www.ctu.dk/tsa/downloads.aspx.">TSA 2011</a>). We calculated the diversity‐adjusted required information size (DARIS, i.e. the number of participants needed in a meta‐analysis to detect or reject a certain intervention effect) (<a href="./references#CD000553-bbs2-0051" title="BrokJ , ThorlundK , GluudC , WetterslevJ . Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses. Journal of Clinical Epidemiology2008;61(8):763-9. [DOI: 10.1016/j.jclinepi.2007.10.007] [MEDLINE: 18411040]">Brok 2008</a>; <a href="./references#CD000553-bbs2-0104" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [MEDLINE: 18083463]">Wetterslev 2008</a>; <a href="./references#CD000553-bbs2-0052" title="BrokJ , ThorlundK , WetterslevJ , GluudC . Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. International Journal of Epidemiology2009;38(1):287-98. [DOI: 10.1093/ije/dyn188] [MEDLINE: 18824466]">Brok 2009</a>; <a href="./references#CD000553-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology2009;9:86. [DOI: 10.1186/1471-2288-9-86] [MEDLINE: 20042080]">Wetterslev 2009</a>; <a href="./references#CD000553-bbs2-0096" title="ThorlundK , AnemaA , MillsE . Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals. Clinical Epidemiology2010;2:57-66. [MEDLINE: 20865104] [10.2147/clep.s9242]">Thorlund 2010</a>; <a href="./references#CD000553-bbs2-0106" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [DOI: 10.1186/s12874-017-0315-7] [MEDLINE: 28264661]">Wetterslev 2017</a>). </p> <p>The underlying assumption of Trial Sequential Analysis is that testing for statistical significance may be performed each time a new trial is added to the meta‐analysis. We added trials according to the year of publication, and if more than one trial was published in a year, we added trials alphabetically according to the last name of the first author. On the basis of the DARIS, we constructed the trial sequential monitoring boundaries for benefit, harm, and futility (<a href="./references#CD000553-bbs2-0104" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. Journal of Clinical Epidemiology2008;61(1):64-75. [DOI: 10.1016/j.jclinepi.2007.03.013] [MEDLINE: 18083463]">Wetterslev 2008</a>; <a href="./references#CD000553-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology2009;9:86. [DOI: 10.1186/1471-2288-9-86] [MEDLINE: 20042080]">Wetterslev 2009</a>; <a href="./references#CD000553-bbs2-0097" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed June 2019).">Thorlund 2011</a>; <a href="./references#CD000553-bbs2-0106" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [DOI: 10.1186/s12874-017-0315-7] [MEDLINE: 28264661]">Wetterslev 2017</a>). These boundaries determine the statistical inference one may draw regarding the cumulative meta‐analysis that has not reached the DARIS; if the trial sequential monitoring boundary for benefit or harm is crossed before the DARIS is reached, firm evidence may be established and further trials may be superfluous. However, if the boundaries for benefit or harm are not crossed, it is most probably necessary to continue doing trials to detect or reject a certain intervention effect. However, if the cumulative Z‐curve crosses the trial sequential monitoring boundaries for futility, no additional trials may be needed. </p> <p>In our Trial Sequential Analysis of the two primary dichotomous outcomes, we based the DARIS on event proportions in the control group assuming a plausible relative risk reduction (RRR) for all‐cause mortality of 10% and for rebleeding of 20%; risk of type I error of 2.5% due to the three primary outcomes (<a href="./references#CD000553-bbs2-0077" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [MEDLINE: 25416419]">Jakobsen 2014</a>); risk of type II error of 20%; and the diversity of trials included in the meta‐analysis. We repeated the analysis with a plausible RRR of 40% for rebleeding. For the continuous outcome, health‐related quality of life, we planned to estimate the DARIS using a minimal relevant difference of the standard deviation/2; type I error risk of 2.5% due to the three primary outcomes (<a href="./references#CD000553-bbs2-0077" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [MEDLINE: 25416419]">Jakobsen 2014</a>); risk of type II error of 20%; and diversity as estimated from trials in the meta‐analysis (<a href="./references#CD000553-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology2009;9:86. [DOI: 10.1186/1471-2288-9-86] [MEDLINE: 20042080]">Wetterslev 2009</a>). We also calculated Trial Sequential Analysis–adjusted confidence intervals (CIs) (<a href="./references#CD000553-bbs2-0097" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed June 2019).">Thorlund 2011</a>; <a href="./references#CD000553-bbs2-0106" title="WetterslevJ , JakobsenJC , GluudC . Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Medical Research Methodology2017;17(1):39. [DOI: 10.1186/s12874-017-0315-7] [MEDLINE: 28264661]">Wetterslev 2017</a>). </p> <p>In our Trial Sequential Analysis of secondary outcomes, we based the DARIS for dichotomous outcomes on the event proportion in the control group; we made an assumption of an RRR of 20% for death due to rebleeding, development of acute hepatic encephalopathy, development of chronic hepatic encephalopathy and complications; type I error risk of 1.4% due to the six secondary outcomes (<a href="./references#CD000553-bbs2-0077" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [MEDLINE: 25416419]">Jakobsen 2014)</a>; risk of type II error of 20%; and the diversity of trials included in the meta‐analysis. We repeated the analysis with a plausible RRR or increase of 40% for mortality due to rebleeding, development of acute hepatic encephalopathy, and development of chronic hepatic encephalopathy. For the continuous outcome, hospital stay and cost, we planned to estimate the DARIS using a minimal relevant difference of the standard deviation/2; type I error risk of 1.4% due to the six secondary outcomes (<a href="./references#CD000553-bbs2-0077" title="JakobsenJ , WetterslevJ , WinkelP , LangeT , GluudC . Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Medical Research Methodology2014;14:120. [DOI: 10.1186/1471-2288-14-120] [MEDLINE: 25416419]">Jakobsen 2014</a>); beta of 20%; and diversity as estimated from trials in the meta‐analysis (<a href="./references#CD000553-bbs2-0105" title="WetterslevJ , ThorlundK , BrokJ , GluudC . Estimating required information size by quantifying diversity in a random-effects meta-analysis. BMC Medical Research Methodology2009;9:86. [DOI: 10.1186/1471-2288-9-86] [MEDLINE: 20042080]">Wetterslev 2009</a>). </p> <p>We reported results of the comparison of GRADE and Trial Sequential Analysis. We downgraded imprecision in Trial Sequential Analysis by two levels if the accrued number of participants was below 50% of the diversity‐adjusted required information size (DARIS), and one level if between 50% and 100% of DARIS. We did not downgrade if the cumulative Z curve crossed the monitoring boundaries for benefit, harm, or futility, or if DARIS was reached. </p> <p>A more detailed description of Trial Sequential Analysis and the software programme can be found at <a href="http://www.ctu.dk/tsa/" target="_blank">www.ctu.dk/tsa/</a> (<a href="./references#CD000553-bbs2-0097" title="ThorlundK , EngstrømJ , WetterslevJ , BrokJ , ImbergerG , GluudC . User manual for Trial Sequential Analysis (TSA). ctu.dk/tsa/files/tsa_manual.pdf 2011 (accessed June 2019).">Thorlund 2011</a>). </p> </section> </section> <section id="CD000553-sec-0047"> <h4 class="title">'Summary of findings' tables and GRADE</h4> <p>We constructed 'Summary of findings' tables for the update of the review. We created 'Summary of findings' tables for the pooled analysis of all shunt interventions ('shunt therapy pooled') versus endoscopic intervention with or without medical treatment (<a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>), and we presented individual tables for TS (<a href="./full#CD000553-tbl-0002">summary of findings Table 2</a>), DSRS (<a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>), and TIPS (<a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>) for the following outcomes: all‐cause mortality, rebleeding, health‐related quality of life, mortality due to rebleeding, acute hepatic encephalopathy, and chronic hepatic encephalopathy. We used dichotomous data to assess absolute effects. </p> <p>We created 'Summary of findings' tables using GRADEpro software and GRADE Interactive software (<a href="http://www.gradepro.org" target="_blank">www.gradepro.org</a>; <a href="./references#CD000553-bbs2-0072" title="GRADEpro GDT. Version accessed 4 April 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>), in accordance with Cochrane guidelines and the GRADE Handbook (<a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">Grade Handbook</a>). GRADE appraises the certainty of evidence, assessing the degree to which we can be confident that the estimate of effect truly reflects the effect being assessed. The GRADE factors for assessing the evidence are trial risk of bias (methodological quality), indirectness of the evidence (population, intervention, control, outcomes), heterogeneity or inconsistency of results, imprecision of effect estimates (considering width of confidence intervals, optimal information size, and whether confidence intervals exclude important benefit or important harm), and possible publication bias (including use of funnel plots) (<a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">Grade Handbook</a>). To calculate the optimal information size (OIS), we used the conservative estimates of a RRR of 25%, beta 20%, and alpha 0.05. </p> <p>Overall, we graded the level of evidence as 'high', 'moderate', 'low', or 'very low' (<a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">Grade Handbook</a>; <a href="./references#CD000553-bbs2-0072" title="GRADEpro GDT. Version accessed 4 April 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT</a>). </p> <p> <ul id="CD000553-list-0012"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000553-sec-0048" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000553-sec-0048"></div> <section id="CD000553-sec-0049"> <h3 class="title">Description of studies</h3> <section id="CD000553-sec-0050"> <h4 class="title">Results of the search</h4> <p>The updated search identified in total 210 records of possible interest for our review (<a href="#CD000553-fig-0001">Figure 1</a>). Three additional records were identified through other sources (<a href="#CD000553-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD000553-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram. Searches performed up to June 2020" data-id="CD000553-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram. Searches performed up to June 2020</p> </div> </div> </div> <p>Of these 213 records, 25 were screened further for inclusion. We excluded ten records reporting six trials based on reading the full‐text publications, as they did not fulfil the inclusion criteria of our review (<a href="./references#CD000553-bbs2-0036" title="OrloffM , IsenbergJ , WheelerH , HaynesK , Jinich-BrookH , RapierR , et al. Portal-systemic encephalopathy in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt treatment of acutely bleeding esophageal varices in cirrhosis. Annals of Surgery2009;250(4):598-610. [DOI: 10.1097/SLA.0b013e3181b73126] [MEDLINE: 19730244]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Direct costs of care in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt for bleeding esophageal varices in cirrhosis - Part 4. Journal of Gastrointestinal Surgery2011;15(1):38-47. [DOI: 10.1007/s11605-010-1332-6] [MEDLINE: 20824373]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Emergency portacaval shunt versus rescue portacaval shunt in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis - Part 3. Journal of Gastrointestinal Surgery2010;14(11):1782-95. [DOI: 10.1007/s11605-010-1279-7] [MEDLINE: 20658205]OrloffMJ . Fifty-three years' experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in cirrhosis: 1958 - 2011. Journal of the American Medical Association Surgery2014;149(2):155-69. [DOI: 10.1001/jamasurg.2013.4045] [MEDLINE: 24402314]">Orloff 2009</a>; <a href="./references#CD000553-bbs2-0031" title="García-PagánJC , CacaK , Bureau C , LalemanW , AppenrodtB , LucaA , et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. New England Journal of Medicine2010;362(25):2370-9. [DOI: 10.1056/NEJMoa0910102.] [MEDLINE: 20573925] [ISRCTN58150114]">Garcia‐Pagan 2010</a>; <a href="./references#CD000553-bbs2-0033" title="LiGQ , YangB , LiuJ , WangGC , YuanHP , ZhaoJR , et al. Hepatic venous pressure gradient is a useful predictor in guiding treatment on prevention of variceal rebleeding in cirrhosis. International Journal of Clinical and Experimental Medicine2015;8(10):19709-16. [MEDLINE: 26770635]">Li 2015</a>; <a href="./references#CD000553-bbs2-0042" title="SauerbruchT , MengelM , DollingerM , ZipprichA , RossleM , PantherE , et al, German Study Group for Prophaxis of Variceal Rebleeding. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology2015;149(3):660-8. [MEDLINE: 10.1053/j.gastro.2015.05.011] [PMID: 25989386]">Sauerbruch 2015</a>; <a href="./references#CD000553-bbs2-0037" title="OrloffMJ , HyeRJ , WheelerHO , IsenbergJI , HaynesKS , VaidaF , et al. Randomized trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt versus portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis. Surgery2015;157(6):1028-45. OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. Journal of the American College of Surgeons2009;209(1):25-40. [DOI: 10.1016/j.jamcollsurg.2009.02.059] [MEDLINE: 19651060]">Orloff 2015</a>; <a href="./references#CD000553-bbs2-0045" title="WangZ , ZhaoH , WangX , ZhangH , JiangM , TsauoJ , et al. Clinical outcome comparison between TIPS and EBL in patients with cirrhosis and portal vein thrombosis. Abdominal Imaging2015;40(6):1813-20. [DOI: 10.1007/s00261-014-0320-9] [MEDLINE: 25504374]">Wang 2015</a>). Two further records were later publications of two other trials already included in the previous review version (<a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>: a full report of a previous abstract; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>: long‐term follow‐up of the Spina 1990 trial). We listed these two references within their trial identifiers in <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>. One record reported a randomised clinical trial (<a href="./references#CD000553-bbs2-0046" title="LvY , YangZ , LiuL , LiK , HeC , WangZ , et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. The Lancet Gastroenterology and Hepatology2019;4(8):587-98. [DOI: 10.1016/S2468-1253(19)30090-1] [MEDLINE: 31153882] [NCT01370161]">Lv 2019</a>) which is under evaluation (<a href="./references#CD000553-bbs1-0003" title="">Studies awaiting classification</a>), because it is not clear if participants with active uncontrolled bleeding after randomisation were included. A letter was sent to the study authors to request more information. Two records described the protocols of two ongoing trials for which we did not find related publications at the time of our analysis (<a href="./references#CD000553-bbs2-0047" title="NCT02477384. 8mm-TIPS versus endoscopic variceal ligation (EVL) plus propranolol for prevention of variceal rebleeding [Randomised trial of 8mm transjugular intrahepatic portosystemic shunt versus endoscopic variceal ligation plus propranolol for prevention of variceal rebleeding]. clinicaltrials.gov/ct2/show/study/NCT02477384 (first received 15 June 2015). ">NCT02477384</a>; <a href="./references#CD000553-bbs2-0048" title="NCT03094234. 8mm-TIPS versus endoscopic variceal ligation (EVL) plus propranolol for prevention of variceal rebleeding in patients with child A cirrhosis. clinicaltrials.gov/ct2/show/study/NCT03094234 (first received 23 March 2017). ">NCT03094234</a>) (<a href="./references#CD000553-sec-0185" title="">Characteristics of ongoing studies</a>). Ten records reported on six new trials, which we have included in the present review update (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> <p>From the previous review version with 22 included trials, we had to reassess fulfilment of the inclusion criteria of two trial publications (<a href="./references#CD000553-bbs2-0029" title="CelloJP , GrendellJH , CrassRA , TrunkeyDD , CobbEE , HeibronDC . Endoscopic sclerothearpy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage. New England Journal of Medicine1984;311(25):1589-94. [DOI: 10.1056/NEJM198412203112501] [MEDLINE: 6334234]Cello JP , GrendellJH , CrassRA , WeberTE , TrunkeyDD . Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. New England Journal of Medicine1987;316(1):11-5. [DOI: 10.1056/NEJM198701013160103] [MEDLINE: 3491317]">Cello 1987</a>; <a href="./references#CD000553-bbs2-0089" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Tranjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(1):A1334.">Sauer 1998</a>). Most participants in the <a href="./references#CD000553-bbs2-0029" title="CelloJP , GrendellJH , CrassRA , TrunkeyDD , CobbEE , HeibronDC . Endoscopic sclerothearpy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage. New England Journal of Medicine1984;311(25):1589-94. [DOI: 10.1056/NEJM198412203112501] [MEDLINE: 6334234]Cello JP , GrendellJH , CrassRA , WeberTE , TrunkeyDD . Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. New England Journal of Medicine1987;316(1):11-5. [DOI: 10.1056/NEJM198701013160103] [MEDLINE: 3491317]">Cello 1987</a> trial had acute uncontrolled bleeding at randomisation; hence, we excluded the trial from the current review version. The trial publication <a href="./references#CD000553-bbs2-0089" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Tranjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(1):A1334.">Sauer 1998</a> and the trial publication <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a> seemed to be reports of the same trial, which was confirmed through personal communication with the trial authors (see the notes field of the <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a> table). In addition, for the previous version of the review (<a href="./references#CD000553-bbs2-0112" title="KhanSA , Tudur SmithC , WilliamsonPR , SuttonR . Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD000553. [DOI: 10.1002/14651858.CD000553.pub2] [MEDLINE: 17054131]">Khan 2006</a>), 14 trial publications have been excluded. Among these records, two publications (Rossi 1994 and Krieger 1997) were recognised as ancillary studies of trials that were already included, i.e.<a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a> and <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>. We listed these two references within their trial identifiers in <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>. One trial was reclassified and was added to the current version of the review (<a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>). </p> <p>For the current review version, we rechecked or updated extracted data with data found in the most recent multiple publications of five trials (<a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). Furthermore, we found data on cost‐effectiveness presented in one conference abstract (see <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>); and we extracted data on hepatic encephalopathy from <a href="./references#CD000553-bbs2-0103" title="WarrenWD , Millikan WJ Jr, HendersonJM , Abu-ElmagdKM , GallowayJR , Shires GT 3rd, et al. Splenopancreatic disconnection. Improved selectivity of distal splenorenal shunt. Annals of Surgery1986;204(4):346-55. [DOI: 10.1097/00000658-198610000-00002] [MEDLINE: 3532968]">Warren 1986</a> (see <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>), as the most recent publication ‐ <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a> ‐ did not report data on hepatic encephalopathy. </p> <p>The <a href="./references#CD000553-sec-0183" title="">Characteristics of excluded studies</a> tables provides the reasons for exclusion of identified publications from the previous and current review versions (i.e. 18 trials with 24 references) (<a href="./references#CD000553-bbs2-0028" title="CelloJP , CrassRC , TrunkeyDD . Endoscopic sclerotherapy versus esophageal transection of Child's class C patients with variceal hemorrhage. Comparison with results of portacaval shunt: preliminary report. Surgery1982;91(3):333-8. [MEDLINE: 7036396]">Cello 1982</a>; <a href="./references#CD000553-bbs2-0029" title="CelloJP , GrendellJH , CrassRA , TrunkeyDD , CobbEE , HeibronDC . Endoscopic sclerothearpy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage. New England Journal of Medicine1984;311(25):1589-94. [DOI: 10.1056/NEJM198412203112501] [MEDLINE: 6334234]Cello JP , GrendellJH , CrassRA , WeberTE , TrunkeyDD . Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and acute variceal hemorrhage. Long-term follow-up. New England Journal of Medicine1987;316(1):11-5. [DOI: 10.1056/NEJM198701013160103] [MEDLINE: 3491317]">Cello 1987</a>; <a href="./references#CD000553-bbs2-0030" title="EscorsellA , BañaresR , García-PagánJC , GilabertR , MoitinhoE , PiquerasB , et al. TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology (Baltimore, Md.)2002;35(2):385-92. [DOI: 10.1053/jhep.2002.30418] [MEDLINE: 11826413]">Escorsell 2002</a>; <a href="./references#CD000553-bbs2-0031" title="García-PagánJC , CacaK , Bureau C , LalemanW , AppenrodtB , LucaA , et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. New England Journal of Medicine2010;362(25):2370-9. [DOI: 10.1056/NEJMoa0910102.] [MEDLINE: 20573925] [ISRCTN58150114]">Garcia‐Pagan 2010</a>; <a href="./references#CD000553-bbs2-0032" title="KitanoS , IsoY , HashizumeM , YamagaH , KoyanagiN , WadaH , et al. Sclerotherapy vs. esophageal transection vs. distal splenorenal shunt for the clinical management of esophageal varices in patients with child class A and B liver function: a prospective randomized trial. Hepatology (Baltimore, Md.)1992;15(1):63-8. [DOI: 10.1002/hep.1840150113] [MEDLINE: 1727801]">Kitano 1992</a>; <a href="./references#CD000553-bbs2-0033" title="LiGQ , YangB , LiuJ , WangGC , YuanHP , ZhaoJR , et al. Hepatic venous pressure gradient is a useful predictor in guiding treatment on prevention of variceal rebleeding in cirrhosis. International Journal of Clinical and Experimental Medicine2015;8(10):19709-16. [MEDLINE: 26770635]">Li 2015</a>; <a href="./references#CD000553-bbs2-0034" title="MeddiP , MerliM , LionettiR , De SantisA , ValerianoV , MasiniA , et al. Cost analysis for the prevention of variceal rebleeding: a comparison between transjugular intrahepatic portosystemic shunt and endoscopic sclerotherapy in a selected group of Italian cirrhotic patients. Hepatology (Baltimore, Md.)1999;29(4):1074-7. [DOI: 10.1002/hep.510290411] [MEDLINE: 10094949]">Meddi 1999</a>; <a href="./references#CD000553-bbs2-0035" title="OrloffMJ , BellRH , OrloffMS , HardisonWGM , GreenburgAG . Prospective randomized trial of emergency portacaval shunt and emergency medical therapy in unselected cirrhotic patients with bleeding varices. Hepatology (Baltimore, Md.)1994;20(4 Pt 1):863-72. [DOI: 10.1002/hep.1840200414] [MEDLINE: 7927227]">Orloff 1994</a>; <a href="./references#CD000553-bbs2-0036" title="OrloffM , IsenbergJ , WheelerH , HaynesK , Jinich-BrookH , RapierR , et al. Portal-systemic encephalopathy in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt treatment of acutely bleeding esophageal varices in cirrhosis. Annals of Surgery2009;250(4):598-610. [DOI: 10.1097/SLA.0b013e3181b73126] [MEDLINE: 19730244]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Direct costs of care in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt for bleeding esophageal varices in cirrhosis - Part 4. Journal of Gastrointestinal Surgery2011;15(1):38-47. [DOI: 10.1007/s11605-010-1332-6] [MEDLINE: 20824373]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Emergency portacaval shunt versus rescue portacaval shunt in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis - Part 3. Journal of Gastrointestinal Surgery2010;14(11):1782-95. [DOI: 10.1007/s11605-010-1279-7] [MEDLINE: 20658205]OrloffMJ . Fifty-three years' experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in cirrhosis: 1958 - 2011. Journal of the American Medical Association Surgery2014;149(2):155-69. [DOI: 10.1001/jamasurg.2013.4045] [MEDLINE: 24402314]">Orloff 2009</a>; <a href="./references#CD000553-bbs2-0037" title="OrloffMJ , HyeRJ , WheelerHO , IsenbergJI , HaynesKS , VaidaF , et al. Randomized trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt versus portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis. Surgery2015;157(6):1028-45. OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. Journal of the American College of Surgeons2009;209(1):25-40. [DOI: 10.1016/j.jamcollsurg.2009.02.059] [MEDLINE: 19651060]">Orloff 2015</a>; <a href="./references#CD000553-bbs2-0038" title="PaquetKJ , LazarA , GadHA . Surgical measures in recurrent hemorrhage from esophageal and gastric varices after sclerotherapy - a prospective study [Chirurgische Massnahmen bei Rezidivblutungen aus Osophagus- und Magenvarizen nach Sklerosierungstherapie - eine prospektive Studie]. Langenbecks Archiv für Chirurgie. Supplement II, Verhandlungen der Deutschen Gesellschaft für Chirurgie1990;Suppl II:397-402. [MEDLINE: 1983579]">Paquet 1990</a>; <a href="./references#CD000553-bbs2-0039" title="ResnickRH , IberFL , IshiharaAM , ChalmersTC , ZimmermanH . A controlled study of the therapeutic portacaval shunt. Gastroenterology1974;6(5):843-57. [MEDLINE: 4547724]">Resnick 1974</a>; <a href="./references#CD000553-bbs2-0040" title="ReynoldsTB , DonovanAJ , MikkelsenWP , RedekerAG , TurrillFL , WeinerJM . Results of a 12-year randomized trial of portacaval shunt in patients with alcoholic liver disease and bleeding varices. Gastroenterology1981;80(5 Pt 1):1005-11. [MEDLINE: 7009309]">Reynolds 1981</a>; <a href="./references#CD000553-bbs2-0041" title="SanyalAJ , FreedmanAM , ShiffmanML , Purdum PP 3rd, LuketicVA , CheathamAK . Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology (Baltimore, Md.)1994;20(1 Pt 1):46-55. [DOI: 10.1016/0270-9139(94)90133-3] [MEDLINE: 8020904]SauerP , TheilmannL , StremmelW , StiehlA . Hepatic encephalopathy after transjugular intrahepatic portosystemic stent shunt (TIPS) [Hepatische Enzephalopathie nach transjugularem intrahepatischem porto-systemischem Stent-Shunt (TIPS)]. Zeitschrift für Gastroenterologie1995;33(5):277-8. [MEDLINE: 7610697]">Sanyal 1994</a>; <a href="./references#CD000553-bbs2-0042" title="SauerbruchT , MengelM , DollingerM , ZipprichA , RossleM , PantherE , et al, German Study Group for Prophaxis of Variceal Rebleeding. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology2015;149(3):660-8. [MEDLINE: 10.1053/j.gastro.2015.05.011] [PMID: 25989386]">Sauerbruch 2015</a>; <a href="./references#CD000553-bbs2-0043" title="TerésJ , BaroniR , BordasJM , VisaJ , PeraC , RodesJ . Randomized trial of portacaval shunt, stapling transection and endoscopic sclerotherapy in uncontrolled variceal bleeding. Journal of Hepatology1987;4(2):159-67. [DOI: 10.1016/s0168-8278(87)80075-2] [MEDLINE: 3295018]">Terés 1987a</a>; <a href="./references#CD000553-bbs2-0044" title="TripathiD , HelmyA , LuiHF , StanleyAJ , ForrestE , RedheadDN , et al. Randomized controlled trial of transjugular intra-hepatic portosystemic stent-shunt (TIPSS) versus TIPSS and variceal band ligation (VBL) in the prevention of variceal re-bleeding. Journal of Hepatology2001;34(Suppl 1):69-70. [DOI: 10.1016/S0168-8278(01)81114-4]">Tripathi 2001</a>; <a href="./references#CD000553-bbs2-0045" title="WangZ , ZhaoH , WangX , ZhangH , JiangM , TsauoJ , et al. Clinical outcome comparison between TIPS and EBL in patients with cirrhosis and portal vein thrombosis. Abdominal Imaging2015;40(6):1813-20. [DOI: 10.1007/s00261-014-0320-9] [MEDLINE: 25504374]">Wang 2015</a>). </p> <p>As a result, 27 randomised clinical trials (three of which described results in abstract format (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>) were included in this review update. The results of all trials were available in English. </p> </section> <section id="CD000553-sec-0051"> <h4 class="title">Included studies</h4> <section id="CD000553-sec-0052"> <h5 class="title">Trial design and setting</h5> <p>All of the 27 included trials were parallel‐group randomised clinical trials. These trials were carried out in 14 countries: the United States (n = 5) (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>), Germany (n = 4) (<a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>), Spain (n = 4) (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>), Italy (n = 2) (<a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>), China (n = 2) (<a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>), United Kingdom (n = 2) (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), France (n = 1) (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>), Austria (n = 1) (<a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>), The Netherlands (n = 1) (<a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>), Sweden (n = 1) (<a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>), Canada (n = 1) (<a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>), Japan (n = 1) (<a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>), Puerto Rico (n=1) (<a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>), and Taiwan (n = 1) (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>). </p> </section> <section id="CD000553-sec-0053"> <h5 class="title">Interventions</h5> <p>Three trials compared total shunt (TS) versus endoscopic intervention (164 participants) (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>), five trials compared distal splenorenal shunt (DSRS) versus endoscopic intervention (352 participants) (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>). Ten trials compared transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic intervention (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>), and nine trials compared transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic intervention combined with beta blockers (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). The 19 TIPS trials included 1312 participants. </p> </section> <section id="CD000553-sec-0054"> <h5 class="title">Comparisons</h5> <p>Eight trials employed banding in the endoscopic intervention group (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). Sixteen trials employed endoscopic sclerotherapy (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). Three trials used combinations of banding and either sclerotherapy or glue injection: one employed either sclerotherapy or band ligation (or combined sclerotherapy and banding) of oesophageal varices, with sclerotherapy of gastric varices (<a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>); one treated oesophageal varices with banding and treated gastric varices with injection of cyanoacrylate/lipiodol (<a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>); one utilised glue injection of gastric varices, followed by banding when there were concomitant oesophageal varices (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>). </p> <p>In summary, three trials compared TS versus sclerotherapy without drugs (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>), and five trials compared DSRSs with sclerotherapy without drugs (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). Among the 19 trials comparing TIPSs versus endoscopy, beta blockers were used in the endoscopic group in nine trials (two sclerotherapy (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>), five band ligation (<a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), and two band ligation and sclerotherapy (<a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>)). <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a> specifically examined trial participants with rebleeding from oesophageal varices under sufficient pharmacological treatment (propranolol and isosorbide mononitrate) and continued medical treatment in the endoscopic banding group. In 10 trials, only endoscopic interventions were used in the control group (in three trials band ligation (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>), in six trials sclerotherapy (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>), and in one trial glue injection into gastric varices and band ligation of oesophageal varices were used (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>)). </p> </section> <section id="CD000553-sec-0055"> <h5 class="title">Participants</h5> <p>Full details of the 27 included trials are given in the <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a> tables. All trials included 1828 participants with cirrhosis, with a history of variceal bleeding. Twenty‐three publications reported on participant age: mean age in 22 of the trials was 53.5 years, and median age in one trial was 49 years for participants treated with TIPS and 46 years for those treated with endoscopic intervention. The same 23 publications reported on sex, with a predominance of men in all trials (68.9% of participants were male) (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> <p>Among trials assessing TSs, one trial included only participants with Child‐Pugh class A (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>), and two trials excluded participants in class C (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>). <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a> did not provide information on trial participants' Child‐Pugh class. <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a> included participants in Child‐Pugh classes B and C. </p> <p>All other trials included participants in all Child‐Pugh classes in different proportions. <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a> excluded participants in Child‐Pugh class C with a score &gt; 13. The Child‐Pugh score in the trials in which it was reported ranged from 6.6 in <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a> to 9.8 in <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>. </p> <p><a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a> randomised participants in Child's classes A and B to DSRS, sclerotherapy, or propranolol, and participants in Child's C class to sclerotherapy or propranolol. </p> <p>Eighteen trials specifically either included participants with oesophageal variceal bleeding only or excluded those with isolated gastric varices or gastric variceal bleeding (<a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). One further trial excluded participants with 'large fundal varices' (<a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>). One trial was unique in focusing on gastric variceal bleeding (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>), excluding participants with acute oesophageal bleeds. One trial included participants with oesophageal or gastric variceal bleeding (or both) (<a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>). In four trial publications, the source of variceal bleeding was not specified (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>), although <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a> discusses treatment of both oesophageal and gastric varices. Two trials included participants with both oesophageal and gastric variceal bleeding; however, participants with gastric varices were excluded from the endoscopic intervention group after randomisation (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>). </p> <p>Five trials did not provide information on the cause of cirrhosis (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>). Of the remaining trials, alcohol was judged to be the specific cause of cirrhosis in 55.9% of trial participants (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). The <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>, <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>, and <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a> trials reported that alcohol contributed to liver cirrhosis in only 25.9%, 16.6%, and 2.0%, respectively, of trial participants. Viral aetiology was reported in 13 trials (<a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), and this ranged from 3% in <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a> to 90% of participants in <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>. </p> <p>Portal vein thrombosis was an explicit exclusion criterion in at least 11 trials (<a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>); three further trials excluded individuals with complete portal vein thrombosis or cavernous portal vein thrombosis (<a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>). In contrast, <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a> and <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a> specifically included only individuals with coexistent liver cirrhosis and portal vein thrombosis. </p> <p>We provide full details of the included trials in the <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a> tables. </p> </section> </section> <section id="CD000553-sec-0056"> <h4 class="title">For‐profit funding</h4> <p>Among 11 trials in which information on funding was reported, no trials were funded by industry or received any other type of for‐profit support. For the remaining 16 trials, no information on funding was available. </p> <section id="CD000553-sec-0057"> <h5 class="title">Total shunt (TS) versus endoscopic intervention</h5> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>, which assessed TS versus endoscopic intervention, was funded by the National Research Council. For all other trials, no information on the source of funding was available (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>). </p> </section> <section id="CD000553-sec-0058"> <h5 class="title">Distal splenorenal shunt (DSRS) versus endoscopic intervention</h5> <p><a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>,, <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>, and <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>,,which assessed DSRS versus endoscopic intervention, were supported by grants provided by public research bodies. No information on the source of funding was available in <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a> nor <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996.</a> </p> </section> <section id="CD000553-sec-0059"> <h5 class="title">Transjugular intrahepatic portacaval shunt (TIPS) versus endoscopic intervention</h5> <p><a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a> and <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>, which assessed TIPS versus endoscopic intervention, were supported by local institutional grants: <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a> and <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> were supported by national research organisations; and <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>, <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>, and <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a> were supported by regional and institutional grants. The remaining 12 trials provided no information (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> </section> </section> <section id="CD000553-sec-0060"> <h4 class="title">Excluded studies</h4> <p>Overall, we excluded 18 trials.</p> <p>In brief, the reasons for exclusion of the six trials identified in the last search performed for the present review version were absence of randomised design (<a href="./references#CD000553-bbs2-0033" title="LiGQ , YangB , LiuJ , WangGC , YuanHP , ZhaoJR , et al. Hepatic venous pressure gradient is a useful predictor in guiding treatment on prevention of variceal rebleeding in cirrhosis. International Journal of Clinical and Experimental Medicine2015;8(10):19709-16. [MEDLINE: 26770635]">Li 2015</a>; <a href="./references#CD000553-bbs2-0045" title="WangZ , ZhaoH , WangX , ZhangH , JiangM , TsauoJ , et al. Clinical outcome comparison between TIPS and EBL in patients with cirrhosis and portal vein thrombosis. Abdominal Imaging2015;40(6):1813-20. [DOI: 10.1007/s00261-014-0320-9] [MEDLINE: 25504374]">Wang 2015</a>), comparisons not relevant to the review (<a href="./references#CD000553-bbs2-0042" title="SauerbruchT , MengelM , DollingerM , ZipprichA , RossleM , PantherE , et al, German Study Group for Prophaxis of Variceal Rebleeding. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology2015;149(3):660-8. [MEDLINE: 10.1053/j.gastro.2015.05.011] [PMID: 25989386]">Sauerbruch 2015</a>), shunts and endoscopic interventions were performed as emergency treatment in an acute setting (<a href="./references#CD000553-bbs2-0036" title="OrloffM , IsenbergJ , WheelerH , HaynesK , Jinich-BrookH , RapierR , et al. Portal-systemic encephalopathy in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt treatment of acutely bleeding esophageal varices in cirrhosis. Annals of Surgery2009;250(4):598-610. [DOI: 10.1097/SLA.0b013e3181b73126] [MEDLINE: 19730244]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Direct costs of care in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt for bleeding esophageal varices in cirrhosis - Part 4. Journal of Gastrointestinal Surgery2011;15(1):38-47. [DOI: 10.1007/s11605-010-1332-6] [MEDLINE: 20824373]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Emergency portacaval shunt versus rescue portacaval shunt in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis - Part 3. Journal of Gastrointestinal Surgery2010;14(11):1782-95. [DOI: 10.1007/s11605-010-1279-7] [MEDLINE: 20658205]OrloffMJ . Fifty-three years' experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in cirrhosis: 1958 - 2011. Journal of the American Medical Association Surgery2014;149(2):155-69. [DOI: 10.1001/jamasurg.2013.4045] [MEDLINE: 24402314]">Orloff 2009</a>; <a href="./references#CD000553-bbs2-0037" title="OrloffMJ , HyeRJ , WheelerHO , IsenbergJI , HaynesKS , VaidaF , et al. Randomized trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt versus portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis. Surgery2015;157(6):1028-45. OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. Journal of the American College of Surgeons2009;209(1):25-40. [DOI: 10.1016/j.jamcollsurg.2009.02.059] [MEDLINE: 19651060]">Orloff 2015</a>), and participants with uncontrolled bleeding were included (<a href="./references#CD000553-bbs2-0031" title="García-PagánJC , CacaK , Bureau C , LalemanW , AppenrodtB , LucaA , et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. New England Journal of Medicine2010;362(25):2370-9. [DOI: 10.1056/NEJMoa0910102.] [MEDLINE: 20573925] [ISRCTN58150114]">Garcia‐Pagan 2010</a>). </p> <p>We provide the reasons for exclusion in the <a href="./references#CD000553-sec-0183" title="">Characteristics of excluded studies</a> tables. </p> </section> </section> <section id="CD000553-sec-0061"> <h3 class="title">Risk of bias in included studies</h3> <p>Please see <a href="#CD000553-fig-0002">Figure 2</a> and <a href="#CD000553-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD000553-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000553-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD000553-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000553-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD000553-sec-0062"> <h4 class="title">Portosystemic shunts versus endoscopic intervention</h4> <p>As expected, due to the nature of the intervention, no trial blinded participants or personnel. We acknowledge that blinding could have been unrealistic in trials of surgical shunts versus endoscopic treatment. Perhaps evaluation of mortality was not affected, but assessment of the other outcomes could have been influenced. In addition, the rate of protocol deviations in each trial for non‐clinical reasons could have been influenced by knowledge of the assignment. We judged trials with a large number of protocol deviations to be at high risk of bias, as assignment of participants to treatments groups could have been distorted, whereas we judged trials with a small number of protocol deviations to be at unclear risk of bias. </p> <p>For the domain 'other bias', we judged trials to be at high risk of bias if they reported a large number of participants being crossed‐over because of bleeding, and it is not known when the data were censored. </p> <p>As we performed quantitative analysis according to shunt type (TS, DSRS, or TIPS), we also presented risk of bias according to shunt type to allow clearer conclusions when each shunt type was individually examined. </p> <section id="CD000553-sec-0063"> <h5 class="title">Total shunt (TS) versus endoscopic intervention</h5> <section id="CD000553-sec-0064"> <h6 class="title">Random sequence generation and allocation concealment (selection bias)</h6> <p>All three trials had unclear generation of the randomisation sequence and unclear allocation concealment (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0065"> <h6 class="title">Blinding (performance bias and detection bias)</h6> <p>For blinding of participants and personnel (performance bias), two trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>), whereas <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> was at high risk (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p>None of the trials reported blinding of outcome assessors (to minimise detection bias) (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0066"> <h6 class="title">Incomplete outcome data (attrition bias)</h6> <p>Two trials were at low risk of bias (<a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>), and one trial was at high risk of bias (<a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0067"> <h6 class="title">Selective reporting (reporting bias)</h6> <p>Two trials were at low risk of bias (<a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>; <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>), and one trial was at high risk risk of bias (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p><b>Other sources of bias</b> </p> <p>One trial was at low risk of bias (<a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>). One trial, published as a conference abstract, was at unclear risk of bias (<a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a>). This is why we cannot exclude other potential sources of bias. One trial was at high risk of bias because of the large number of participants who were crossed‐over from one treatment group to another when a participant bled (<a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>). It is unknown whether they were censored at the time of cross‐over (<a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> </section> <section id="CD000553-sec-0068"> <h5 class="title">Distal splenorenal shunt (DSRS) versus endoscopic intervention</h5> <section id="CD000553-sec-0069"> <h6 class="title">Random sequence generation and allocation concealment (selection bias)</h6> <p>For random sequence generation, four trials were at low risk of bias (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>), and one trial was at unclear risk of bias (<a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p>For allocation concealment, all five trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0070"> <h6 class="title">Blinding (performance bias and detection bias)</h6> <p>For blinding of participants and personnel, four trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>), whereas one trial was at high risk of bias (<a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p>For blinding of outcome assessors, all five trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0071"> <h6 class="title">Incomplete outcome data (attrition bias)</h6> <p>Three trials were at low risk of bias (<a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>), and two trials were at high risk of bias (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0072"> <h6 class="title">Selective reporting (reporting bias)</h6> <p>We judged all five trials to be at high risk of reporting bias (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p><b>Other bias</b> </p> <p>One trial was at low risk (<a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>), and four trials were at high risk of bias (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> </section> <section id="CD000553-sec-0073"> <h5 class="title">Transjugular intrahepatic portacaval shunt (TIPS) versus endoscopic intervention</h5> <section id="CD000553-sec-0074"> <h6 class="title">Random sequence generation and allocation concealment (selection bias)</h6> <p>For random sequence generation, 12 trials were at low risk of bias (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), and seven trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p>For allocation concealment, nine trials were at low risk of bias (<a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), and 10 trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0075"> <h6 class="title">Blinding (performance bias and detection bias)</h6> <p>For blinding of participants and personnel, all trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p>For blinding of outcome assessors, two trials were at low risk of bias (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>). The other 17 trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0076"> <h6 class="title">Incomplete outcome data (attrition bias)</h6> <p>Fifteen trials were at low risk (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), and three trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>). One trial was at high risk of bias (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> </section> <section id="CD000553-sec-0077"> <h6 class="title">Selective reporting (reporting bias)</h6> <p>Ten trials were at low risk of bias (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>). Four trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). Five trials were at high risk of bias (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p><b>Other bias</b> </p> <p>Four trials were at low risk of bias (<a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>), two trials were at unclear risk of bias (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>), and 13 trials were at high risk of bias (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>) (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p><b>Overall judgement</b> </p> <p>We judged all trials to be at unclear or high risk of bias in at least one domain. As a result, all trials were at overall high risk of bias, which could result in systematic errors (<a href="#CD000553-fig-0002">Figure 2</a>; <a href="#CD000553-fig-0003">Figure 3</a>; <a href="./references#CD000553-sec-0182" title="">Characteristics of included studies</a>). </p> <p>However, in <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a> and <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>, the judgement of high risk is based exclusively on lack of blinding of participants and personnel, which is not feasible for the kind of treatments, but did not exclude deviations of intended interventions (i.e. additional interventions given). In <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>, the judgement of high risk is based only on the lack of blinding of participants and personnel and of outcome assessors, which could influence all outcomes assessed. </p> <p>We classified trials as having risk of 'other bias' when participants were crossed over to the alternative treatment after bleeding and it is not reported when they were censored. For this reason, rebleeding is not influenced by the cross‐over. On the contrary, mortality, mortality due to rebleeding, and hepatic encephalopathy could have been influenced by the cross‐over. </p> </section> </section> </section> </section> <section id="CD000553-sec-0078"> <h3 class="title" id="CD000553-sec-0078">Effects of interventions</h3> <p>See: <a href="./full#CD000553-tbl-0001"><b>Summary of findings 1</b> Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</a>; <a href="./full#CD000553-tbl-0002"><b>Summary of findings 2</b> Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</a>; <a href="./full#CD000553-tbl-0003"><b>Summary of findings 3</b> Distal splenorenal shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</a>; <a href="./full#CD000553-tbl-0004"><b>Summary of findings 4</b> Transjugular intrahepatic portosystemic shunt compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</a> </p> <p>Results of the meta‐analysis of all shunt types (i.e. TS, DSRS, and TIPS) versus endoscopic intervention with or without medical treatment are summarised in <a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>. </p> <p>Results of the meta‐analysis of total shunt (TS) versus endoscopic intervention with or without medical treatment are summarised in <a href="./full#CD000553-tbl-0002">summary of findings Table 2</a>. </p> <p>Results of the meta‐analysis of distal splenorenal shunt (DSRS) versus endoscopic intervention with or without medical treatment are summarised in <a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>. </p> <p>Results of the meta‐analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic intervention with or without medical treatment are summarised in <a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>. </p> <p>Time‐to‐event data for mortality could be obtained for only 23 trials, for rebleeding in only 16 trials, and for acute hepatic encephalopathy only in 12 trials. These results were similar to those obtained by the analysis of dichotomous data. No information on the other outcomes could be obtained. So, we decided to report only the dichotomous results. Morever, there was no pre‐defined time point for reporting time‐to‐event outcomes across all trials. </p> <section id="CD000553-sec-0079"> <h4 class="title">All shunt types (i.e. TS, DSRS, and TIPS) versus endoscopic treatment</h4> <section id="CD000553-sec-0080"> <h5 class="title">All‐cause mortality</h5> <p>Twenty‐seven trials reported all‐cause mortality (3 trials using TS, 5 trials using DSRS, 19 trials using TIPS). Mortality data were available for time‐to‐event analysis in 23 trials (2 trials used TS, 4 trials used DSRS, and 17 trials used TIPS). When we meta‐analysed data for all shunt modalities, we found no evidence of a difference between shunts and endoscopic interventions with or without medical treatment in all‐cause mortality (risk ratio (RR) 0.99, 95% confidence interval (CI) 0.86 to 1.13; 1828 participants; 27 trials; I² = 3%; very low‐certainty evidence; <a href="./references#CD000553-fig-0009" title="">Analysis 1.1</a>). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>; <a href="#CD000553-tbl-0005">Table 1</a>; <a href="#CD000553-fig-0004">Figure 4</a>). </p> <div class="table" id="CD000553-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of portosystemic shunts versus endoscopic intervention with or without medical therapy for prevention of rebleeding in patients with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Comparison of imprecision by GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction while also considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrade 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrade 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The Z‐curve did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.<br/><sup>b</sup>The Z‐curve reached the monitoring boundary for benefit.<br/><sup>c</sup>The Z‐curve reached the monitoring boundary for futility.<br/><sup>d</sup>The Z‐ curve reached the monitoring boundary for harm.<br/><sup>e</sup>The TSA figure was not constructed due to too little information. </p> </div> </div> <div class="figure" id="CD000553-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.1 All‐cause mortality" data-id="CD000553-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.1 All‐cause mortality </p> </div> </div> </div> <section id="CD000553-sec-0081"> <h6 class="title">Sensitivity analysis</h6> <section id="CD000553-sec-0082"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default relative risk reduction (RRR) of 25% for GRADE as suggested in the GRADE Handbook (<a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">Grade Handbook</a>), along with the plausible RRR of 10% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed with 28.8% for all‐cause mortality in the endoscopic intervention with or without medical treatment group; an RRR of 10% with the portosystemic shunt; type I error of 2.5%; and type II error of 20% (80% power). There was no diversity (D² = 0%). The diversity‐adjusted required information size (DARIS) was 9111 participants. In Trial Sequential Analysis, the cumulative Z‐curve (blue line) did not approach the monitoring boundaries (red lines) for benefit, harm, or futility (figure not shown). </p> <p>The GRADE optimal information size (OIS) was met by using the default RRR of 25% as suggested in the GRADE Handbook, but not when we used a more realistic RRR of 10% chosen by review authors for GRADE and Trial Sequential Analysis (<a href="#CD000553-tbl-0005">Table 1</a>). </p> </section> </section> </section> <section id="CD000553-sec-0083"> <h5 class="title">Rebleeding</h5> <p>Across all shunt modalities, 26 trials reported on rebleeding (2 trials using TS, 5 trials using DSRS, 19 trials using TIPS). Data on rebleeding were available for time‐to‐event analysis in 16 trials (0 trials using TS, 1 trial using DSRS, 15 trials using TIPS). When all shunt modalities were meta‐analysed and compared with endoscopic interventions with or without medical treatment, shunt intervention reduced rebleeding (RR 0.40, 95% CI 0.33 to 0.50; 1769 participants; 26 trials; I² = 31%; very low‐certainty evidence; <a href="./references#CD000553-fig-0010" title="">Analysis 1.2</a>). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>; <a href="#CD000553-tbl-0005">Table 1</a>; <a href="#CD000553-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD000553-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.2 Rebleeding" data-id="CD000553-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.2 Rebleeding </p> </div> </div> </div> <section id="CD000553-sec-0084"> <h6 class="title">Sensitivity analysis</h6> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% for GRADE as suggested in the GRADE Handbook, as well as a plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on a rebleeding risk of 43.2% in the endoscopic intervention with or without medical treatment group; type I error of 2.5%; and type II error of 20% (80% power). The cumulative Z‐curve crossed the monitoring boundary for benefit before reaching the required information size both when RRR with portosystemic shunt was set to 40% (D² = 35%, DARIS 441 participants), and when it was set to 20% (D² = 35%, DARIS 1854 participants) (figures not shown). </p> <p>The OIS was met by using the default RRR of 25% as suggested in the GRADE Handbook, and when we used an RRR of 40% and 20% for GRADE and 40% for TSA, but not when the RRR was 20% for TSA (<a href="#CD000553-tbl-0005">Table 1</a>). </p> </section> </section> <section id="CD000553-sec-0085"> <h5 class="title">Health‐related quality of life</h5> <p>No trials examined health‐related quality of life.</p> </section> <section id="CD000553-sec-0086"> <h5 class="title">Mortality due to rebleeding</h5> <p>We were able to extract data on death caused by rebleeding from 26 trials across all shunt modalities (3 trials using TS, 5 trials using DSRS, and 18 trials using TIPS). No data could be extracted to allow analysis of death due to rebleeding as a time‐to‐event outcome. </p> <p>Portosystemic shunts reduced mortality due to rebleeding (RR 0.51, 95% CI 0.34 to 0.76; 1779 participants; 26 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0011" title="">Analysis 1.3</a>). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels) due to imprecision, because OIS as calculated by GRADE was not met (‐1 level), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>; <a href="#CD000553-tbl-0005">Table 1</a>; <a href="#CD000553-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD000553-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.3 Mortality due to rebleeding" data-id="CD000553-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.3 Mortality due to rebleeding </p> </div> </div> </div> <section id="CD000553-sec-0087"> <h6 class="title">Sensitivity analysis</h6> <section id="CD000553-sec-0088"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on mortality due to rebleeding risk of 9.5% in the endoscopic intervention with or without medical treatment group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve reached the futility area before reaching the required information size when RRR with portosystemic shunt was set to 40% (D² = 0%, DARIS 2117 participants). When RRR was set to 20%, the cumulative Z‐curve did not approach the monitoring boundaries for benefit or harm or futility (D² = 0%; DARIS 9429 participants) (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, by using an RRR of 40% and 20% for GRADE, or by using an RRR of 40% and 20% for Trial Sequential Analysis (<a href="#CD000553-tbl-0005">Table 1</a>). </p> </section> </section> </section> <section id="CD000553-sec-0089"> <h5 class="title">Acute hepatic encephalopathy</h5> <p>Across all shunt modalities, 24 trials reported on development of acute hepatic encephalopathy as a dichotomous outcome (2 trials using TS, 4 trials using DSRS, 18 trials using TIPS). Portosystemic shunts increased acute hepatic encephalopathy (RR 1.60, 95% CI 1.33 to 1.92; 1649 participants; 24 trials; I² = 10%; <a href="./references#CD000553-fig-0012" title="">Analysis 1.4</a>; very low‐certainty evidence). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level), and because of publication bias (<a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>; <a href="#CD000553-tbl-0005">Table 1</a>; <a href="#CD000553-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD000553-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.4 Acute hepatic encephalopathy" data-id="CD000553-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-07.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.4 Acute hepatic encephalopathy </p> </div> </div> </div> <section id="CD000553-sec-0090"> <h6 class="title">Sensitivity analysis</h6> <section id="CD000553-sec-0091"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on an incidence of acute hepatic encephalopathy of 18.5% in the endoscopic intervention with or without medical treatment group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve approached the monitoring boundary for harm before reaching the required information size when the RRR with portosystemic shunt was set to 40% (D² = 14%, DARIS 1160 participants), and when the RRR was set to 20% (D² = 14%, DARIS 5108 participants) (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, by using an RRR of 20% for GRADE, or by using an RRR of 20% for Trial Sequential Analysis. It was reached with an RRR of 40% for GRADE and for Trial Sequential Analysis (<a href="#CD000553-tbl-0005">Table 1</a>). </p> </section> </section> </section> <section id="CD000553-sec-0092"> <h5 class="title">Chronic hepatic encephalopathy</h5> <p>Across all shunt modalities, 13 trials reported on development of chronic hepatic encephalopathy (1 trial using TS, 2 trials using DSRS, 10 trials using TIPS). No time‐to‐event data could be extracted for chronic hepatic encephalopathy for any shunt type. Portosystemic shunts versus endoscopic intervention with or without medical treatment increased chronic hepatic encephalopathy (RR 2.51, 95% CI 1.38 to 4.55; 956 participants; 13 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0013" title="">Analysis 1.5</a>). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>; <a href="#CD000553-tbl-0005">Table 1</a>; <a href="#CD000553-fig-0008">Figure 8</a>). </p> <div class="figure" id="CD000553-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.5 Chronic hepatic encephalopathy" data-id="CD000553-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-08.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.5 Chronic hepatic encephalopathy </p> </div> </div> </div> <section id="CD000553-sec-0093"> <h6 class="title">Sensitivity analysis</h6> <section id="CD000553-sec-0094"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on an incidence of chronic hepatic encephalopathy of 2.7% in the endoscopic intervention with or without medical treatment group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve did not approach the monitoring boundaries for benefit, harm, or futility when RRR with portosystemic shunt was set to 40% (D² = 0%, DARIS 7888 participants). The Trial Sequential Analysis curve was not constructed due to little information (2.7%, DARIS) when RRR was set to 20% (D² = 0%, DARIS 35,394 participants) (figures not shown). </p> <p>The required information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, by using an RRR of 20% and 40% for GRADE, or by using an RRR of 20% and 40% for Trial Sequential Analysis (<a href="#CD000553-tbl-0005">Table 1</a>). </p> </section> </section> </section> <section id="CD000553-sec-0095"> <h5 class="title">Complications</h5> <p>Full details of complications are summarised according to each individual shunt modality in <a href="#CD000553-tbl-0006">Table 2</a>, <a href="#CD000553-tbl-0007">Table 3</a>, and <a href="#CD000553-tbl-0008">Table 4</a>. </p> <div class="table" id="CD000553-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Total shunt versus endoscopic intervention: shunt surveillance and complications</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Method of shunt surveillance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Incidence of shunt dysfunction</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported shunt complications or adverse events<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported endoscopic or medical therapy complications or adverse events<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography at 4 months, then ultrasound every 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/24: acute shunt thrombosis (percentage and 95% CI 4.2%, 0.7% to 20%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophagitis 8 patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal stenosis 2 patients</p> <p>Oesophagitis 7 patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ultrasound 3 to 10 months after surgery or at the time of variceal rebleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/41: shunt thrombosis (percentage and 95% CI 2.4%, 0.4% to 13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from lesions other than oesophageal or gastric varices 3 patients</p> <p>Other complications 7 patients (wound abscess 2, sepsis 1, pneumonia 2, chylous pleural effusion 1, cholestasis 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from lesions other than oesophageal or gastric varices 4 patients</p> <p>Other complications 12 patients (deep oesophageal ulcers 3, stenosis 1, pneumonia 1, transient dysphagia 4, fever 2, pleural effusion 1) </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Acute hepatic encephalopathy, chronic hepatic encephalopathy, mortality, and shunt dysfunction not included, as reported elsewhere in this review. </p> </div> </div> <div class="table" id="CD000553-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Distal splenorenal shunt versus endoscopic intervention: shunt surveillance and complications</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Method of shunt surveillance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Incidence of shunt dysfunction</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported shunt complications or adverse events<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported endoscopic or medical therapy complications or adverse events<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from deep oesophageal ulcers 2 patients</p> <p>Insufficient information on other complications or adverse events</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography at 3 months, then at 1, 3, and 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/30</p> <p>(percentage and 95% CI 10%, 3.5% to 26%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal stenosis 3 patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography on 10th day, then at 1, 3, and 6 months after discharge, then at least twice yearly </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/40</p> <p>(percentage and 95% CI 0%, 0% to 9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on surgical complications</p> <p>Bleeding from duodenal ulcers 5 patients</p> <p>Ascites 11 patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from oesophageal ulcers 5 patients</p> <p>Bleeding from unknown sources 2 patients</p> <p>Dyspagia due to oesophageal ulcers 8 patients</p> <p>Oesophageal stenosis 5 patients</p> <p>Pleural effusion 1 patient</p> <p>Ascites 19 patients</p> <p>Liver failure 1 patient</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography, ultrasound, and/or isotopic splenoportography 7 to 10 months after surgery and when variceal rebleeding occurred </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43</p> <p>(percentage and 95% CI 12%, 5% to 24%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on surgical complications</p> <p>Bleeding from sources other than varices (peptic ulcers or gastritis) 5 patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from sources other than varices (peptic ulcers or gastritis) 7 patients</p> <p>Oesophageal ulcers 2 patients</p> <p>Oesophageal stenosis 3 patients</p> <p>Transient dysphagia 15 patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Acute hepatic encephalopathy, chronic hepatic encephalopathy, mortality, and shunt dysfunction not included, as reported elsewhere in this review. </p> </div> </div> <div class="table" id="CD000553-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical treatments: shunt surveillance and complications</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stent type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Method of shunt surveillance</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Incidence of shunt dysfunction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported shunt complications or adverse events<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported endoscopic or medical therapy complications or adverse events<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐mm Wallstent endoprosthesis 15 patients</p> <p>Strecker stent 15 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography 6‐monthly and after any episode of ascites or variceal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/27 (percentage and 95% CI 55%, 37% to 72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complications 7 patients (portal vein thrombosis 2, spontaneous bacterial peritonitis 2, haemobilia 1, sepsis 1, pneumonia 2, congestive heart failure 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complications 11 patients (bleeding oesophageal ulcers 5, oesophageal stenosis 4, pneumonia 2, sepsis 1, spontaneous bacterial peritonitis 2) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallstents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/22 (percentage and 95% CI 18%, 7% to 38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>e‐PTFE‐covered stent (Viatorr TIPSS endoprosthesis, W.L. Gore &amp; Associates, Inc., Newark, NJ, USA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasonography or TIPSS venography at 6 months and at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No technical failures or major complications of the TIPSS procedure</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Banding ulcer 3</p> <p>Mallory Weiss 2</p> <p>Portal hypertensive gastropathy 1</p> <p>Seizure 2, fractured bone 3, cellulitis 1, arrhythmia 1, urinary tract infection 1, alcohol hepatitis 1, left ventricular thrombus 1, pneumonia 2, spontaneous bacterial peritonitis 1, spontaneous retroperitoneal bleeding 1, hyponatraemia 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on procedure‐related complications</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Banding ulcer 2</p> <p>Mallory Weiss 1</p> <p>Fractured bone 2, arrhythmia 1, abscess 1, compartment syndrome 1, urinary tract infection 1, alcohol hepatitis 2, spontaneous bacterial peritonitis 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTFE‐coated TIPS</p> <p>(not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stent thrombosis 3 patients/21 (14%,</p> <p>95% CI 5% to 35%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient Information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient Information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography at 1 month and every 6 months thereafter, and if variceal bleeding or ascites occurred </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/18 at 6 months (percentage and 95% CI 78%, 55% to 91%)</p> <p>10/13 at 12 months (percentage and 95% CI 77%, 50% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest discomfort almost all patients</p> <p>Oesophageal ulcer 5 patients</p> <p>Oesophageal stenosis 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler sonography at 1 month, at 3 months, and at 3‐monthly intervals thereafter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perforation of liver capsule with peritoneal haemorrhage (death) 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perforation of oesophagus 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTFE‐covered stent</p> <p>(Viatorr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical evaluation every 6 weeks to 3 months. Duplex ultrasound undertaken when dysfunction suspected (new‐onset or progressive ascites, or variceal rebleeding) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/37: partial/complete occlusion (percentage and 95% CI 5%, 1.5% to 17.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events 24</p> <p>Number of complications or adverse events<sup>c</sup>: </p> <p>Bleeding from banding ulcer 1</p> <p>Bleeding from other upper gastrointestinal sources 1</p> <p>Ascites 5</p> <p>Spontaneous bacterial peritonitis 2</p> <p>Hepatocellular carcinoma or cholangiocarcinoma 2</p> <p>Acute‐on‐chronic liver failure 4</p> <p>Cholangitis 6</p> <p>Alcoholic hepatitis 1</p> <p>Sepsis 4</p> <p>Cardiac event 1</p> <p>Neurological disorder 1</p> <p>Other complications 3</p> <p>Severe itching 1</p> <p>Gynaecomastia 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events 24 patients</p> <p>Number of complications or adverse events<sup>c</sup>: </p> <p>Bleeding from banding ulcer 2</p> <p>Bleeding from other upper gastrointestinal sources 1</p> <p>Intra‐abdominal bleeding from collaterals 1</p> <p>Laceration of hepatic artery (during TIPS placement) 1</p> <p>Ascites 13</p> <p>Spontaneous bacterial peritonitis 3</p> <p>Hepatorenal syndrome 1</p> <p>Hepatocellular carcinoma or cholangiocarcinoma 4</p> <p>Acute‐on‐chronic liver failure 3</p> <p>Cholangitis 2</p> <p>Alcoholic hepatitis 2</p> <p>Sepsis 1</p> <p>Cardiac event 3</p> <p>Neurological disorder 3</p> <p>Other complications 3</p> <p>Severe itching 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐mm expandable metal stent (Wallstent)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound at 1 week</p> <p>Angiography at 1 month, then at 6‐monthly intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/28: shunt thrombosis 6 patients (variceal rebleeding in 2 patients), pseudointimal hyperplasia 3 patients (percentage and 95% CI 32%, 18% to 51%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sepsis 3 patients (aspiration pneumonia 1 patient, staphylococcal septicaemia 2 patients)</p> <p>Perforation of liver capsule 1 patient</p> <p>Respiratory depression caused by sedation 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal ulcer 12 patients</p> <p>Bleeding from oesophageal ulcer 1 patient</p> <p>Aspiration pneumonia 2 patients</p> <p>Sepsis 4 patients (aspiration pneumonia 2 patients, spontaneous bacterial peritonitis 1 patient, central line‐related sepsis 1 patient) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metallic endoprosthesis (Wallstent)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound at discharge and every 3 months, or when clinically indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/35 (percentage and 95% CI 23%, 12% to 39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteremia 5 patients</p> <p>Hepatic failure 2 patients</p> <p>Bleeding from peptic ulcer 5 patients</p> <p>Bleeding from undetermined source 2 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ulcer on gastric varices 3 patients</p> <p>Bacteraemia 10 patients</p> <p>Spontaneous bacterial peritonitis 1 patient</p> <p>Bleeding from peptic ulcer 1 patient</p> <p>Bleeding from undetermined source 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐mm expanded PTFE‐covered stent</p> <p>(Fluency)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether routine surveillance was carried out</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/37: stent occlusion 7 patients and stent stenosis 4 patients (percentage and 95% CI 30%, 17% to 46%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No 'major' complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient retrosternal pain 11 patients</p> <p>Post‐ligation bleeding ulcer 2 patients</p> <p>Bradycardia propranolol‐related 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐mm PTFE‐covered stent (Fluency)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound and CT at 1, 3, and 6 months, then every 6 months or whenever clinical recurrence of portal hypertension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐year and 2‐year shunt dysfunction 15% and 20%, respectively</p> <p>4/24 shunt dysfunction<sup>d</sup> (percentage and 95% CI 17%, 7% to 36%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of patients with complications or adverse events is not obtainable<sup>e</sup> </p> <p>Ascites 1</p> <p>Hepatocellular carcinoma 2</p> <p>Fatigue 2</p> <p>Pneumonia 1</p> <p>Intraperitoneal bleeding 1</p> <p>Pulmonary embolism 1</p> <p>Acute‐on‐chronic liver failure 1</p> <p>Fever 2</p> <p>Dizziness 1</p> <p>Vomiting 1</p> <p>Peripheral oedema 2</p> <p>Mispuncture of bile duct 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of patients with complications or adverse events is not obtainable<sup>e</sup> </p> <p>Ascites 3</p> <p>Hepatic hydrothorax 1</p> <p>Spontaneous bacterial peritonitis 1</p> <p>Hepatorenal syndrome 1</p> <p>Hepatocellular carcinoma 1</p> <p>Bleeding from banding ulcer 1</p> <p>Dysphagia 3</p> <p>Deep venous thrombosis 1</p> <p>Oesophageal stenosis 1</p> <p>Haematuria 1</p> <p>Chest pain after ligation 2</p> <p>Fever 1</p> <p>Fatigue 1</p> <p>Dizzines 2</p> <p>Abdominal pain 1</p> <p>Diarrhoea 1</p> <p>Peripheral oedema 1</p> <p>Rash 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 × 52‐mm Wallstent or 10 × 70/80‐mm Nitinol Strecker stent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound 6‐monthly and angiography 6‐monthly or whenever clinically indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/33 (percentage and 95% CI 64%, 47% to 78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemolysis 1 patient</p> <p>Intrahepatic haematoma 1 patient</p> <p>Cardiac arrest 1 patient</p> <p>Pulmonary embolism 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sclerotherapy‐induced ulcer 2 patients</p> <p>Oesophageal stenosis 2 patients</p> <p>Aspiration pneumonia 1 patient</p> <p>Embolic stroke 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gianturco‐Rösch biliary expandable Z‐stent (21 patients), Spiral‐Z stent (4 patients), Wallstent (13 patients) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/38 (percentage and 95% CI 71%, 55% to 83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure‐related complications:</p> <p>Haemobilia 2 patients</p> <p>Segmental hepatic infarction 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure‐related complications:</p> <p>Dysphagia 2 patients</p> <p>Transient pleural effusion 6 patients</p> <p>Bleeding ulcer secondary to sclerotherapy 3 patients</p> <p>Oesophageal stenosis 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound at 24 hours and then 3‐monthly for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/41 (percentage and 95% CI 58%, 43% to 72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from non‐variceal sources 6 patients</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Oesophageal ulcer due to ligation 3</p> <p>Oesophagitis 3</p> <p>Haemobilia 1</p> <p>Gastropathy 1</p> <p>Peptic ulcer 2</p> <p>No information on other complications or adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from non‐variceal sources 9 patients</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Oesophageal ulcer due to ligation 7</p> <p>Mallory‐Weiss 2</p> <p>Oesophagitis 2</p> <p>No information on other complications or adverse events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmaz stent (39 patients, 92 stents), Memotherm stent (16 patients, 19 stents), Wallstent (6 patients, 6 stents) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound at 1, 3, 6, 9, and 12 months, then 6‐monthly or when needed for clinical reason </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/61 (percentage and 95% CI 29%, 19% to 42%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stent migration or dislocation 2 patients</p> <p>Haemobilia 3 patients</p> <p>Haemoperitoneum 2 patients</p> <p>Bleeding in the liver 1 patient</p> <p>Sepsis 1 patient</p> <p>Bradycardia 4 patients</p> <p>Fever 11 patients</p> <p>Transient abdominal pain 6 patients</p> <p>Bradyarrhytmia due to stent migration into the right ventricle requiring pacemaker 1 patient </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulcer 8 patients</p> <p>Dysphagia 5 patients</p> <p>Mediastinitis 1 patient</p> <p>Hypopyon with eye enucleation (likely caused by sclerotherapy‐bacteraemia) 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallstent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound at day 1, at week 1, at 1 and 3 months, then 3‐monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/34 at 6 months (percentage and 95%CI 59%, 42% to 74%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemolysis TIPS‐associated 5 patients (severe in 1 patient)</p> <p>Sepsis 6 patients</p> <p>Renal failure 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest discomfort</p> <p>Oesophageal ulcer 22 patients</p> <p>Dysphagia + Stenosis 3 patients</p> <p>Dysphagia 2 patients</p> <p>Sepsis 2 patients</p> <p>Ascites 5 patients</p> <p>Seizures 1 patient</p> <p>Renal failure 2 patients</p> <p>Bleeding 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmaz stent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound every 3 months and after variceal bleeding or other complications</p> <p>Angiography every 3 months and if dysfunction suspected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/42 at 2 years (percentage and 95% CI 76%, 61% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not report number of patients with adverse events but did report numbers of events: </p> <p>Stent dislocation 4</p> <p>Renal failure 6</p> <p>Pneumonia 5</p> <p>Septicaemia 3</p> <p>Liver failure 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not report number of patients with adverse events but did report numbers of events: </p> <p>Oesophageal ulcer 19</p> <p>Bleeding ulcer 3</p> <p>Post‐therapeutic haemorrhage 5</p> <p>Renal failure 3</p> <p>Pneumonia 6</p> <p>Septicaemia 2</p> <p>Liver failure 2</p> <p>Heart failure propranolol‐related 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmaz stent or Wallstent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex sonography and angiography every 3 months in the first year, every 6 months in the second year, and at yearly intervals thereafter; also if shunt dysfunction suspected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative dysfunction: 38/43 (89%) during follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia 4 patients</p> <p>Haemobilia 2 patients</p> <p>Stent dislocation 1 patient</p> <p>Septicaemia 3 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysphagia 3 patients</p> <p>Pneumonia 3 patients</p> <p>Septicaemia 2 patients</p> <p>Post‐therapeutic haemorrhage 2 patients</p> <p>Severe side effects (type non‐specified) propranolol‐related 2 patients</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Acute hepatic encephalopathy, chronic hepatic encephalopathy, mortality, and shunt dysfunction not included, as reported elsewhere in this review.<br/><sup>b</sup>Data for other complications and adverse events were extracted as numbers of events across all time points (&lt; 2 years and ≥ 2 years combined).<sup>c</sup>Data for other complications and adverse events were extracted as numbers of adverse events across all time points (&lt; 6 months and &gt; 2 months until end of follow‐up combined).<br/><sup>d</sup>Data extracted from plot in <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>.<br/><sup>e</sup>Number of episodes. </p> <p>PTFE: polytetrafluorethylene.</p> </div> </div> <p>It was not possible to perform a meta‐analysis of all complications because trialists often reported the number of events and not the number of participants who had events. As some complications are treatment‐specific (e.g. shunt occlusion or thrombosis in shunt intervention, oesophageal ulcers or thoracic pain in endoscopic intervention), they cannot be compared in the two treatment groups. Below we report the number of cases of shunt dysfunction or occlusion (thrombosis) in the shunt group. For the endoscopy group, see details in <a href="#CD000553-tbl-0006">Table 2</a>, <a href="#CD000553-tbl-0007">Table 3</a>, and <a href="#CD000553-tbl-0008">Table 4</a>. </p> <section id="CD000553-sec-0096"> <h6 class="title">Shunt occlusion or dysfunction</h6> <p>The overall incidence of shunt occlusion or dysfunction was 37% (95% CI 33 to 40).</p> </section> </section> <section id="CD000553-sec-0097"> <h5 class="title">Inpatient stay</h5> <p>For the update of this review, we decided that because of the variability of definitions and of time periods measured, data for length of stay could not be combined across trials; therefore, we presented this outcome in a tabular format. The impact of shunt intervention on duration of inpatient stay remains unclear, and only limited conclusions may be drawn, with results summarised in <a href="#CD000553-tbl-0009">Table 5</a>. </p> <div class="table" id="CD000553-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Duration of hospital stay</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Time measured</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Shunt group</b> </p> <p><b>Mean (SD) or Median (range) [days]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Endoscopic therapy with or without drugs group</b> </p> <p><b>Mean (SD) or Median (range) [days]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Statistical significance</b> </p> <p><b>P value</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Total shunt (TS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation for treatment</p> <p>Total hospitalisation due to treatment or complications during follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.9 (14.1)</p> <p>41.2 (13.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3 (7.1)</p> <p>38.1 (12.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total hospital stay including operation and readmission</p> <p>ICU stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5 (9 to 122)</p> <p>4 (0 to 41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (15 to 64)</p> <p>3.3 (0 to 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Distal splenorenal shunt (DSRS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation for treatment</p> <p>Hospital stay for treatment of rebleeding and encephalopathy (shunt group)/treatment of rebleeding and sclerosis (sclerotherapy group) during follow‐up </p> <p>Hospital stay for treatment or for complications during follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (12.8)</p> <p>7.13 (16.1)</p> <p>47.7 (20.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5 (11.9)</p> <p>16.5 (30.5)</p> <p>51.5 (28.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> <p>0.027</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Transjugular intrahepatic portosystemic shunt (TIPS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation for treatment</p> <p>Hospitalisation for rebleeding</p> <p>Hospitalisation for causes other than bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1 (3.1)</p> <p>2.9 (6)</p> <p>6.96 (14.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7 (6.2)</p> <p>7.7 (9.8)</p> <p>4.45 (10.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>&lt; 0.05</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for variceal rebleeding</p> <p>Hospitalisation for any rebleeding</p> <p>Hospitalisation for portosystemic encephalopathy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.54 (2.13)</p> <p>20.8 (3.2)</p> <p>3.7 (1.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.92 (3.54)</p> <p>20.1 (4.6)</p> <p>1.2 (0.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>NS</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for any reason after initial discharge</p> <p>Hospitalisation for variceal rebleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.9 (20.2)</p> <p>1.5 (4.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3 (18.7)</p> <p>4.6 (7.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>&lt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation during follow‐up</p> <p>ICU stay</p> <p>Stay in the high‐dependency unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.2 (15)</p> <p>0.2 (0.8)</p> <p>0.7 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2 (19)</p> <p>1.15 (2.3)</p> <p>3.1 (3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> <p>0.03</p> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation</p> <p>Hospitalisation during 2‐year follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8 (1.8)</p> <p>45 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4 (2.4)</p> <p>40 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation (after randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stays per patient per year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.1 (30.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8 (21.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (5.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7 (6.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (11.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.095</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Data for length of hospital stay have been presented in a narrative/tabular format due to variation in time points measured between studies and resultant substantial heterogeneity. </p> <p>Results are given as mean and SE.<br/>ICU: intensive care unit.<br/>NS: not statistically significant. </p> </div> </div> <p>Full details are summarised according to each individual shunt modality (please see relevant sections). </p> </section> <section id="CD000553-sec-0098"> <h5 class="title">Cost analysis</h5> <p>There was variation in the methods and definitions used to estimate cost of treatment, with results summarised in <a href="#CD000553-tbl-0010">Table 6</a>. Full details are summarised according to each individual shunt modality. </p> <div class="table" id="CD000553-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cost of treatment: shunt versus endoscopic intervention with or without medical treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Costs measured</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes reported</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shunt</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Endoscopic therapy</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Total shunt (TS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Healthcare costs" (not defined)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ± SD</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 9761 ± 750</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 9047 ± 704</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital costs included laboratory and X‐ray examinations, transfusions, drugs, grafts, hotel service, endoscopy investigations and treatment, and costs of surgical procedure (calculated according to Alinder G, et al. World J Surg 1985;9:329‐34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 12,949 (7802 to 64,835)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 12,027</p> <p>(2525 to 39,018)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Distal splenorenal shunt (DSRS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both initial and total medical costs for each therapy were calculated and compared. Initial medical costs were defined as those incurred during the hospitalisation in which shunt surgery was performed or sclerotherapy initiated. Total costs included initial hospitalisation, all subsequent hospitalisations required for treatment of recurrent haemorrhage and complications of therapy or chronic liver disease, and outpatient endoscopic evaluation with or without variceal sclerosis. Analysis included only patients treated at University hospitals. </p> <p>Data from Rikkers LF, Burnett DA, Volentine GD, Buchi KN, Cormier RA. Shunt surgery vs endoscopic sclerotherapy for long‐term treatment of variceal bleeding. Early results of a randomized trial. Ann Surg 1987;206(3):261‐71. PMID: 3307653 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total medical costs during mean follow‐up interval of 20 ± 5 and 24 ± 6 months for shunt and sclerotherapy patients </p> <p>Mean ± SEM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 34,474 ± 5499</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 37,648 ± 6392</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Transjugular intrahepatic portosystemic shunt (TIPS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total cost of health care per patient calculated as the sum of all real costs for inpatient and outpatient hospital care, including hospital expenditures and costs for professional services, and all outpatient costs for endoscopic sclerotherapy, doppler ultrasonography, and stent revision from day of randomisation until death or latest follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ± SE</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 29,790 ± 3422</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 27,540 ± 5088</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estimated cost of procedure (not including personnel) and costs of inpatient treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure: GBP 2749</p> <p>Hospital treatment: GBP 4310</p> <p>Total: GBP 7059</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure: GBP 1422</p> <p>Hospital treatment: GBP 7010</p> <p>Total: GBP 8432</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Costs for admissions, consultations, initial treatment, imaging, diagnostics, transfusions, medications in the first year </p> <p>Abstract only: Harki J, Holster IL, Polinder S, Moelker A, van Buuren HR, Kuipers EJ, et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt vs endoscopic treatment for secondary prevention of gastro‐oesophageal variceal bleeding, Journal of Hepatoloy 2016;64(2 Suppl):S265‐S266. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 27,746</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 16,816</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation.<br/>SE: standard error.<br/>SEM: standard error of the mean. </p> </div> </div> </section> </section> <section id="CD000553-sec-0099"> <h4 class="title">Total shunt (TS) versus endoscopic intervention</h4> <section id="CD000553-sec-0100"> <h5 class="title">All‐cause mortality</h5> <p>All‐cause mortality was reduced with total shunt (RR 0.46, 95% CI 0.19 to 1.13; 164 participants; 3 trials; I² = 1%; very low‐certainty evidence; <a href="./references#CD000553-fig-0009" title="">Analysis 1.1</a>.1). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels) and because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level) (<a href="./full#CD000553-tbl-0002">summary of findings Table 2</a>; <a href="#CD000553-tbl-0011">Table 7</a>). </p> <div class="table" id="CD000553-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of total shunt (TS) versus endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction, while considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="5" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ TSA<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ TSA<sup>d</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The TSA curve was not constructed due to too little information.<br/><sup>b</sup>The Z‐curve did not did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.<br/><sup>c</sup>The Z‐curve reached the monitoring boundary for benefit.<br/><sup>d</sup>There was a single trial with 3/34 events in the TS group and 0/35 in the endoscopy with or without drugs group. </p> </div> </div> <section id="CD000553-sec-0101"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of rebleeding of gastric varices; sclerotherapy was the endoscopic intervention in all trials; and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0102"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis, by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 10% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis was constructed with risk of 19.7% for all‐cause mortality in the endoscopic intervention group; an RRR of 10% with the TS; type I error of 2.5%; and type II error of 20% (80% power). There was no diversity (D² = 0%). The DARIS was 14,904 participants. Due to the fact that only 164 participants were recruited (which is 1.1% of the DARIS of 14,904 participants), the Trial Sequential Analysis figure was not drawn by the programme because too little information was available (figure not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook or when we used a more realistic RRR of 10% as chosen by review authors for GRADE and for Trial Sequential Analysis (<a href="#CD000553-tbl-0011">Table 7</a>). </p> </section> </section> </section> <section id="CD000553-sec-0103"> <h5 class="title">Rebleeding</h5> <p>Risk of rebleeding was reduced by TS (RR 0.28, 95% CI 0.14 to 0.56; 127 participants; 2 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0010" title="">Analysis 1.2</a>.1). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels) and because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level) (<a href="./full#CD000553-tbl-0002">summary of findings Table 2</a>; <a href="#CD000553-tbl-0011">Table 7</a>). </p> <section id="CD000553-sec-0104"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of rebleeding of gastric varices; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0105"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on risk of rebleeding, with 43.5% in the endoscopic intervention group; type I error of 2.5%; and type II error of 20% (80% power). The cumulative Z‐curve crossed the monitoring boundary for benefit before reaching the required information size when RRR with TS was set to 40% (D² = 0%, DARIS 285 participants) ‐ not when RRR was set to 20% (D² = 0%, DARIS 1197 participants) (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook and an RRR of 20% and 40% as chosen by review authors for GRADE and TSA (<a href="#CD000553-tbl-0011">Table 7</a>). </p> </section> </section> </section> <section id="CD000553-sec-0106"> <h5 class="title">Mortality due to rebleeding</h5> <p>Mortality due to rebleeding was reduced with TS (RR 0.25, 95% CI 0.06 to 0.96; 164 participants; 3 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0011" title="">Analysis 1.3</a>.1). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels) and because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level) (<a href="./full#CD000553-tbl-0002">summary of findings Table 2</a>; <a href="#CD000553-tbl-0011">Table 7</a>). </p> <section id="CD000553-sec-0107"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of gastric variceal rebleeding; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0108"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on a risk of mortality due to rebleeding of 13.6% in the endoscopic intervention group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve did not cross the sequential boundaries for benefit, harm, or futility before reaching the required information size when RRR with TS was set to 40% (D² = 0%, DARIS 1427 participants); the Trial Sequential Analysis figure was not obtained due to the fact that only 164 participants were recruited (2.59% of the DARIS) when the RRR was set to 20% (D² = 0%, DARIS 6321 participants) (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, by using an RRR of 40% and 20% for GRADE, or by using an RRR of 40% and 20 % for Trial Sequential Analysis (<a href="#CD000553-tbl-0011">Table 7</a>). </p> </section> </section> </section> <section id="CD000553-sec-0109"> <h5 class="title">Acute encephalopathy</h5> <p>There was no difference between TS and endoscopic intervention in the development of acute hepatic encephalopathy (RR 1.66, 95% CI 0.70 to 3.92; 115 participants; 2 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0012" title="">Analysis 1.4</a>.1). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was not met ‐ and because there were very few events and CI included appreciable benefit and harm (‐2 levels) (<a href="./full#CD000553-tbl-0002">summary of findings Table 2</a>; <a href="#CD000553-tbl-0011">Table 7</a>). </p> <section id="CD000553-sec-0110"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of gastric variceal rebleeding; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0111"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. Trial Sequential Analysis of this comparison was constructed on an incidence of acute encephalopathy of 12.3% in the endoscopic intervention group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve did not reach the monitoring boundaries for benefit, harm, and futility when RRR with TS was set to 40% (D² = 0%, DARIS 1596 participants). When the RRR was set to 20% (D² = 0%, DARIS 7082 participants), the figure could not be constructed because of the small number of participants (1.62% of the DARIS). The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook,and the RRR of 20% and 40% for GRADE and for Trial Sequential Analysis (<a href="#CD000553-tbl-0011">Table 7</a>). </p> </section> </section> </section> <section id="CD000553-sec-0112"> <h5 class="title">Chronic hepatic encephalopathy</h5> <p>Only one trial reported on development of chronic hepatic encephalopathy, with 3 out of 34 participants in the TS group compared with none out 35 in the endoscopic intervention group (Fisher's test P = 0.11; 69 participants) (<a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>). </p> <section id="CD000553-sec-0113"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of gastric variceal rebleeding; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> </section> </section> <section id="CD000553-sec-0114"> <h5 class="title">Complications</h5> <p>Complications are summarised in <a href="#CD000553-tbl-0006">Table 2</a>. </p> <p>Two of the trials reported shunt occlusion or dysfunction, which developed in 3% (95% CI 0.8% to 10%) of participants (<a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>). </p> </section> <section id="CD000553-sec-0115"> <h5 class="title">Inpatient stay</h5> <p>Only <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> reported mean (± standard deviation) inpatient stay (days) (MD between groups 3.1 days, 95% CI ‐2.3 to 8.5 days). </p> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> reported the median inpatient stay in the TS group as 34.5 days (range 9 to 122 days) and in the endoscopic intervention group as 33 days (range 15 to 64 days). </p> </section> <section id="CD000553-sec-0116"> <h5 class="title">Cost analysis</h5> <p>Details of cost analyses are provided in <a href="#CD000553-tbl-0010">Table 6</a>. Two trials reported cost analyses (<a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a>; <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a>). <a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> calculated hospital costs by including costs of laboratory, radiology, transfusions, drugs, grafts, hotel service, endoscopy, and surgical procedures. <a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> reported data but did not provide details on how costs were calculated. Both trials reported comparable costs between patients treated with TS and patients treated with endoscopic intervention. </p> </section> </section> <section id="CD000553-sec-0117"> <h4 class="title">Distal splenorenal shunt (DSRS) versus endoscopic intervention</h4> <section id="CD000553-sec-0118"> <h5 class="title">All‐cause mortality</h5> <p>No differences were found between the two groups for all‐cause mortality (RR 0.93, 95% CI 0.65 to 1.33; 352 participants; 5 trials; I² = 56%; very low‐certainty evidence; <a href="./references#CD000553-fig-0009" title="">Analysis 1.1</a>.2). There was heterogeneity because two trials reported an increase in mortality with DSRS versus endoscopic intervention (<a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>), whereas the other three trials reported a reduction (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). The large number of participants randomised to sclerotherapy who were treated by DSRS when they bled (35% in <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>) prevent us from considering this result as due to DSRS alone. In <a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a>, there was an unbalanced selection of participants because DSRS was performed in Child's class A and B, whereas sclerotherapy was performed also in Child's class C. We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was nor met (‐1 level), and because of heterogeneity (‐1 level) (<a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>; <a href="#CD000553-tbl-0012">Table 8</a>). </p> <div class="table" id="CD000553-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of DSRS versus endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction, while considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4284</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,538</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1096</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3878</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>928</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6890</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1552</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6892</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1554</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2768</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6164</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1390</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8382</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1892</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,542</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,924</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,926</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The TSA curve was not constructed due to too little information.<br/><sup>b</sup>The Z‐curve did not did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility. </p> </div> </div> <section id="CD000553-sec-0119"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of rebleeding of gastric varices; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopy with medical treatment. </p> <section id="CD000553-sec-0120"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 10% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on a risk of all‐cause mortality of 46.8% in the endoscopic intervention group; an RRR of 10% with DSRS; type I error of 2.5%; and type II error of 20% (80% power). There was diversity (D² = 78%). The DARIS was 13,538 participants. Due to the fact that only 324 participants were recruited (which is 2.45% of the DARIS of 13,538 participants), the Trial Sequential Analysis figure was not constructed by the programme because too little information was available.The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, or when we used a more realistic RRR of 10% chosen by review authors for GRADE and for Trial Sequential Analysis (<a href="#CD000553-tbl-0012">Table 8</a>). </p> </section> </section> </section> <section id="CD000553-sec-0121"> <h5 class="title">Rebleeding</h5> <p>Rebleeding was reduced by DSRS (RR 0.26, 95% CI 0.11 to 0.65; 330 participants; 5 trials; I² = 66%); very low‐certainty evidence; <a href="./references#CD000553-fig-0010" title="">Analysis 1.2</a>.2). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level), and because of heterogeneity (‐1 level) (<a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>; <a href="#CD000553-tbl-0012">Table 8</a>). </p> <section id="CD000553-sec-0122"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of rebleeding of gastric varices; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0123"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on a rebleeding risk of 45.8% in the endoscopic intervention group; type I error of 2.5%; and type II error of 20% (80% power). The cumulative Z‐curve crossed the monitoring boundary for benefit when RRR with DSRS was set to 40% (D² = 72%, DARIS 928 participants). When RRR was set to 20% (D² = 72%, DARIS 3878 participants), the cumulative Z‐curve did not cross the boundaries for benefit, harm, or futility (figures not shown). Overall, as the observed RRR greatly exceeded 40% (observed RRR of 81%), Trial Sequential Analysis would tend to support conclusions that DSRS shunt reduce the rate of rebleeding compared with endoscopic treatment. </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook nor when we used an RRR of 20% for GRADE and an RRR of 20% and 40% for Trial Sequential Analysis. It was reached when we used a plausible RRR of 40% chosen by the review authors for GRADE (<a href="#CD000553-tbl-0012">Table 8</a>). </p> </section> </section> </section> <section id="CD000553-sec-0124"> <h5 class="title">Mortality due to rebleeding</h5> <p>Cause of death was reported in four trials (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). Mortality from rebleeding was reduced by DSRS (RR 0.31, 95% CI 0.13 to 0.74; 352 participants; 5 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0011" title="">Analysis 1.3</a>.2). All four trials included death from gastrointestinal bleeding of all causes (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels) and because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level) (<a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>; <a href="#CD000553-tbl-0012">Table 8</a>). </p> <section id="CD000553-sec-0125"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of gastric variceal rebleeding; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0126"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 40% and 20% for modified GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on a risk of mortality due to rebleeding of 12.6% in the endoscopic intervention group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve did not cross the monitoring boundaries before reaching the required information size when RRR with DSRS was set to 40% (D² = 0%, DARIS 1554 participants) nor when RRR was set to 20% (D² = 0%, DARIS 6892 participants) (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, by using an RRR of 40% and 20% for GRADE, or by using an RRR of 40% and 20% for Trial Sequential Analysis (<a href="#CD000553-tbl-0012">Table 8</a>). </p> </section> </section> </section> <section id="CD000553-sec-0127"> <h5 class="title">Acute hepatic encephalopathy</h5> <p>Acute hepatic encephalopathy was increased by DSRS (RR 1.70, 95% CI 0.94 to 3.08; 287 participants; 4 trials; I² = 25%; very low‐certainty evidence; <a href="./references#CD000553-fig-0012" title="">Analysis 1.4</a>.2). <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a> did not report data on hepatic encephalopathy; however, development of acute hepatic encephalopathy was reported in a preliminary analysis (see the reference to Warren 1985 in <a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a>). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels) and because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level) (<a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>; <a href="#CD000553-tbl-0012">Table 8</a>). </p> <section id="CD000553-sec-0128"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of gastric variceal rebleeding; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0129"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on an incidence of acute hepatic encephalopathy of 13.9% in the endoscopic intervention group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve did not reach the monitoring boundaries for harm, benefit, and futility when RRR with DSRS was set to 40% (D² = 26%, DARIS 1892 participants). When the RRR was set to 20% (D² = 26%, DARIS 8382 participants), the figure could not be constructed because of the small number of participants (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, by using an RRR of 20% and 40% for GRADE, or by using an RRR of 40% and 20% for Trial Sequential Analysis (<a href="#CD000553-tbl-0012">Table 8</a>). </p> </section> </section> </section> <section id="CD000553-sec-0130"> <h5 class="title">Chronic hepatic encephalopathy</h5> <p>Chronic hepatic encephalopathy was increased by DSRS (RR 4.87, 95% CI 1.46 to 16.23; 170 participants; 2 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0013" title="">Analysis 1.5</a>.2). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels) and because of imprecision ‐ there were few events and CI included appreciable benefit and harm (‐2 levels) (<a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>; <a href="#CD000553-tbl-0012">Table 8</a>). </p> <section id="CD000553-sec-0131"> <h6 class="title">Sensitivity analysis</h6> <p>We did not perform sensitivity analyses according to site of variceal bleeding, modality of endoscopy, or association with beta blockers because no trials were restricted to prevention of gastric variceal rebleeding; sclerotherapy was the endoscopic intervention in all trials, and no trials combined endoscopic intervention with medical treatment. </p> <section id="CD000553-sec-0132"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on an incidence of chronic hepatic encephalopathy of 3.4% in the endoscopic intervention group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve was not constructed because too little information was available when the RRR was set to 40% (D² = 0%, DARIS 6228 participants) and to 20% (D² = 0%, DARIS 27,926 participants) (figures not shown). </p> <p>The required information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook nor when we used an RRR of 20% or 40% for GRADE and Trial Sequential Analysis (<a href="#CD000553-tbl-0012">Table 8</a>). </p> </section> </section> </section> <section id="CD000553-sec-0133"> <h5 class="title">Complications</h5> <p>Complications are summarised in <a href="#CD000553-tbl-0007">Table 3</a>. It is apparent that reporting of complications may be incomplete in all trials. </p> <p>Shunt occlusion or dysfunction was reported in three trials (<a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>; <a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>; <a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a>). Shunt occlusion or dysfunction occurred in 8 out of 113 (7%), 95% CI 3% to 13%) participants treated by shunts. </p> </section> <section id="CD000553-sec-0134"> <h5 class="title">Inpatient stay</h5> <p><a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a> reported the number of inpatient days following randomisation (weighted mean difference (WMD) between groups ‐3.4 days, 95% CI ‐13.7 to 6.9 days) and was the only trialist to do so. Whilst participants treated with DSRS stayed significantly longer in hospital for initial treatment, participants treated with endoscopic intervention stayed significantly longer in hospital undergoing treatment during follow‐up after initial treatment. Therefore, overall, there was no significant difference in the total number of days spent in hospital ) (<a href="#CD000553-tbl-0009">Table 5</a>; <a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a>). </p> </section> <section id="CD000553-sec-0135"> <h5 class="title">Cost analysis</h5> <p>One trial provided a cost analysis in the preliminary report, but it included only participants who were admitted to the University Hospital and it did not include the full cohort of participants (<a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a>). Whilst medical costs for the index hospitalisation were higher for participants treated with DSRS (mean ± SD for DSRS: USD 22,473 ± USD 3521) versus endoscopic intervention (USD 10,410 ± USD 1893), costs were comparable over a longer follow‐up period: DSRS (mean ± SD for DSRS: USD 34,474 ± USD 5499) versus endoscopic intervention (USD 37,648 ± USD 6392) (<a href="#CD000553-tbl-0010">Table 6</a>). </p> </section> </section> <section id="CD000553-sec-0136"> <h4 class="title">Transjugular intrahepatic portacaval shunt (TIPS) versus endoscopic intervention</h4> <section id="CD000553-sec-0137"> <h5 class="title">All‐cause mortality</h5> <p>We found no evidence of a difference between TIPS and endoscopic intervention with or without medical treatment for all‐cause mortality (RR 1.10, 95% CI 0.92 to 1.31; 1312 participants; 19 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0009" title="">Analysis 1.1</a>.3). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>; <a href="#CD000553-tbl-0013">Table 9</a>; <a href="#CD000553-fig-0004">Figure 4</a>). </p> <div class="table" id="CD000553-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of TIPS versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction, while considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34,096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34,099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The Z‐curve did not did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.<br/><sup>b</sup>The Z‐curve reached the monitoring boundary for benefit.<br/><sup>c</sup>The Z‐curve reached the monitoring boundary for futility.<br/><sup>d</sup>The Z‐curve reached the monitoring boundary for harm.<br/><sup>e</sup>The TSA curve was not constructed due to too little information. </p> </div> </div> <section id="CD000553-sec-0138"> <h6 class="title">Sensitivity analysis</h6> <p>The results did not change by excluding the trial assessing prevention of gastric variceal rebleeding (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>) (RR 1.08, 95% CI 0.90 to 1.29; 1240 participants; 18 trials; I² = 0%); by including trials that have used only PTFE‐covered stents (RR 1.02, 95% CI 0.70 to 1.49; 292 participants; 5 trials; I² = 6%) (<a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>); or by including trials that did not use PTFE‐covered stents or did not declare whether PTFE stents were covered or not (RR 1.13, 95% CI 0.93 to 1.39; 1020 participants; 14 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>). </p> <p>We did not observe a difference in all‐cause mortality when we excluded trials employing pharmacotherapy in addition to endoscopic intervention (RR 1.17, 95% CI 0.91 to 1.50; 661 participants; 10 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>), nor when we restricted the analysis to trials that used only endoscopic banding with or without medical treatment (RR 1.00, 95% CI 0.76 to 1.31; 497 participants; 8 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), as well as to trials in which band ligation and beta blockers were combined (RR 1.02, 95% CI 0.73 to 1.43; 377 participants; 6 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> <section id="CD000553-sec-0139"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 10% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on an all‐cause mortality of 25.2% in the endoscopic intervention with or without medical treatment group; an RRR of 10% with TIPS, type I error of 2.5%; and type II error of 20% (80% power). There was no diversity (D² = 0%). The DARIS was 10,902 participants. The Z‐curve did not cross the sequential boundaries for benefit, harm, or futility (figure not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, nor when we used a more realistic RRR of 10% chosen by review authors for GRADE and Trial Sequential Analysis (<a href="#CD000553-tbl-0013">Table 9</a>). </p> </section> </section> </section> <section id="CD000553-sec-0140"> <h5 class="title">Rebleeding</h5> <p>Rebleeding was reduced by TIPS (RR 0.44, 95% CI 0.36 to 0.55; 1312 participants; 19 trials; I² = 18%; very low‐certainty evidence; <a href="./references#CD000553-fig-0010" title="">Analysis 1.2</a>.3). We downgraded the evidence by three levels because all trials were at overall high risk of bias (‐2 levels), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>; <a href="#CD000553-tbl-0013">Table 9</a>; <a href="#CD000553-fig-0005">Figure 5</a>). </p> <section id="CD000553-sec-0141"> <h6 class="title">Sensivity analysis</h6> <p>The results did not change by excluding the only trial assessing prevention of gastric variceal rebleeding (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>) (RR 0.44, 95% CI 0.35 to 0.56; 1240 participants; 18 trials; I² = 22%); by including trials that specified only use of PTFE‐covered stents (RR 0.38, 95% CI 0.24 to 0.59; 292 participants; 5 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>); by including trials that did not specify the use of PTFE‐covered stents (RR 0.35, 95% CI 0.19 to 0.64; 234 participants;14 trials; I² = 15%) (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>); by excluding trials employing pharmacotherapy for the endoscopic intervention group (RR 0.45, 95% CI 0.33 to 0.62; 661 participants; 10 trials; I² = 26%) (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>); or by including trials that utilised only endoscopic banding with or without medical treatment (RR 0.43, 95% CI 0.31 to 0.60; 497 participants; 8 trials; I² = 4%) (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), as well as trials that used only band ligation and beta blockers (RR 0.43, 95% CI 0.29 to 0.64; 377 participants; 6 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> <section id="CD000553-sec-0142"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on a rebleeding risk of 42.5% for the endoscopic intervention with or without medical treatment group; type I error of 2.5%; and type II error of 20% (80% power). The cumulative Z‐curve crossed the monitoring boundary for benefit when RRR with TIPS was set to 40% (D² = 16 %, DARIS 351 participants), and when RRR was set to 20% (D² = 16%, DARIS 1474 participants) (figures not shown). </p> <p>The optimal information size was reached by using the default RRR of 25% as suggested in the GRADE Handbook, and when we used an RRR of 40% and 20% for GRADE and an RRR of 40% for Trial Sequential Analysis. It was not reached with an RRR of 20% for Trial Sequential Analysis (<a href="#CD000553-tbl-0013">Table 9</a>). </p> </section> </section> </section> <section id="CD000553-sec-0143"> <h5 class="title">Mortality due to rebleeding</h5> <p>There was no evidence of a difference between TIPS and endoscopic treatment with or without medical treatment (RR 0.65, 95% CI 0.40 to 1.04; 1263 participants; 18 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0011" title="">Analysis 1.3</a>.3). In four trials, it is unclear whether deaths were due to variceal rebleeding or to other causes of gastrointestinal haemorrhage (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>). However exclusion of these trials had no substantial effect on results (RR 0.38, 95% CI 0.18 to 0.78; 937 participants; 13 trials; I² = 0%). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>; <a href="#CD000553-tbl-0013">Table 9</a>; <a href="#CD000553-fig-0006">Figure 6</a>). </p> <section id="CD000553-sec-0144"> <h6 class="title">Sensitivity analysis</h6> <p>The result was confirmed when we excluded the trial assessing prevention of rebleeding from gastric varices (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>) (RR 0.66, 95% CI 0.40 to 1.08; 1191 participants; 17 trials; I² = 1%); when we restricted analysis to trials that did not specify use of PTFE‐covered stents (<a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a>; <a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>) (RR 0.57, 95% CI 0.31 to 1.03; 971 participants; 13 trials; I² = 14%); and when we excluded trials employing pharmacotherapy in the endoscopic intervention group (RR 0.51, 95% CI 0.24 to 1.10; 612 participants; 9 trials; I² = 11%) (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>). </p> <p>Analysis of trials that utilised only endoscopic banding (not in combination with other endoscopic therapies) confirmed the reduction in mortality due to rebleeding with TIPS (RR 0.41, 95% CI 0.17 to 1.00; 497 participants; 8 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> <p>There were no differences in mortality due to rebleeding between groups when we restricted the analysis to trials that specified use of PTFE‐covered TIPS (RR 0.59, 95% CI 0.18 to 1.99; 292 participants; 5 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), and when we restricted the analysis to trials in which band ligation associated with beta blockers was used (RR 0.57, 95% CI 0.19 to 1.67; 377 participants; 6 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> <section id="CD000553-sec-0145"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on a mortality due to rebleeding of 8.2% in the endoscopic intervention with or without medical treatment group; type I error of 1.4%, and type II error of 20% (80% power). The cumulative Z‐curve reached the futility area before reaching the required information size when RRR with TIPS was set to 40% (D² = 0%, DARIS 2481 participants); the cumulative Z‐curve did not approach the monitoring boundaries for benefit or harm or futility when the RRR was set to 20% (D² = 0%, DARIS 11,073 participants) (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook nor when we used an RRR of 40% and 20% for GRADE and Trial Sequential Analysis (<a href="#CD000553-tbl-0013">Table 9</a>). </p> </section> </section> </section> <section id="CD000553-sec-0146"> <h5 class="title">Acute hepatic encephalopathy</h5> <p>We found evidence of an increase in acute hepatic encephalopathy with TIPS (RR 1.61, 95% CI 1.29 to 1.99; 1247 participants; 18 trials; I² = 20%; very low‐certainty evidence; <a href="./references#CD000553-fig-0012" title="">Analysis 1.4</a>.3). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels), because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level), and because of publication bias (<a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>; <a href="#CD000553-tbl-0013">Table 9</a>; <a href="#CD000553-fig-0007">Figure 7</a>) . </p> <section id="CD000553-sec-0147"> <h6 class="title">Sensitivity analysis</h6> <p>The increase in acute hepatic encephalopathy was confirmed by excluding the trial assessing prevention of gastric variceal rebleeding (<a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>) (RR 1.55, 95% CI 1.27 to 1.90; 1175 participants; 17 trials; I² = 9%); by excluding trials employing medical treatment in the endoscopic intervention group (RR 1.61, 95% CI 1.13 to 2.29; 661 participants; 10 trials; I² = 33%) (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>); by restricting analysis to trials that utilised only endoscopic banding (RR 1.27, 95% CI 0.97 to 1.67; 497 participants; 8 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>); and by restricting the analysis to trials in which band ligation and beta blockers were used (RR 1.45, 95% CI 1.08 to 1.95; 377 participants; 6 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>). </p> <p>The differences between groups were reduced when we restricted analysis to trials that specified use of only PTFE‐covered stents (RR 1.39, 95% CI 0.98 to 1.98; 292 participants; 5 trials; I² = 9%) (<a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>; <a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a>), and differences were increased when we restricted analysis to trials that did not specify use of PTFE‐covered stents (RR 1.71, 95% CI 1.30 to 2.25; 955 participants; 13 trials; I² = 24%) (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>). </p> <section id="CD000553-sec-0148"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis, by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for modified GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on an incidence of acute hepatic encephalopathy of 20.1% in the endoscopic intervention with or without medical treatment group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve crossed the monitoring boundary for harm when RRR with TIPS was set to 40% (D² = 25%, DARIS 1217 participants). When the RRR was set to 20% (D² = 25%, DARIS 5282 participants), the cumulative Z‐curve did not approach the boundaries for benefit, harm, or futility (figures not shown). </p> <p>The optimal information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook,nor by using a more realistic RRR of 20% for GRADE and 20% for Trial Sequential Analysis. It was reached with an RRR of 40% for GRADE and TSA (<a href="#CD000553-tbl-0013">Table 9</a>). </p> </section> </section> </section> <section id="CD000553-sec-0149"> <h5 class="title">Chronic hepatic encephalopathy</h5> <p>Chronic hepatic encephalopathy was increased by TIPS (RR 1.88, 95% CI 0.93 to 3.80; 717 participants; 10 trials; I² = 0%; very low‐certainty evidence; <a href="./references#CD000553-fig-0013" title="">Analysis 1.5</a>.3). We downgraded the evidence by four levels because all trials were at overall high risk of bias (‐2 levels); because of imprecision ‐ the OIS as calculated by GRADE was not met (‐1 level), and because of publication bias (‐1 level) (<a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>; <a href="#CD000553-tbl-0013">Table 9</a>; <a href="#CD000553-fig-0008">Figure 8</a>). </p> <section id="CD000553-sec-0150"> <h6 class="title">Sensitivity analysis</h6> <p>The result was confirmed when we excluded trials in which pharmacotherapy was combined with endoscopic intervention (RR 2.30, 95% CI 0.75 to 7.02; 301 participants; 5 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>). No clear increase in chronic hepatic encephalopathy was noted when we restricted analysis to trials that utilised only endoscopic banding (RR 1.52, 95% CI 0.63 to 3.66; 399 participants; 6 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>); when we restricted the analysis to trials in which band ligation and beta blockers were used (RR 1.54, 95% CI 0.51 to 4.65; 207 participants; 3 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>), or when we restricted the analysis only to trials in which PTFE‐covered TIPS were used (RR 1.25, 95% CI 0.35 to 4.46; 122 participants; 2 trials; I² = 0%) (<a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>). </p> <section id="CD000553-sec-0151"> <p><b>Assessment of imprecision with Trial Sequential Analysis and comparison with GRADE</b></p> <p>We compared the assessment of imprecision of intervention effects as assessed by GRADE and Trial Sequential Analysis by using the default RRR of 25% as suggested in the GRADE Handbook and the plausible RRR of 20% and 40% for GRADE and for Trial Sequential Analysis. </p> <p>Trial Sequential Analysis of this comparison was constructed on an incidence of chronic hepatic encephalopathy of 2.8% in the endoscopic intervention with or without medical treatment group; type I error of 1.4%; and type II error of 20% (80% power). The cumulative Z‐curve did not approach the boundaries for benefit, harm, or futility when RRR with TIPS was set to 40% (D² = 0%, DARIS 7600 participants). When RRR was set to 20% (D² = 0%, DARIS 34,099 participants), the cumulative Z‐curve was not constructed due because we had insufficient information (2.1% of the DARIS) (figures not shown). </p> <p>The required information size was not reached by using the default RRR of 25% as suggested in the GRADE Handbook, nor when we used an RRR of 20% and 40% for GRADE and Trial Sequential Analysis (<a href="#CD000553-tbl-0013">Table 9</a>). </p> </section> </section> </section> <section id="CD000553-sec-0152"> <h5 class="title">Complications</h5> <p>Complications are summarised in <a href="#CD000553-tbl-0008">Table 4</a>. </p> <p>Shunt occlusion or dysfunction was the most common problem following TIPS implantation. Rates of shunt occlusion or dysfunction were recorded in 16 trials, with a reported incidence varying from 8% to 89% (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>). </p> <p>Overall, across all trials utilising TIPS, the incidence of shunt occlusion or dysfunction was 47.1% (95% CI 43% to 51%) (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>). There was substantial variation in shunt surveillance methods and protocols. </p> <p>Four trials specified that PTFE‐covered stents were used (<a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>; <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>); of these, three trials reported the incidence of shunt dysfunction (<a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>), and one reported the incidence of thrombosis (<a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a>). <a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a> and <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> reported incidences of shunt dysfunction of 30% and 5%, respectively, whilst <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a> reported shunt patency rates of 80% at two‐year follow‐up. When we pooled results, the incidence of shunt dysfunction or thrombosis in trials utilising PTFE‐covered stents was 17% (95% CI 11.0 to 24%) (<a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>). </p> <p>The remaining trials appear to have used bare‐metal stents. The incidence of shunt dysfunction varied from 18% to 89% across trials that did not specify use of PTFE‐covered stents (12 trials) (<a href="#CD000553-tbl-0008">Table 4</a>). When we pooled results from these 12 trials, 55% (95% CI 50 to 59) of trial participants developed shunt dysfunction (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a>; <a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a>; <a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>). </p> <p>For the shunt group, few complications are reported, suggesting potential under‐reporting of complications. </p> <p>For endoscopy, the most common complications were oesophageal ulcers and stenosis with or without bleeding and infection (<a href="#CD000553-tbl-0006">Table 2</a>; <a href="#CD000553-tbl-0007">Table 3</a>; <a href="#CD000553-tbl-0008">Table 4</a>). </p> </section> <section id="CD000553-sec-0153"> <h5 class="title">In‐hospital stay</h5> <p>Nine trials reported on length of hospital stay (<a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a>; <a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a>; <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a>; <a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a>; <a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>). The data (when reported) were found to be skewed, with significant statistical heterogeneity and variation in the time scales measured. Results are summarised in <a href="#CD000553-tbl-0009">Table 5</a>. </p> </section> <section id="CD000553-sec-0154"> <h5 class="title">Cost</h5> <p>Three trials have reported costs of TIPS versus endoscopic intervention (<a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a>; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a>; <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016;</a><a href="#CD000553-tbl-0010">Table 6</a>). </p> <p><a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> reported total costs from the day of randomisation to death or last follow‐up and reported comparable costs in both groups. </p> <p><a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> reported that the mean cost for the TIPS procedure was GBP 5782 per person (excluding personnel costs), and the mean cost for endoscopic intervention was GBP 4020 per person; <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> also reported that the mean cost of inpatient treatment was GBP 7059 for TIPS and GBP 8432 for endoscopic intervention. </p> <p>Although <a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> and <a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> found comparable costs in both groups, <a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> reported significantly higher financial costs of TIPS, with a mean cost of EUR 27,746 for TIPS versus a mean cost of EUR 16,816 for endoscopy over one year of follow‐up (including admissions, consultations, procedures, investigations, transfusions, and medications). However, it must be noted that we extracted cost‐effectiveness data from a conference abstract and noted that these data were not based on the full cohort of participants (<a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>). </p> </section> <section id="CD000553-sec-0155"> <h5 class="title">Rebleeding from all causes</h5> <p>We added an unplanned analysis of gastrointestinal rebleeding from all causes (portal hypertension‐related and non‐portal hypertension‐related). </p> <p>The rate of rebleeding was lower in the portosystemic shunts group than in the endoscopic intervention with or without medical treatment group for all three modalities of treatment: shunt intervention meta‐analysed together (RR 0.42, 95% CI 0.34 to 0.52; 1769 participants; 26 trials; I² = 42%; <a href="./references#CD000553-fig-0014" title="">Analysis 1.6</a>); TS (RR 0.34, 95% CI 0.19 to 0.61; 127 participants; 2 trials; I² = 0%; <a href="./references#CD000553-fig-0014" title="">Analysis 1.6</a>.1); DSRS (RR 0.35, 95% CI 0.18 to 0.68; 330 participants; 5 trials; I² = 63%; <a href="./references#CD000553-fig-0014" title="">Analysis 1.6</a>.2); TIPS (RR 0.45, 95% CI 0.35 to 0.56; 1312 participants; 19 trials; I² = 41%; <a href="./references#CD000553-fig-0014" title="">Analysis 1.6</a>.3). </p> </section> <section id="CD000553-sec-0156"> <h5 class="title">Subgroup analyses</h5> <p>We were unable to perform subgroup analysis of trials according to risk of bias because all trials were at overall high risk of bias. </p> <section id="CD000553-sec-0157"> <h6 class="title">Subgroup analysis regarding funding</h6> <p>We found no evidence of differences between the subgroup of trials without for‐profit funding and the subgroup of trials in which the source of funding was unknown (no trials had definite for‐profit funding; see above for details) for all outcomes. </p> <p>The test for subgroup differences showed no differences in:</p> <p> <ul id="CD000553-list-0013"> <li> <p>all‐cause mortality (P = 0.25; I² = 24.8): trials without for‐profit funding (RR 1.12, 95% CI 0.85 to 1.49; 754 participants; 11 trials; I² = 39%; <a href="./references#CD000553-fig-0015" title="">Analysis 2.1</a>.1), trials with funding unknown (RR 0.93, 95% CI 0.78 to 1.10; 1074 participants; 16 trials; I² = 0%; <a href="./references#CD000553-fig-0015" title="">Analysis 2.1</a>.2); </p> </li> <li> <p>rebleeding (P = 0.37; I² = 0%): trials without for‐profit funding (RR 0.36, 95% CI 0.25 to 0.51; 732 participants; 11 trials; I² = 37%; <a href="./references#CD000553-fig-0016" title="">Analysis 2.2</a>.1), trials with funding unknown (RR 0.44, 95% CI 0.33 to 0.58; 1037 participants; 15 trials; I² = 29%; <a href="./references#CD000553-fig-0016" title="">Analysis 2.2</a>.2); </p> </li> <li> <p>mortality due to rebleeding (P = 0.61; I² = 0%): trials without for‐profit funding (RR 0.45, 95% CI 0.23 to 0.86; 705 participants; 10 trials; I² = 1%; <a href="./references#CD000553-fig-0017" title="">Analysis 2.3</a>.1), trials with funding unknown (RR 0.55, 95% CI 0.33 to 0.91; 1074 participants; 16 trials; I² = 0%; <a href="./references#CD000553-fig-0017" title="">Analysis 2.3</a>.2); </p> </li> <li> <p>acute hepatic encephalopathy (P = 0.59%; I² = 0%): trials without for‐profit funding (RR 1.52, 95% CI 1.09 to 2.12; 705 participants; 11 trials; I² = 24%; <a href="./references#CD000553-fig-0018" title="">Analysis 2.4</a>.1), trials with funding unknown ( (RR 1.69, 95% CI 1.36 to 2.11; 944 participants; 13 trials; I² = 0%; <a href="./references#CD000553-fig-0018" title="">Analysis 2.4</a>.2); or </p> </li> <li> <p>chronic hepatic encephalopathy (P = 0.61; I² = 0%): trials without for‐profit funding (RR 2.00, 95% CI 0.70 to 5.73; 282 participants; 4 trials; I² = 0%; <a href="./references#CD000553-fig-0019" title="">Analysis 2.5</a>.1), trials with funding unknown (RR 2.79, 95% CI 1.35 to 5.75; 674 participants; 9 trials; I² = 0%; <a href="./references#CD000553-fig-0019" title="">Analysis 2.5</a>.2). </p> </li> </ul> </p> </section> </section> </section> <section id="CD000553-sec-0158"> <h4 class="title">Assessment for publication bias</h4> <p>The presence of publication bias was assessed by performing a dichotomous analysis. It was possible to assess it for all treatments together and for TIPS, given that there were at least 10 trials for TS and DSRS. </p> <p>Asymmetry was present in the funnel plot, both for all portosystemic shunts analysed together, and for TIPS, which suggests that small trials favouring shunts are missing for analysis of all‐cause mortality (<a href="#CD000553-fig-0004">Figure 4</a>), rebleeding (<a href="#CD000553-fig-0005">Figure 5</a>), and mortality due to rebleeding (<a href="#CD000553-fig-0006">Figure 6</a>) , and small trials favouring endoscopy are missing for analysis of development of acute hepatic encephalopathy (<a href="#CD000553-fig-0007">Figure 7</a>) and for development of chronic hepatic encephalopathy (<a href="#CD000553-fig-0008">Figure 8</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000553-sec-0159" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000553-sec-0159"></div> <section id="CD000553-sec-0160"> <h3 class="title" id="CD000553-sec-0160">Summary of main results</h3> <p>In this systematic review we compared portosystemic shunting procedures (total shunt (TS), distal splenorenal shunt (DSRS), and transjugular intrahepatic portosystemic shunt (TIPS)) versus endoscopic interventions (endoscopic sclerotherapy or banding, or both) with or without medical treatment for prevention of rebleeding from oesophagogastric varices in people with cirrhosis. We included 27 trials with up to 1828 participants, which provided data for analyses. </p> <p>Overall, we found very low‐certainty evidence suggesting that all modalities of shunt intervention compared with endoscopic intervention with or without medical treatment may make little or no difference in all‐cause mortality. </p> <p>We found very low‐certainty evidence suggesting that shunts reduced the risk of rebleeding. Estimates for the risk of all‐cause mortality and rebleeding were precise, as optimal information sizes (OISs) were met and confidence intervals (CIs) were narrow. There was no heterogeneity. However, the overall high risk of bias of the included trials and the risk of publication bias are limitations that reduce the strength of the results of this review. </p> <p>We found very low‐certainty evidence suggesting that shunts reduced mortality due to rebleeding, and that shunts increased the risk of acute and chronic hepatic encephalopathy. A summary of our results is reported in <a href="./full#CD000553-tbl-0001">summary of findings Table 1</a>. </p> <p>We found very low‐certainty evidence suggesting that DSRS and TIPS compared with endoscopic treatment with or without medical treatment may make little or no difference in all cause‐mortality, and that TS seemed to reduce mortality. We found very low‐certainty evidence suggesting that each shunt modality reduced rebleeding and mortality due to rebleeding. Although meta‐analysis did not demonstrate an impact of treatment with total shunt on the development of acute hepatic encephalopathy (very low‐certainty evidence), risk was increased with DSRS (very low‐certainty evidence) as with TIPS (very low‐certainty evidence). Chronic hepatic encephalopathy was not increased with TS but was increased with DSRS, and the tendency toward chronic hepatic encephalopathy was increased with TIPS (very low‐certainty evidence). </p> <p>Differences between types of treatment in effects on all‐cause mortality and acute and chronic encephalopathy must be interpreted cautiously because of the low certainty of evidence, and because of the absence of statistical differences between them. When we analysed TS, DSRS, and TIPS as subgroups, the test for subgroup differences showed no differences between the three treatments on mortality (P = 0.14; I² = 48.8%; <a href="./references#CD000553-fig-0009" title="">Analysis 1.1</a>), acute encephalopathy (P = 0.98; I² = 0%; <a href="./references#CD000553-fig-0012" title="">Analysis 1.4</a>), or chronic encephalopathy (P = 0.31; I² = 13.5%; <a href="./references#CD000553-fig-0013" title="">Analysis 1.5</a>). </p> <p>We found no substantial heterogeneity among the included trials. This was confirmed by the absence of differences in the main analyses. Sensitivity analysis performed in trials with TIPS, band ligation, medical treatment (beta blocker), and polytetrafluoroethylene (PFTE)‐covered stent did not show any changes in results. </p> <p>Shunt dysfunction was a problem commonly encountered among individuals treated with TIPS. Summaries of our results comparing TS, DSRS, and TIPS versus endoscopic treatment with or without medical treatment are provided in <a href="./full#CD000553-tbl-0002">summary of findings Table 2</a>, <a href="./full#CD000553-tbl-0003">summary of findings Table 3</a>, and <a href="./full#CD000553-tbl-0004">summary of findings Table 4</a>. </p> </section> <section id="CD000553-sec-0161"> <h3 class="title" id="CD000553-sec-0161">Overall completeness and applicability of evidence</h3> <p>Included trial participants had liver disease ranging from Child's class A to C, although the mean Child‐Pugh score, when reported, ranged between 6.6 and 9.8. This suggests that trials excluded participants with initial Child's class A and severe Class C. No analyses of the results according to liver function or grade of hypertension (based on variceal size or hepatic venous pressure gradient (HVPG)) are reported. Results show high variability in the number of previous bleedings and in time from the index bleeding; the start of prevention ranged from a few hours to several weeks. In addition, some of the included trials were conducted more than 30 years ago. Over the past decades, treatments such as orthotopic liver transplantation for advanced stages of cirrhosis and improved surgical, interventional, and endoscopic procedures have influenced the natural history of cirrhosis and have reduced the applicability of the results of old trials (usually assessing surgical procedures) to patients seen in current practice. </p> </section> <section id="CD000553-sec-0162"> <h3 class="title" id="CD000553-sec-0162">Quality of the evidence</h3> <p>Our current review has identified a number of methodological concerns. All trials were at overall high risk of bias. The a priori number of participants required for a meta‐analysis to be conclusive was reached for all‐cause mortality and rebleeding as shown by the meta‐analysis of all shunt treatments, and for re‐bleeding with TIPS as shown by the meta‐analysis of individual treatments, but not for the other outcomes nor for other individual treatments, meaning that risk of random error was high. </p> <p>Our assessments of risk of bias reflect the lack of, or poor description of, trial design and performance, as well as incomplete reporting of results. We often failed in our attempts to obtain missing information from the authors of trial reports. </p> <p>Regarding lack of blinding of participants and personnel, as we anticipated, blinding was impossible to perform in light of the nature of the interventions, but it could have influenced a shift to alternative treatments after randomisation, not due to medical or technical reasons. </p> <p>Blinding of outcome assessors should have been achievable. Nonetheless, only two trials reported adequate blinding of outcome assessors (<a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a>; <a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a>), leaving the remaining trials at risk of detection and performance bias. A lack of blinding of outcome assessor (detection bias) may not affect the results of all‐cause mortality, but it could influence the results of other outcomes (e.g. hepatic encephalopathy, cause of mortality, etc), considering that outcomes can have a subjective component in the judgement (<a href="./references#CD000553-bbs2-0090" title="SavovićJ , TurnerRM , MawdsleyD , JonesHE , BeynonR , HigginsJPT , et al. Association between risk-of-bias assessments and results of randomized trials in Cochrane Reviews: The ROBES Meta-Epidemiologic Study. American Journal of Epidemiology2018;187(5):1113-22.">Savović 2018</a>). </p> <p>We found high risk of reporting bias. Most trials did not publish protocols, and not all of the outcomes of interest for the review were reported; in particular, the incidence of chronic hepatic encephalopathy was reported by only a relatively small number of trials. </p> <p>Very few adverse events were reported in the shunt group in comparison with the endoscopic group, which could suggest selective under‐reporting of adverse events due to surgical treatment. </p> <p>A large number of participants with treatment failure were crossed‐over to the other available treatment (mainly from endoscopic intervention to portosystemic shunts) after failure. In most cases, it is unclear if and when the data were censored. It is likely that this bias was relevant for all outcomes except rebleeding (this was the reason for the switch to alternative treatments). We classified this bias under 'other bias'. </p> <p>The funnel plots in our review seem to suggest risk of publication bias. The visual inspection might give a misleading impression of the presence or absence of publication bias (<a href="./references#CD000553-bbs2-0092" title="SimmondsM . Quantifying the risk of error when interpreting funnel plots. Systematic Reviews2015;4(24):1-7.">Simmonds 2015</a>) because there is concern that "visual interpretation of funnel plots is inherently subjective" (<a href="./references#CD000553-bbs2-0076" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>). There is not an agreement on the use of statistical tools to interpret publication bias (<a href="./references#CD000553-bbs2-0076" title="HigginsJPT , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019</a>; <a href="https://gdt.gradepro.org/app/handbook/handbook.html" target="_blank">Grade Handbook</a>), and alternative hypotheses to explain the asymmetry in this review does not seem likely because there was no heterogeneity among the trials, asymmetry was present also for each type of treatment (TS, DSRS, TIPS), and if the number of trials for each type of shunt is low. There were no differences between the results with a random‐effects meta‐analysis and a fixed‐effect analysis (data not presented). We cannot exclude the role of chance completely, but we constructed funnel plots only for analyses with more than 10 trials. Publication bias seems to be the most likely explanation of the asymmetry also because a lot of the included trials are very old, being performed before the implementation of the trial registration initiative. Thus, a selective publication of studies was most likely to have taken place, also if it is not possible to exclude that the apparent asymmetry could be a result of factors other than publication bias, and that the direction of bias appears to vary. </p> <p>All trials included in this review presented methodological weaknesses that increase bias risk and reduce the certainty of evidence. All of this has impacted the robustness of our conclusions. </p> <p>Through our GRADE assessment, we considered the influence of the high risk of bias, imprecision, and publication bias in the trials on the trial outcome results. Whereas the precision of the results is high for rate of rebleeding (narrow CI and OIS were met), the limitations due to the overall low quality of trials and publication bias resulted in very low certainty of evidence rating for all outcomes and for each shunt modality. </p> <p>No trial data on health‐related quality of life were reported; therefore, no evidence is available for this outcome. In addition, we were unable to draw clear conclusions with regards to cost and length of patient stay because data were variably reported, were highly heterogeneous, and were inconsistently collected. </p> <p>It was not possible to perform meta‐analyses of complications because in most trials they were reported as single episodes, and the number of participants experiencing them was not reported. </p> </section> <section id="CD000553-sec-0163"> <h3 class="title" id="CD000553-sec-0163">Potential biases in the review process</h3> <p>We performed a comprehensive literature search for published and unpublished studies, and we combined electronic data searches with manual searches of the reference lists of identified trials as well as conference proceedings and abstract books from relevant national and international society meetings. We included trials regardless of their language of publication, and whether they reported data on the outcomes we needed. We contacted relevant study authors to request additional information. </p> <p>Three review authors independently assessed study eligibility, extracted data, and assessed risk of bias in included trials, and we believe that this has reduced potential biases in the review process. </p> <p>This systematic review represents an update of a previously published review, based on a protocol from 1997. Every effort has been made to update the review with up‐to‐date methods, whilst maintaining methods according to the published protocol when possible, hence avoid reporting bias in the current review. However, we acknowledge that changes in Cochrane guidance have resulted in minor deviations from the protocol. </p> </section> <section id="CD000553-sec-0164"> <h3 class="title" id="CD000553-sec-0164">Agreements and disagreements with other studies or reviews</h3> <p>The previous version of this review utilised a systematic approach to assess the effects of portosystemic shunts (TS, DSRS, and TIPS) versus endoscopic treatments (<a href="./references#CD000553-bbs2-0112" title="KhanSA , Tudur SmithC , WilliamsonPR , SuttonR . Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database of Systematic Reviews2006, Issue 4. Art. No: CD000553. [DOI: 10.1002/14651858.CD000553.pub2] [MEDLINE: 17054131]">Khan 2006</a>). Those review authors reported no differences in all‐cause mortality but a reduced incidence of rebleeding and an increased incidence of hepatic encephalopathy for all shunt modalities and with analysis of each modality individually for TIPS. Review results are consistent with our results. </p> <p>The current version, updating data to 2020, has included more trials and, among these, trials that utilised PTFE‐covered stents and band ligation, which are judged better than uncovered stents and sclerotherapy, respectively. In a sensitivity analysis, the results did not change when trials using the modality of TIPS shunt and using endoscopic interventions were added. Second, more outcomes were assessed: among these, mortality due to rebleeding, which seems reduced by the portosystemic shunt in comparison with endoscopy with or without medical treatment. Whilst it is undoubtedly essential to examine the impact of treatments on health‐related quality of life, unfortunately our attempts to conduct this evaluation failed because none of the trials reported on it, suggesting that health‐related quality of life remains to be examined in future trials. </p> <p>Moreover, although an assessment of risk of bias was reported in the previous version of this review, the methodological update of criteria according to Cochrane methods has been applied, and an assessment of the certainty of evidence via GRADE recommendations has been added. </p> <p>Recently, another published meta‐analysis compared portosystemic shunts (including surgical portosystemic shunts and transjugular intrahepatic portosystemic shunt) versus endoscopic intervention (<a href="./references#CD000553-bbs2-0110" title="ZhouGP , SunLY , WeiL , QuW , ZengZG , LiuY , et al. Comparision between portosystemic shunts and endoscopic therapy for prevention of variceal re-bleeding: a systematic review and meta-analysis. Chinese Medical Journal2019;132(9):1087-99. [DOI: 10.1097/CM9.0000000000000212] [MEDLINE: 30913064]">Zhou 2019</a>). The authors of this meta‐analysis stated in the methods section that they assessed trials including participants with "at least one previous episode of gastroesophageal variceal bleeding that had subsequently stabilised, either spontaneously or by the use of non‐surgical therapies..."; however, it appears that they also included trials performed in emergency settings (<a href="./references#CD000553-bbs2-0036" title="OrloffM , IsenbergJ , WheelerH , HaynesK , Jinich-BrookH , RapierR , et al. Portal-systemic encephalopathy in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt treatment of acutely bleeding esophageal varices in cirrhosis. Annals of Surgery2009;250(4):598-610. [DOI: 10.1097/SLA.0b013e3181b73126] [MEDLINE: 19730244]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Direct costs of care in a randomized controlled trial of endoscopic sclerotherapy versus emergency portacaval shunt for bleeding esophageal varices in cirrhosis - Part 4. Journal of Gastrointestinal Surgery2011;15(1):38-47. [DOI: 10.1007/s11605-010-1332-6] [MEDLINE: 20824373]OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Emergency portacaval shunt versus rescue portacaval shunt in a randomized controlled trial of emergency treatment of acutely bleeding esophageal varices in cirrhosis - Part 3. Journal of Gastrointestinal Surgery2010;14(11):1782-95. [DOI: 10.1007/s11605-010-1279-7] [MEDLINE: 20658205]OrloffMJ . Fifty-three years' experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in cirrhosis: 1958 - 2011. Journal of the American Medical Association Surgery2014;149(2):155-69. [DOI: 10.1001/jamasurg.2013.4045] [MEDLINE: 24402314]">Orloff 2009</a>; <a href="./references#CD000553-bbs2-0037" title="OrloffMJ , HyeRJ , WheelerHO , IsenbergJI , HaynesKS , VaidaF , et al. Randomized trials of endoscopic therapy and transjugular intrahepatic portosystemic shunt versus portacaval shunt for emergency and elective treatment of bleeding gastric varices in cirrhosis. Surgery2015;157(6):1028-45. OrloffMJ , IsenbergJI , WheelerHO , HaynesKS , Jinich-BrookH , RapierR , et al. Randomized trial of emergency endoscopic sclerotherapy versus emergency portacaval shunt for acutely bleeding esophageal varices in cirrhosis. Journal of the American College of Surgeons2009;209(1):25-40. [DOI: 10.1016/j.jamcollsurg.2009.02.059] [MEDLINE: 19651060]">Orloff 2015</a>). In addition, they included trials comparing the surgical shunt to TIPS (<a href="./references#CD000553-bbs2-0087" title="RosemurgyAS , FrohmanHA , TetaAF , LubericeK , RossSB . Prosthetic H-graft portacaval shunts vs transjugular intrahepatic portosystemic stent shunts: 18-year follow-up of a randomized trial. Journal of the American College of Surgeons2012;214(4):445-53. [DOI: 10.1016/j.jamcollsurg.2011.12.042] [MEDLINE: 22463885]">Rosemurgy 2012</a>). Therefore, our results represent a different clinical context. Our meta‐analysis is more homogeneous for settings of participants (elective prophylaxis of rebleeding) and comparisons (shunts versus endoscopy). </p> <p>Two previous meta‐analyses compared uncovered TIPS versus endoscopic intervention (<a href="./references#CD000553-bbs2-0080" title="LucaA , D'AmicaG , La GallaR , MidiriM , MorabitoA , PagliaroL . TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials. Radiology1999;212(2):411-21. [DOI: 10.1148/radiology.212.2.r99au46411] [MEDLINE: 10429698]">Luca 1999</a>; <a href="./references#CD000553-bbs2-0082" title="PapatheodoridisGV , GoulisJ , LeandroG , PatchD , BurroughsAK . Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology (Baltimore, Md.)1999;30(3):612-22. [DOI: 10.1002/hep.510300316] [MEDLINE: 10462365]">Papatheodoridis 1999</a>); these were updated by <a href="./references#CD000553-bbs2-0055" title="BurroughsAK , VangeliM . Transjugular Intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scandinavian Journal of Gastroenterology2002;37(3):249-52. [DOI: 10.1080/003655202317284138] [MEDLINE: 11916185]">Burroughs 2002</a>. All these meta‐analyses reported no differences in all‐cause mortality, a decrease in rebleeding risk, and an increase in hepatic encephalopathy. However, none of these meta‐analyses evaluated the certainty of evidence following stringent methods. In addition, these meta‐analyses included fewer trials, and given the years of publications, these meta‐analyses included fewer trials reporting on covered TIPS and/or band ligation with or without beta blockers. </p> <p>In a multiple‐treatment meta‐analysis, <a href="./references#CD000553-bbs2-0091" title="ShiKQ , LiuWY , PanZZ , LinZF , ChenSL , ChenYP , et al. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. European Journal of Clinical Investigation2013;43(8):844-54. [DOI: 10.1111/eci.12115] [MEDLINE: 23725530]">Shi 2013</a> assessed several treatments to prevent rebleeding, including TIPS. Beta blockers combined with endoscopic injection sclerotherapy, and endoscopic banding ligation (EBL) combined with endoscopic injection sclerotherapy, were superior to beta blockers and endoscopic injection sclerotherapy in reducing rebleeding and mortality due to rebleeding; TIPS was more efficacious than beta blockers, endoscopic banding ligation, endoscopic injection sclerotherapy, beta blockers combined with isosorbide‐5‐mononitrate (5‐ISMN), and beta blockers combined with endoscopic injection sclerotherapy. TIPS had the greatest probability of reducing mortality due to rebleeding. Endoscopic banding ligation combined with endoscopic injection sclerotherapy was the best choice according to the cumulative probabilities of being among the three most efficacious interventions for the three outcomes examined in this review. In this meta‐analysis, trials in which drugs or treatments have been previously used were excluded. The list of included trials is not reported in <a href="./references#CD000553-bbs2-0091" title="ShiKQ , LiuWY , PanZZ , LinZF , ChenSL , ChenYP , et al. Secondary prophylaxis of variceal bleeding for cirrhotic patients: a multiple-treatments meta-analysis. European Journal of Clinical Investigation2013;43(8):844-54. [DOI: 10.1111/eci.12115] [MEDLINE: 23725530]">Shi 2013</a>, nor is it updated. Furthermore, the role of this method has yet to be validated. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000553-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram. Searches performed up to June 2020" data-id="CD000553-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram. Searches performed up to June 2020</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD000553-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD000553-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.1 All‐cause mortality" data-id="CD000553-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.1 All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.2 Rebleeding" data-id="CD000553-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.2 Rebleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.3 Mortality due to rebleeding" data-id="CD000553-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.3 Mortality due to rebleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.4 Acute hepatic encephalopathy" data-id="CD000553-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.4 Acute hepatic encephalopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.5 Chronic hepatic encephalopathy" data-id="CD000553-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Portosystemic shunt versus endoscopic intervention with or without medical treatment, outcome: 1.5 Chronic hepatic encephalopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-FIG-08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 1: All‐cause mortality" data-id="CD000553-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 2: Rebleeding" data-id="CD000553-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 2: Rebleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 3: Mortality due to rebleeding" data-id="CD000553-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 3: Mortality due to rebleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 4: Acute hepatic encephalopathy" data-id="CD000553-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 4: Acute hepatic encephalopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 5: Chronic hepatic encephalopathy" data-id="CD000553-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 5: Chronic hepatic encephalopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 6: Rebleeding from all causes" data-id="CD000553-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Portosystemic shunts versus endoscopic intervention with or without medical treatment, Outcome 6: Rebleeding from all causes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 1: All‐cause mortality" data-id="CD000553-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 1: All‐cause mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 2: Rebleeding" data-id="CD000553-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 2: Rebleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 3: Mortality due to rebleeding" data-id="CD000553-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 3: Mortality due to rebleeding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 4: Acute hepatic encephalopathy" data-id="CD000553-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 4: Acute hepatic encephalopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000553-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/urn:x-wiley:14651858:media:CD000553:CD000553-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 5: Chronic hepatic encephalopathy" data-id="CD000553-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_t/tCD000553-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding, Outcome 5: Chronic hepatic encephalopathy </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/media/CDSR/CD000553/image_n/nCD000553-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000553-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis and with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> hospital; tertiary referral centres<br/><b>Intervention:</b> shunt intervention (total shunt (TS), distal splenorenal shunt (DSRS), or transjugular intrahepatic portosystemic shunt (TIPS))<br/><b>Comparison:</b> endoscopic intervention with or without medical treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention with or without medical treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with shunts</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 32.9 months (range 11.7 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.99 (0.86 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1828</p> <p>(27 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝</p> <p>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>288 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>286 per 1000 (248 to 325)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 33.8 months (range 13.5 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.40 (0.33 to 0.50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1769<br/>(26 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>432 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/>(143 to 216) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 33.5 months (range 11.7 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.51 (0.34 to 0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1779</p> <p>(26 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>95 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>48 per 1000 (32 to 72)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 33.8 months (range 13.5 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.60 (1.33 to 1.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1649<br/>(24 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>185 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>296 per 1000<br/>(246 to 355) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 28.5 months (range 13.5 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.51 (1.38 to 4.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>956<br/>(13 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(37 to 123) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; OIS: optimal information size; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); publication bias (‐1 level).<br/><sup>b</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); publication bias (‐1 level).<br/><sup>c</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: optimal information size (OIS) as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>d</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>e</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Portosystemic shunts compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000553-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis and with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> hospital tertiary care centres<br/><b>Intervention</b> : total shunt<br/><b>Comparison:</b> endoscopic intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention with or without medical treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with total shunt</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 32.4 months (range 11.7 to 65.1)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.46 (0.19 to 1.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>164<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>198 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>91 per 1000<br/>(38 to 224) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 42.8 months (range 20.4 to 65.1)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.28 (0.14 to 0.56)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>127<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>435 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>122 per 1000<br/>(61 to 244) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""> <p>No data available</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 32.4 months (range 11.7 to 65.1)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.25 (0.06 to 0.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>164</p> <p>(3 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝</p> <p>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>136 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>34 per 1000 (8 to 131)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 42.8 months (range 20.4 to 65.1)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.66 (0.70 to 3.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>115<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>204 per 1000<br/>(86 to 482) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 20.4 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was a single trial with 3/34 events in total shunt group and 0/35 in endoscopy with or without drugs group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: optimal information size (OIS) as calculated by GRADE was not met (‐1 level).<br/><sup>b</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>c</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>d</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met; there were few events and the CI included appreciable benefit and harm (‐2 levels). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Total shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000553-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Distal splenorenal shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Distal splenorenal shunt (DSRS) compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis and with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> hospital tertiary care centres<br/><b>Intervention:</b> DSRS<br/><b>Comparison:</b> endoscopic intervention </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with distal splenorenal shunt</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.93 (0.65 to 1.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>352<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>469 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>436 per 1000 (305 to 624)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.26 (0.11 to 0.65)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>330<br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>458 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>119 per 1000<br/>(50 to 298) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.31 (0.13 to 0.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>352</p> <p>(5 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>126 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>39 per 1000 (16 to 93)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 68.6 months (range 27.1 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.70 (0.94 to 3.08)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>287<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>139 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>236 per 1000<br/>(131 to 428) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 62.5 months (range 27.1 to 98)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.51 (1.38 to 4.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>170<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>27 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(37 to 123) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: confidence interval; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: optimal information size (OIS) as calculated by GRADE was not met; (‐1 levels); heterogeneity (‐1 level).<br/><sup>b</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); heterogeneity (‐1 level).<br/><sup>c</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>d</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level).<br/><sup>e</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 levels). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Distal splenorenal shunt compared with endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD000553-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Transjugular intrahepatic portosystemic shunt compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Transjugular intrahepatic portosystemic shunt (TIPS) compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> participants with cirrhosis with previous oesophagogastric variceal bleeding<br/><b>Setting:</b> tertiary care centres<br/><b>Intervention:</b> TIPS<br/><b>Comparison:</b> endoscopic intervention with or without medical treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(trials)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk with endoscopic intervention with or without medical treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk with TIPS</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>All‐cause mortality</b> </p> <p>Follow‐up: 24.5 months (range 13.5 to 46.2)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 1.10 (0.92 to 1.31)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1312</p> <p>(19 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>252 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>277 per 1000</p> <p>(232 to 330)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Rebleeding</b> </p> <p>Follow‐up: 24.5 months (range 13.5 to 46.2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.44 (0.36 to 0.55)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1312<br/>(19 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>425 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/>(153 to 234) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Health‐related quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data available</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Mortality due to rebleeding</b> </p> <p>Follow‐up: 24.9 months (range 13.5 to 46.2)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>Medium‐risk population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>RR 0.65 (0.40 to 1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>1263</p> <p>(18 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊝⊝⊝<br/>Very low<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>53 per 1000</p> <p>(33 to 85)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Acute hepatic encephalopathy</b> </p> <p>Follow‐up: 24.5 months (range 13.5 to 46.2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.61 (1.29 to 1.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1247<br/>(18 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>201 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>324 per 1000<br/>(259 to 400) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Chronic hepatic encephalopathy</b> </p> <p>Follow‐up: 22.5 months (range 13.5 to 46.2)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Medium‐risk population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.88 (0.93 to 3.80)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>717<br/>(10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>Very low<sup>e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>28 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(26 to 106) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>The corresponding risk (risk of the intervention group) (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/>CI: Confidence interval; RCT: randomised clinical trial; RR: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty :</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); optimal information size (OIS) as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>b</sup>Downgraded three levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); publication bias (‐1 level).<br/><sup>c</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>d</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level).<br/><sup>e</sup>Downgraded four levels because of within‐study risk of bias: all trials were at overall high risk of bias (‐2 levels); imprecision: OIS as calculated by GRADE was not met (‐1 level); publication bias (‐1 level). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Transjugular intrahepatic portosystemic shunt compared with endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0005"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of portosystemic shunts versus endoscopic intervention with or without medical therapy for prevention of rebleeding in patients with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Comparison of imprecision by GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction while also considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>632</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>286</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>441</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4222</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9426</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2116</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9429</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1986</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrade 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4410</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrade 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>972</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,644</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7886</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35,394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>The Z‐curve did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.<br/><sup>b</sup>The Z‐curve reached the monitoring boundary for benefit.<br/><sup>c</sup>The Z‐curve reached the monitoring boundary for futility.<br/><sup>d</sup>The Z‐ curve reached the monitoring boundary for harm.<br/><sup>e</sup>The TSA figure was not constructed due to too little information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of portosystemic shunts versus endoscopic intervention with or without medical therapy for prevention of rebleeding in patients with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0006"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Total shunt versus endoscopic intervention: shunt surveillance and complications</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Method of shunt surveillance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Incidence of shunt dysfunction</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported shunt complications or adverse events<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported endoscopic or medical therapy complications or adverse events<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography at 4 months, then ultrasound every 12 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/24: acute shunt thrombosis (percentage and 95% CI 4.2%, 0.7% to 20%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophagitis 8 patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal stenosis 2 patients</p> <p>Oesophagitis 7 patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0012" title="KorulaJ , YelinA , YamadaS , WeinerJ , CohenH , ReynoldsTB . A prospective randomised controlled comparison of chronic endoscopic variceal sclerotherapy and portalsystemic shunt for variceal hemorrhage in Child's Class A cirrhotics: a preliminary report. Gastroenterology1987;92:1745. ">Korula 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ultrasound 3 to 10 months after surgery or at the time of variceal rebleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/41: shunt thrombosis (percentage and 95% CI 2.4%, 0.4% to 13%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from lesions other than oesophageal or gastric varices 3 patients</p> <p>Other complications 7 patients (wound abscess 2, sepsis 1, pneumonia 2, chylous pleural effusion 1, cholestasis 1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from lesions other than oesophageal or gastric varices 4 patients</p> <p>Other complications 12 patients (deep oesophageal ulcers 3, stenosis 1, pneumonia 1, transient dysphagia 4, fever 2, pleural effusion 1) </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Acute hepatic encephalopathy, chronic hepatic encephalopathy, mortality, and shunt dysfunction not included, as reported elsewhere in this review. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Total shunt versus endoscopic intervention: shunt surveillance and complications</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0007"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Distal splenorenal shunt versus endoscopic intervention: shunt surveillance and complications</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Method of shunt surveillance</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Incidence of shunt dysfunction</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported shunt complications or adverse events<sup>a</sup> </b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported endoscopic or medical therapy complications or adverse events<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0008" title="HendersonJM , KutnerMH , MillikanWJ , GalambosJT , RiepeSP , BrooksS , et al. Endoscopic variceal sclerosis compared with distal splenorenal shunt to prevent recurrent variceal bleeding in cirrhosis, a prospective randomized trial. Annals of Internal Medicine1990;112(4):262-9. [DOI: 10.7326/0003-4819-112-4-262] [MEDLINE: 2404448]WarrenWD , HendersonJM , MillikanWJ , GalambosJT , BrooksWS , RiepeSP , et al. Distal splenorenal shunt versus endoscopic sclerotherapy for long-term management of variceal bleeding: preliminary report of a prospective, randomised trial. Annals of Surgery1986;203(5):454-62. [DOI: 10.1097/00000658-198605000-00002] [MEDLINE: 3486641]">Henderson 1990</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from deep oesophageal ulcers 2 patients</p> <p>Insufficient information on other complications or adverse events</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography at 3 months, then at 1, 3, and 6 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/30</p> <p>(percentage and 95% CI 10%, 3.5% to 26%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal stenosis 3 patients</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0022" title="SantambrogioR , OpocherE , CostaM , BrunoS , CarettiAP , SpinaGP . Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World Journal of Gastroenterology2006;12(39):6331-8. [DOI: 10.3748/wjg.v12.i39.6331] [MEDLINE: 17072957]SpinaGP , SantambrogrioR , OpocherE , CosentinoF , ZambelliA , PassoniGR , et al. Distal splenorenal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. First stage of a randomized, controlled trial. Annals of Surgery1990;211(2):178-86. [MEDLINE: 2405792]">Santambrogio 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography on 10th day, then at 1, 3, and 6 months after discharge, then at least twice yearly </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/40</p> <p>(percentage and 95% CI 0%, 0% to 9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on surgical complications</p> <p>Bleeding from duodenal ulcers 5 patients</p> <p>Ascites 11 patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from oesophageal ulcers 5 patients</p> <p>Bleeding from unknown sources 2 patients</p> <p>Dyspagia due to oesophageal ulcers 8 patients</p> <p>Oesophageal stenosis 5 patients</p> <p>Pleural effusion 1 patient</p> <p>Ascites 19 patients</p> <p>Liver failure 1 patient</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography, ultrasound, and/or isotopic splenoportography 7 to 10 months after surgery and when variceal rebleeding occurred </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/43</p> <p>(percentage and 95% CI 12%, 5% to 24%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information on surgical complications</p> <p>Bleeding from sources other than varices (peptic ulcers or gastritis) 5 patients</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from sources other than varices (peptic ulcers or gastritis) 7 patients</p> <p>Oesophageal ulcers 2 patients</p> <p>Oesophageal stenosis 3 patients</p> <p>Transient dysphagia 15 patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000553-bbs2-0027" title="UrbistondoM , TorresEA , CastroF , OharrizJ , MedinaR , MolinaA , et al. Prevention of recurrent esophageal bleeding and survival in patients with alcoholic cirrhosis: a randomized study. Puerto Rico Health Sciences Journal1996;15(3):195-9. [MEDLINE: 8994285]">Urbistondo 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insufficient information</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Acute hepatic encephalopathy, chronic hepatic encephalopathy, mortality, and shunt dysfunction not included, as reported elsewhere in this review. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Distal splenorenal shunt versus endoscopic intervention: shunt surveillance and complications</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0008"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical treatments: shunt surveillance and complications</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Stent type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Method of shunt surveillance</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Incidence of shunt dysfunction</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported shunt complications or adverse events<sup>a</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Other reported endoscopic or medical therapy complications or adverse events<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐mm Wallstent endoprosthesis 15 patients</p> <p>Strecker stent 15 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography 6‐monthly and after any episode of ascites or variceal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/27 (percentage and 95% CI 55%, 37% to 72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complications 7 patients (portal vein thrombosis 2, spontaneous bacterial peritonitis 2, haemobilia 1, sepsis 1, pneumonia 2, congestive heart failure 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Complications 11 patients (bleeding oesophageal ulcers 5, oesophageal stenosis 4, pneumonia 2, sepsis 1, spontaneous bacterial peritonitis 2) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallstents</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/22 (percentage and 95% CI 18%, 7% to 38%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0003" title="DunnePDJ , SinhaR , StanleyAJ , LachlanN , IrelandH , ShamsA , et al. Randomised clinical trial: standard of care versus early-transjugular intrahepatic porto-systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding. Alimentary Pharmacology &amp; Therapeutics2020;52(1):98-106. [MEDLINE: 32452561]">Dunne 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>e‐PTFE‐covered stent (Viatorr TIPSS endoprosthesis, W.L. Gore &amp; Associates, Inc., Newark, NJ, USA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasonography or TIPSS venography at 6 months and at 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No technical failures or major complications of the TIPSS procedure</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Banding ulcer 3</p> <p>Mallory Weiss 2</p> <p>Portal hypertensive gastropathy 1</p> <p>Seizure 2, fractured bone 3, cellulitis 1, arrhythmia 1, urinary tract infection 1, alcohol hepatitis 1, left ventricular thrombus 1, pneumonia 2, spontaneous bacterial peritonitis 1, spontaneous retroperitoneal bleeding 1, hyponatraemia 1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information on procedure‐related complications</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Banding ulcer 2</p> <p>Mallory Weiss 1</p> <p>Fractured bone 2, arrhythmia 1, abscess 1, compartment syndrome 1, urinary tract infection 1, alcohol hepatitis 2, spontaneous bacterial peritonitis 2 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0004" title="FerlitschA , UlbrichG , MaieronA , SalzlP , ReibergerT , PayerBA , et al. A randomized, controlled, multicentre trial comparing endoscopic band ligation versus tips in cirrhotic patients with recurrent variceal bleeding non-responding to pharmacological therapy. Journal of Hepatology2012;56(Suppl 2):S555. ">Ferlitsch 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTFE‐coated TIPS</p> <p>(not specified)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stent thrombosis 3 patients/21 (14%,</p> <p>95% CI 5% to 35%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient Information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient Information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Angiography at 1 month and every 6 months thereafter, and if variceal bleeding or ascites occurred </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/18 at 6 months (percentage and 95% CI 78%, 55% to 91%)</p> <p>10/13 at 12 months (percentage and 95% CI 77%, 50% to 92%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest discomfort almost all patients</p> <p>Oesophageal ulcer 5 patients</p> <p>Oesophageal stenosis 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0006" title="Groupe d'Etude de Anastomoses Intra-Hepatiques. TIPS versus sclerotherapy + propranolol in the prevention of variceal rebleeding: preliminary results of a multicenter randomised trial. Hepatology (Baltimore, Md.)1995;22(S4):297A. ">GDEAIH 1995</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0007" title="GülbergN , SchepkeG , GeigenbergerG , HollJ , BrensingKA , WaggershauserT , et al. Transjugular intrahepatic portosystemic shunting is not superior to endoscopic variceal band ligation for prevention of variceal rebleeding in cirrhotic patients: a randomized, controlled trial. Scandinavian Journal of Gastroenterology2002;37(3):338-43. [DOI: 10.1080/003655202317284255] [MEDLINE: 11916197]">Gülberg 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler sonography at 1 month, at 3 months, and at 3‐monthly intervals thereafter</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perforation of liver capsule with peritoneal haemorrhage (death) 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Perforation of oesophagus 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PTFE‐covered stent</p> <p>(Viatorr)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical evaluation every 6 weeks to 3 months. Duplex ultrasound undertaken when dysfunction suspected (new‐onset or progressive ascites, or variceal rebleeding) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/37: partial/complete occlusion (percentage and 95% CI 5%, 1.5% to 17.7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events 24</p> <p>Number of complications or adverse events<sup>c</sup>: </p> <p>Bleeding from banding ulcer 1</p> <p>Bleeding from other upper gastrointestinal sources 1</p> <p>Ascites 5</p> <p>Spontaneous bacterial peritonitis 2</p> <p>Hepatocellular carcinoma or cholangiocarcinoma 2</p> <p>Acute‐on‐chronic liver failure 4</p> <p>Cholangitis 6</p> <p>Alcoholic hepatitis 1</p> <p>Sepsis 4</p> <p>Cardiac event 1</p> <p>Neurological disorder 1</p> <p>Other complications 3</p> <p>Severe itching 1</p> <p>Gynaecomastia 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe adverse events 24 patients</p> <p>Number of complications or adverse events<sup>c</sup>: </p> <p>Bleeding from banding ulcer 2</p> <p>Bleeding from other upper gastrointestinal sources 1</p> <p>Intra‐abdominal bleeding from collaterals 1</p> <p>Laceration of hepatic artery (during TIPS placement) 1</p> <p>Ascites 13</p> <p>Spontaneous bacterial peritonitis 3</p> <p>Hepatorenal syndrome 1</p> <p>Hepatocellular carcinoma or cholangiocarcinoma 4</p> <p>Acute‐on‐chronic liver failure 3</p> <p>Cholangitis 2</p> <p>Alcoholic hepatitis 2</p> <p>Sepsis 1</p> <p>Cardiac event 3</p> <p>Neurological disorder 3</p> <p>Other complications 3</p> <p>Severe itching 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐mm expandable metal stent (Wallstent)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound at 1 week</p> <p>Angiography at 1 month, then at 6‐monthly intervals</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/28: shunt thrombosis 6 patients (variceal rebleeding in 2 patients), pseudointimal hyperplasia 3 patients (percentage and 95% CI 32%, 18% to 51%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sepsis 3 patients (aspiration pneumonia 1 patient, staphylococcal septicaemia 2 patients)</p> <p>Perforation of liver capsule 1 patient</p> <p>Respiratory depression caused by sedation 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oesophageal ulcer 12 patients</p> <p>Bleeding from oesophageal ulcer 1 patient</p> <p>Aspiration pneumonia 2 patients</p> <p>Sepsis 4 patients (aspiration pneumonia 2 patients, spontaneous bacterial peritonitis 1 patient, central line‐related sepsis 1 patient) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Metallic endoprosthesis (Wallstent)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound at discharge and every 3 months, or when clinically indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/35 (percentage and 95% CI 23%, 12% to 39%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bacteremia 5 patients</p> <p>Hepatic failure 2 patients</p> <p>Bleeding from peptic ulcer 5 patients</p> <p>Bleeding from undetermined source 2 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Refractory ulcer on gastric varices 3 patients</p> <p>Bacteraemia 10 patients</p> <p>Spontaneous bacterial peritonitis 1 patient</p> <p>Bleeding from peptic ulcer 1 patient</p> <p>Bleeding from undetermined source 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0014" title="LuoX , WangZ , TsauoJ , ZhouB , ZhangH , LiZ . Advanced cirrhosis combined with portal vein thrombosis: a randomized trial of TIPS versus endoscopic band ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding. Radiology2015;276(1):286-93. [DOI: 10.1148/radiol.15141252] [MEDLINE: 25759969]">Luo 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐mm expanded PTFE‐covered stent</p> <p>(Fluency)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether routine surveillance was carried out</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/37: stent occlusion 7 patients and stent stenosis 4 patients (percentage and 95% CI 30%, 17% to 46%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No 'major' complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Transient retrosternal pain 11 patients</p> <p>Post‐ligation bleeding ulcer 2 patients</p> <p>Bradycardia propranolol‐related 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐mm PTFE‐covered stent (Fluency)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound and CT at 1, 3, and 6 months, then every 6 months or whenever clinical recurrence of portal hypertension </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐year and 2‐year shunt dysfunction 15% and 20%, respectively</p> <p>4/24 shunt dysfunction<sup>d</sup> (percentage and 95% CI 17%, 7% to 36%) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of patients with complications or adverse events is not obtainable<sup>e</sup> </p> <p>Ascites 1</p> <p>Hepatocellular carcinoma 2</p> <p>Fatigue 2</p> <p>Pneumonia 1</p> <p>Intraperitoneal bleeding 1</p> <p>Pulmonary embolism 1</p> <p>Acute‐on‐chronic liver failure 1</p> <p>Fever 2</p> <p>Dizziness 1</p> <p>Vomiting 1</p> <p>Peripheral oedema 2</p> <p>Mispuncture of bile duct 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of patients with complications or adverse events is not obtainable<sup>e</sup> </p> <p>Ascites 3</p> <p>Hepatic hydrothorax 1</p> <p>Spontaneous bacterial peritonitis 1</p> <p>Hepatorenal syndrome 1</p> <p>Hepatocellular carcinoma 1</p> <p>Bleeding from banding ulcer 1</p> <p>Dysphagia 3</p> <p>Deep venous thrombosis 1</p> <p>Oesophageal stenosis 1</p> <p>Haematuria 1</p> <p>Chest pain after ligation 2</p> <p>Fever 1</p> <p>Fatigue 1</p> <p>Dizzines 2</p> <p>Abdominal pain 1</p> <p>Diarrhoea 1</p> <p>Peripheral oedema 1</p> <p>Rash 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0016" title="MerliM , RiggioO , CapoccacciaL , ZiparoV , BologneseA , RossiP , et al. Transjugular intrahepatic portosystemic shunt (TIPS) vs endoscopic sclerotherapy (ES) in preventing variceal rebleeding preliminary results of a randomized controlled trial. Hepatology (Baltimore, Md.)1994;20(4):A107. MerliM , SalernoF , RiggioO , deFranchisR , FiaccadoriF , MeddiP , et al. Transjugular intrahepatic portosystemic shunt versus endoscopic sclerotherapy for the prevention of variceal bleeding in cirrhosis: a randomized multicenter trial. Gruppo Italiano Studio TIPS (G.I.S.T.). Hepatology (Baltimore, Md.)1998;27(1):48-53. [DOI: 10.1002/hep.510270109] [MEDLINE: 9425916]RossiP , MaccioniF , SalvatoriFM , BezziM , GandiniR , BrogliaL , et al. Transjugular intrahepatic portosystemic shunt (TIPS): indications and results after 22 months of experience [Derivazione porto-sistemica intraepatica transgiugulare (TIPS): indicazioni e risultati dopo 22 anni di esperienza]. Radiologica Medica1994;87(5):585-96. [MEDLINE: 8008887]">Merli 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 × 52‐mm Wallstent or 10 × 70/80‐mm Nitinol Strecker stent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound 6‐monthly and angiography 6‐monthly or whenever clinically indicated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/33 (percentage and 95% CI 64%, 47% to 78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemolysis 1 patient</p> <p>Intrahepatic haematoma 1 patient</p> <p>Cardiac arrest 1 patient</p> <p>Pulmonary embolism 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sclerotherapy‐induced ulcer 2 patients</p> <p>Oesophageal stenosis 2 patients</p> <p>Aspiration pneumonia 1 patient</p> <p>Embolic stroke 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0017" title="NaraharaY , KanazawaH , KawamataH , TadaN , SaitohH , MatsuzakaS , et al. A randomized clinical trial comparing transjugular intrahepatic portosystemic shunt with endoscopic sclerotherapy in the long-term management of patients with cirrhosis after recent variceal hemorrhage. Hepatology Research2001;21(3):189-98. [MEDLINE: 11673103]">Narahara 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gianturco‐Rösch biliary expandable Z‐stent (21 patients), Spiral‐Z stent (4 patients), Wallstent (13 patients) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound every 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/38 (percentage and 95% CI 71%, 55% to 83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure‐related complications:</p> <p>Haemobilia 2 patients</p> <p>Segmental hepatic infarction 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure‐related complications:</p> <p>Dysphagia 2 patients</p> <p>Transient pleural effusion 6 patients</p> <p>Bleeding ulcer secondary to sclerotherapy 3 patients</p> <p>Oesophageal stenosis 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound at 24 hours and then 3‐monthly for 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/41 (percentage and 95% CI 58%, 43% to 72%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from non‐variceal sources 6 patients</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Oesophageal ulcer due to ligation 3</p> <p>Oesophagitis 3</p> <p>Haemobilia 1</p> <p>Gastropathy 1</p> <p>Peptic ulcer 2</p> <p>No information on other complications or adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Bleeding from non‐variceal sources 9 patients</p> <p>Causes of non‐variceal gastrointestinal rebleeding<sup>b</sup>: </p> <p>Oesophageal ulcer due to ligation 7</p> <p>Mallory‐Weiss 2</p> <p>Oesophagitis 2</p> <p>No information on other complications or adverse events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmaz stent (39 patients, 92 stents), Memotherm stent (16 patients, 19 stents), Wallstent (6 patients, 6 stents) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound at 1, 3, 6, 9, and 12 months, then 6‐monthly or when needed for clinical reason </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/61 (percentage and 95% CI 29%, 19% to 42%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stent migration or dislocation 2 patients</p> <p>Haemobilia 3 patients</p> <p>Haemoperitoneum 2 patients</p> <p>Bleeding in the liver 1 patient</p> <p>Sepsis 1 patient</p> <p>Bradycardia 4 patients</p> <p>Fever 11 patients</p> <p>Transient abdominal pain 6 patients</p> <p>Bradyarrhytmia due to stent migration into the right ventricle requiring pacemaker 1 patient </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ulcer 8 patients</p> <p>Dysphagia 5 patients</p> <p>Mediastinitis 1 patient</p> <p>Hypopyon with eye enucleation (likely caused by sclerotherapy‐bacteraemia) 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0023" title="SanyalAJ , FreedmanAM , LuketicVA , Purdum PP 3rd, ShiffmanML , ColePE , et al. Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Annals of Internal Medicine1997;126(11):849-57. [DOI: 10.7326/0003-4819-126-11-199706010-00001] [MEDLINE: 9163285]">Sanyal 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wallstent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Doppler ultrasound at day 1, at week 1, at 1 and 3 months, then 3‐monthly</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/34 at 6 months (percentage and 95%CI 59%, 42% to 74%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Haemolysis TIPS‐associated 5 patients (severe in 1 patient)</p> <p>Sepsis 6 patients</p> <p>Renal failure 1 patient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest discomfort</p> <p>Oesophageal ulcer 22 patients</p> <p>Dysphagia + Stenosis 3 patients</p> <p>Dysphagia 2 patients</p> <p>Sepsis 2 patients</p> <p>Ascites 5 patients</p> <p>Seizures 1 patient</p> <p>Renal failure 2 patients</p> <p>Bleeding 1 patient</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0024" title="KriegerS , JaussM , JansenO , StiehlA , SauerP , GeisslerM , et al. MRI findings in chronic hepatic encephalopathy depend on portosystemic shunt: results of a controlled prospective clinical investigation. Journal of Hepatology1997;27(1):121-6. [DOI: 10.1016/s0168-8278(97)80290-5] [MEDLINE: 9252084]SauerP , TheilmannL , StremmelW , BenzC , RichterGM , StiehlA . Transjugular intrahepatic portosystemic stent shunt versus sclerotherapy plus propranolol for variceal rebleeding. Gastroenterology1997;113(5):1623-31. [DOI: 10.1053/gast.1997.v113.pm9352865] [MEDLINE: 9352865]">Sauer 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmaz stent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex ultrasound every 3 months and after variceal bleeding or other complications</p> <p>Angiography every 3 months and if dysfunction suspected</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/42 at 2 years (percentage and 95% CI 76%, 61% to 86%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not report number of patients with adverse events but did report numbers of events: </p> <p>Stent dislocation 4</p> <p>Renal failure 6</p> <p>Pneumonia 5</p> <p>Septicaemia 3</p> <p>Liver failure 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study authors did not report number of patients with adverse events but did report numbers of events: </p> <p>Oesophageal ulcer 19</p> <p>Bleeding ulcer 3</p> <p>Post‐therapeutic haemorrhage 5</p> <p>Renal failure 3</p> <p>Pneumonia 6</p> <p>Septicaemia 2</p> <p>Liver failure 2</p> <p>Heart failure propranolol‐related 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Palmaz stent or Wallstent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Duplex sonography and angiography every 3 months in the first year, every 6 months in the second year, and at yearly intervals thereafter; also if shunt dysfunction suspected </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cumulative dysfunction: 38/43 (89%) during follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pneumonia 4 patients</p> <p>Haemobilia 2 patients</p> <p>Stent dislocation 1 patient</p> <p>Septicaemia 3 patients</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysphagia 3 patients</p> <p>Pneumonia 3 patients</p> <p>Septicaemia 2 patients</p> <p>Post‐therapeutic haemorrhage 2 patients</p> <p>Severe side effects (type non‐specified) propranolol‐related 2 patients</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Acute hepatic encephalopathy, chronic hepatic encephalopathy, mortality, and shunt dysfunction not included, as reported elsewhere in this review.<br/><sup>b</sup>Data for other complications and adverse events were extracted as numbers of events across all time points (&lt; 2 years and ≥ 2 years combined).<sup>c</sup>Data for other complications and adverse events were extracted as numbers of adverse events across all time points (&lt; 6 months and &gt; 2 months until end of follow‐up combined).<br/><sup>d</sup>Data extracted from plot in <a href="./references#CD000553-bbs2-0015" title="LvY , QiX , HeC , WangZ , YinZ , NiuJ , et al. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut2018;67(12):2156-68. [DOI: 10.1136/ gutjnl-2017-314634] [MEDLINE: 28970291]QiXS , HeCY , YinZX , WangZY , ZhangHB , ZiaJL , et al. Transjugular intrahepatic portosystemic shunt for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: study protocol for a randomised controlled trial. BMJ Open2013;3(7):1162-71. ">Lv 2018</a>.<br/><sup>e</sup>Number of episodes. </p> <p>PTFE: polytetrafluorethylene.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Transjugular intrahepatic portosystemic shunt versus endoscopic intervention with and without medical treatments: shunt surveillance and complications</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0009"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Duration of hospital stay</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Time measured</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Shunt group</b> </p> <p><b>Mean (SD) or Median (range) [days]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Endoscopic therapy with or without drugs group</b> </p> <p><b>Mean (SD) or Median (range) [days]</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Statistical significance</b> </p> <p><b>P value</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Total shunt (TS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation for treatment</p> <p>Total hospitalisation due to treatment or complications during follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.9 (14.1)</p> <p>41.2 (13.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3 (7.1)</p> <p>38.1 (12.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total hospital stay including operation and readmission</p> <p>ICU stay</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.5 (9 to 122)</p> <p>4 (0 to 41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (15 to 64)</p> <p>3.3 (0 to 16)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Distal splenorenal shunt (DSRS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0026" title="TerésJ , BordasJM , BravoD , VisaJ , GrandeL , Garcia-ValdecasasJC , et al. Sclerotherapy vs. distal splenorenal shunt in the elective treatment of variceal hemorrhage: a randomized controlled trial. Hepatology (Baltimore, Md.)1987;7(3):430-6. [DOI: DOI: 10.1002/hep.1840070303] [MEDLINE: 3552920]">Terés 1987</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation for treatment</p> <p>Hospital stay for treatment of rebleeding and encephalopathy (shunt group)/treatment of rebleeding and sclerosis (sclerotherapy group) during follow‐up </p> <p>Hospital stay for treatment or for complications during follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (12.8)</p> <p>7.13 (16.1)</p> <p>47.7 (20.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.5 (11.9)</p> <p>16.5 (30.5)</p> <p>51.5 (28.8)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0001</p> <p>0.027</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Transjugular intrahepatic portosystemic shunt (TIPS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0001" title="CabreraJ , MaynarM , GranadosR , GorrizE , ReyesR , Pulido-DuqueJM , et al. Transjugular intrahepatic portosystemic shunt versus sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1996;110(3):832-9. [DOI: 10.1053/gast.1996.v110.pm8608893] [MEDLINE: 8608893]">Cabrera 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation for treatment</p> <p>Hospitalisation for rebleeding</p> <p>Hospitalisation for causes other than bleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1 (3.1)</p> <p>2.9 (6)</p> <p>6.96 (14.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.7 (6.2)</p> <p>7.7 (9.8)</p> <p>4.45 (10.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>&lt; 0.05</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for variceal rebleeding</p> <p>Hospitalisation for any rebleeding</p> <p>Hospitalisation for portosystemic encephalopathy</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.54 (2.13)</p> <p>20.8 (3.2)</p> <p>3.7 (1.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.92 (3.54)</p> <p>20.1 (4.6)</p> <p>1.2 (0.7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>NS</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0005" title="García-VillarrealL , Martinez-LagaresF , SierraA , GuevaraC , MarreroJM , JiménezE , et al. Transjugular Intrahepatic portosystemic shunt versus prevention of rebleeding after recent variceal hemorrhage. Hepatology (Baltimore, Md.)1999;29(1):27-32. [DOI: 10.1002/hep.510290125] [MEDLINE: 9862845]">García‐Villarreal 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation for any reason after initial discharge</p> <p>Hospitalisation for variceal rebleeding</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.9 (20.2)</p> <p>1.5 (4.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3 (18.7)</p> <p>4.6 (7.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>&lt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospitalisation during follow‐up</p> <p>ICU stay</p> <p>Stay in the high‐dependency unit</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.2 (15)</p> <p>0.2 (0.8)</p> <p>0.7 (1.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.2 (19)</p> <p>1.15 (2.3)</p> <p>3.1 (3.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> <p>0.03</p> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0019" title="Pomier-LayrarguesG , DufresneMP , BuliB , LambertJ , FenyvesD , WillemsB , et al. TIPS versus endoscopic variceal ligation in the prevention of variceal rebleeding in cirrhotic patients: a comparative randomized clinical trial (interm analysis). Hepatology (Baltimore, Md.)1997;26(4):137A. Pomier-LayrarguesG , VilleneuveJP , DeschenesM , BuiB , PerreaultP , FenyvesD , et al. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut2001;48(3):390-6. [DOI: 10.1136/gut.48.3.390] [MEDLINE: 11171831]">Pomier‐Layrargues 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation</p> <p>Hospitalisation during 2‐year follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.8 (1.8)</p> <p>45 (7)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.4 (2.4)</p> <p>40 (6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0021" title="RossleM , DeibertP , HaagK , OchsA , OlschewskiM , SiegerstetterV , et al. Randomised trial of transjugular intrahepatic portosystemic shunt versus endoscopy plus propranolol for prevention of variceal rebleeding. Lancet1997;349(9058):1043-9. [DOI: 10.1016/s0140-6736(96)08189-5] [MEDLINE: 9107241]">Rossle 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation (after randomisation)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (28)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0025" title="SauerP , BenzC , TheilmannG , RichterW , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: final results of a randomized study. Gastroenterology1998;114(4):A1334. SauerP , HansmannJ , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: a long-term randomized trial. Gastroenterology2000;118(4 Pt 2):A1485. SauerP , HansmannJ , RichterGM , StremmelW , StiehlA . Endoscopic variceal ligation plus propranolol versus transjugular intrahepatic portosystemic stent shunt: a long-term randomized trial. Endoscopy2002;34(9):690-7. [DOI: 10.1055/s-2002-33565] [MEDLINE: 12195325]SauerP , TheilmannL , BenzC , RichterG , StremmelW , StiehlA . Transjugular intrahepatic portosystemic stent shunt (TIPS) vs. endoscopic banding in the prevention of variceal rebleeding: interim analysis of a randomized study. Gastroenterology1997;112(4):A1374. ">Sauer 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital stays per patient per year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34.1 (30.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.8 (21.9)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.05</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0013" title="LoGH , LiangHL , ChenWC , ChenMH , LaiKH , HsuPI , et al. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy2007;39(8):679-85. [DOI: 10.1055/s-2007-966591] [MEDLINE: 17661241]">Lo 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.2 (5.3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7 (6.5)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NS</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Index hospitalisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4 (11.2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.8 (5.4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.095</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Data for length of hospital stay have been presented in a narrative/tabular format due to variation in time points measured between studies and resultant substantial heterogeneity. </p> <p>Results are given as mean and SE.<br/>ICU: intensive care unit.<br/>NS: not statistically significant. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Duration of hospital stay</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0010"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cost of treatment: shunt versus endoscopic intervention with or without medical treatment</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Trial</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Costs measured</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Outcomes reported</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Shunt</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Endoscopic therapy</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Total shunt (TS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0018" title="PlanasR , BoixJ , BroggiM , CabreE , Gomes-VieiraMC , MorillasR , et al. Portacaval shunt versus endoscopic sclerotherapy in the elective treatment of variceal hemorrhage. Gastroenterology1991;100(4):1078-86. [DOI: 10.1016/0016-5085(91)90285-s] [MEDLINE: 2001806]">Planas 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Healthcare costs" (not defined)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ± SD</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 9761 ± 750</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 9047 ± 704</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0010" title="IsakssonB , JeppssonB , BengtssonF , HannessonP , HerlinP , BengmarkS . Mesocaval shunt or repeated sclerotherapy: effects on rebleeding and encephalopathy - a randomized trial. Surgery1995;117(5):498-504. [MEDLINE: 7740420]">Isaksson 1995</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital costs included laboratory and X‐ray examinations, transfusions, drugs, grafts, hotel service, endoscopy investigations and treatment, and costs of surgical procedure (calculated according to Alinder G, et al. World J Surg 1985;9:329‐34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (range)</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 12,949 (7802 to 64,835)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 12,027</p> <p>(2525 to 39,018)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Distal splenorenal shunt (DSRS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0020" title="RikkersLF , BurnettDA , VolentineGD , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Annals of Surgery1987;206(3):261-71. [DOI: 10.1097/00000658-198709000-00004] [MEDLINE: 3307653]RikkersLF , JinG , BurnettDA , BuchiKN , CormierRA . Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. American Journal of Surgery1993;165(1):27-32. [DOI: 10.1016/s0002-9610(05)80400-3] [MEDLINE: 8418700]">Rikkers 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both initial and total medical costs for each therapy were calculated and compared. Initial medical costs were defined as those incurred during the hospitalisation in which shunt surgery was performed or sclerotherapy initiated. Total costs included initial hospitalisation, all subsequent hospitalisations required for treatment of recurrent haemorrhage and complications of therapy or chronic liver disease, and outpatient endoscopic evaluation with or without variceal sclerosis. Analysis included only patients treated at University hospitals. </p> <p>Data from Rikkers LF, Burnett DA, Volentine GD, Buchi KN, Cormier RA. Shunt surgery vs endoscopic sclerotherapy for long‐term treatment of variceal bleeding. Early results of a randomized trial. Ann Surg 1987;206(3):261‐71. PMID: 3307653 </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total medical costs during mean follow‐up interval of 20 ± 5 and 24 ± 6 months for shunt and sclerotherapy patients </p> <p>Mean ± SEM</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 34,474 ± 5499</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 37,648 ± 6392</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Transjugular intrahepatic portosystemic shunt (TIPS)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0002" title="CelloJP , RingEJ , OlcottEW , KochJ , GordonR , SandhuJ , et al. Endoscopic sclerotherapy compared with percutaneous transjugular Intrahepatic portosystemic shunt after initial sclerotherapy in patients with acute variceal haemorrhage. A randomised controlled trial. Annals of Internal Medicine1997;126(11):858-65. [DOI: 10.7326/0003-4819-126-11-199706010-00002] [MEDLINE: 9163286]">Cello 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total cost of health care per patient calculated as the sum of all real costs for inpatient and outpatient hospital care, including hospital expenditures and costs for professional services, and all outpatient costs for endoscopic sclerotherapy, doppler ultrasonography, and stent revision from day of randomisation until death or latest follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean ± SE</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 29,790 ± 3422</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USD 27,540 ± 5088</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0011" title="JalanR , ForrestEH , RedheadDN , DillonJF , BzeiziKI , FinlaysonNDC , et al. TIPSS vs variceal band ligation in the secondary prevention of variceal hemorrhage in cirrhosis: preliminary results of a randomised, controlled study. Hepatology (Baltimore, Md.)1995;22(4):251A. JalanR , ForrestEH , StanleyAJ , RedheadDN , ForbesJ , DillonJF , et al. A randomized trial comparing transjugular intrahepatic portosystemic stent-shunt with variceal band ligation in the prevention of rebleeding from esophageal varices. Hepatology (Baltimore, Md.)1997;26(5):1115-22. [DOI: 10.1002/hep.510260505] [MEDLINE: 9362350]">Jalan 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Estimated cost of procedure (not including personnel) and costs of inpatient treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure: GBP 2749</p> <p>Hospital treatment: GBP 4310</p> <p>Total: GBP 7059</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Procedure: GBP 1422</p> <p>Hospital treatment: GBP 7010</p> <p>Total: GBP 8432</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD000553-bbs2-0009" title="HarkiJ , HolsterIL , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal rebleeding. Gastroenterology2016;150(4 Suppl 1):S1160. HarkiJ , HolsterLI , PolinderS , MoelkerA , Van BuurenHR , KuipersEJ , et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt versus endoscopic treatment for secondary prevention of gastro-oesophageal variceal bleeding. Journal of Hepatology2016;64(2 Suppl):S265-6. [DOI: doi.org/10.1016/S0168-8278(16)00303-2]HolsterIL , MoelkerA , TjwaET , WilsA , KupersEJ , PattynamaP , et al. Early transjugular intrahepatic portosystemic shunt (TIPS) as compared to endoscopic treatment reduces rebleeding but not mortality in cirrhotic patients with a 1st or 2nd episode of variceal bleeding: a multicentre randomized controlled trial. United European Gastroenterology Journal2013;1(S1):A84. HolsterIL , TjwaETTL , MoelkerA , WilsA , HansenBE , VermeijdenJR , et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + ß-blocker for prevention of variceal rebleeding. Hepatology (Baltimore, Md.)2016;63(2):581-9. [DOI: 10.1002/hep.28318] [MEDLINE: 26517576]">Holster 2016</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Costs for admissions, consultations, initial treatment, imaging, diagnostics, transfusions, medications in the first year </p> <p>Abstract only: Harki J, Holster IL, Polinder S, Moelker A, van Buuren HR, Kuipers EJ, et al. Cost effectiveness of covered transjugular intrahepatic portosystemic shunt vs endoscopic treatment for secondary prevention of gastro‐oesophageal variceal bleeding, Journal of Hepatoloy 2016;64(2 Suppl):S265‐S266. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> <p>per patient</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 27,746</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>EUR 16,816</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>SD: standard deviation.<br/>SE: standard error.<br/>SEM: standard error of the mean. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Cost of treatment: shunt versus endoscopic intervention with or without medical treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0011"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of total shunt (TS) versus endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction, while considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1842</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14,904</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>628</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1197</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>285</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2846</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6318</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1424</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1427</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7080</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7082</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.3%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1596</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="7" rowspan="5" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ TSA<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chronic hepatic encephalopathy ‐ TSA<sup>d</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>The TSA curve was not constructed due to too little information.<br/><sup>b</sup>The Z‐curve did not did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.<br/><sup>c</sup>The Z‐curve reached the monitoring boundary for benefit.<br/><sup>d</sup>There was a single trial with 3/34 events in the TS group and 0/35 in the endoscopy with or without drugs group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis (TSA) in the comparison of total shunt (TS) versus endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0012"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of DSRS versus endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign="top"> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction, while considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>554</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4284</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause mortality ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,538</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>574</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1096</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>262</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3878</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45.8%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>928</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>No data</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6890</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1552</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6892</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.6%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1554</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2768</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6164</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1390</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8382</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1892</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>b</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12,542</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,924</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6226</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27,926</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>The TSA curve was not constructed due to too little information.<br/><sup>b</sup>The Z‐curve did not did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of DSRS versus endoscopic intervention for prevention of rebleeding in people with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000553-tbl-0013"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of TIPS versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> <tbody> <tr> <th align="" class="headercell" colspan="8" rowspan="1" scope="col" valign=""> <p><b>Comparison of imprecision evaluation with GRADE based on the GRADE Handbook, with GRADE based on our choice of plausible relative risk reduction (RRR) and multiplicity correction, and according to our Trial Sequential Analysis (TSA) based on our similar choice of plausible relative risk reduction and multiplicity correction, while considering choice of meta‐analytic model and diversity</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outcome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion in control group</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relative risk reduction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alpha</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beta</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diversity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Required information size</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgrading of evidence for imprecision</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,900</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All‐cause mortality ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10,902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>648</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>b</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE Handbook</p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ GRADE plausible RRR</p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Health‐related quality of life ‐ TSA</p> </td> <td align="center" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>No data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4974</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11,063</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mortality due to rebleeding ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not downgraded<sup>c</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1798</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>906</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Acute hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1217</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not downgraded<sup>d</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE Handbook</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15,312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34,096</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ GRADE plausible RRR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not used</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7598</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 1 level</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34,099</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chronic hepatic encephalopathy ‐ TSA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Downgraded 2 levels<sup>a</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>The Z‐curve did not did not reach 50% of the diversity‐adjusted required information size and did not cross any of the sequential boundaries for benefit, harm, or futility.<br/><sup>b</sup>The Z‐curve reached the monitoring boundary for benefit.<br/><sup>c</sup>The Z‐curve reached the monitoring boundary for futility.<br/><sup>d</sup>The Z‐curve reached the monitoring boundary for harm.<br/><sup>e</sup>The TSA curve was not constructed due to too little information. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Comparison of imprecision by GRADE and Trial Sequential Analysis in the comparison of TIPS versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/full#CD000553-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000553-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Portosystemic shunts versus endoscopic intervention with or without medical treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 TS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.19, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 DSRS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.65, 1.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.3 TIPS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.92, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Rebleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 TS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.14, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 DSRS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.11, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.3 TIPS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.36, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Mortality due to rebleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.34, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 TS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.06, 0.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 DSRS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>352</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.13, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 TIPS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.40, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Acute hepatic encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.33, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 TS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>115</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [0.70, 3.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 DSRS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>287</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [0.94, 3.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.3 TIPS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.29, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Chronic hepatic encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.38, 4.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 TS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.20 [0.39, 134.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 DSRS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.87 [1.46, 16.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.3 TIPS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>717</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.88 [0.93, 3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Rebleeding from all causes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.34, 0.52]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 TS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.19, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 DSRS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>330</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.18, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.3 TIPS vs endoscopic intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1312</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.35, 0.56]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Portosystemic shunts versus endoscopic intervention with or without medical treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000553-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.86, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>754</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.85, 1.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.78, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Rebleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1769</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>732</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.25, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1037</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.33, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Mortality due to rebleeding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1779</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.34, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.23, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.33, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Acute hepatic encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.33, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>705</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.09, 2.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>944</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.69 [1.36, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Chronic hepatic encephalopathy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>956</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.51 [1.38, 4.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Trials without for‐profit funding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.70, 5.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Trials with for‐profit funding or unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>674</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.79 [1.35, 5.75]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Portosystemic shunts versus endoscopic intervention with or without medical treatment regarding funding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000553.pub3/references#CD000553-tbl-0015">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000553.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000553-note-0029">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000553-note-0026">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000553-note-0027">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD000553-note-0025">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD000553-note-0028">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000553-note-0024">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000553\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000553\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000553\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000553\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000553\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=wbKFI7vu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000553.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000553.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000553.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000553.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000553.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719382535"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000553.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719382539"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000553.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918de75f1c53f55b',t:'MTc0MDcxOTM4My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 